

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2019219057 B2**

(54) Title
FAP inhibitor

(51) International Patent Classification(s)
C07D 401/12 (2006.01) **C07D 401/14** (2006.01)
A61K 31/4709 (2006.01) **C07D 405/14** (2006.01)
A61P 35/00 (2006.01)

(21) Application No: **2019219057** (22) Date of Filing: **2019.02.06**

(87) WIPO No: **WO19/154886**

(30) Priority Data

| (31) Number | (32) Date | (33) Country |
|-------------------|-------------------|--------------|
| 18155420.5 | 2018.02.06 | EP |
| 18155419.7 | 2018.02.06 | EP |
| 18199641.4 | 2018.10.10 | EP |

(43) Publication Date: **2019.08.15**

(44) Accepted Journal Date: **2022.11.24**

(71) Applicant(s)
Universität Heidelberg

(72) Inventor(s)
HABERKORN, Uwe; LOKTEV, Anastasia; LINDNER, Thomas; MIER, Walter; GIESEL, Frederik; KRATOCHWIL, Clemens

(74) Agent / Attorney
Spruson & Ferguson, GPO Box 3898, Sydney, NSW, 2001, AU

(56) Related Art
WO 2013107820 A1
WO 2013/033396 A2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

15 August 2019 (15.08.2019)



(10) International Publication Number

WO 2019/154886 A1

(51) International Patent Classification:

C07D 401/12 (2006.01) A61K 31/4709 (2006.01)

C07D 401/14 (2006.01) A61P 35/00 (2006.01)

C07D 405/14 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2019/052952

(22) International Filing Date:

06 February 2019 (06.02.2019)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18155420.5 06 February 2018 (06.02.2018) EP

18155419.7 06 February 2018 (06.02.2018) EP

18199641.4 10 October 2018 (10.10.2018) EP

(71) Applicant: UNIVERSITÄT HEIDELBERG [DE/DE];

Grabengasse 1, 69117 Heidelberg (DE).

(72) Inventors: HABERKORN, Uwe; Königsäcker 82, 68723

Schwetzingen (DE). LOKTEV, Anastasia; Albert-Fritz-Str. 37a, 69124 Heidelberg (DE). LINDNER, Thomas; Erfurter Str. 10, 68723 Schwetzingen (DE). MIER, Walter; Brückweg 21, 64625 Bensheim (DE). GIESEL, Frederik; Alte Eppelheimer Str. 24/1, 69115 Heidelberg (DE). KRA-TOCHWIL, Clemens; Gartenstr. 9, 69493 Hirschberg a.d.B. (DE).

(74) Agent: ZWICKER, Jörk; Zwicker Schnappauf & Part-

ner Patentanwälte PartG mbB, Hansastr. 32, 80686 Munich (DE).


(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: FAP INHIBITOR



(57) Abstract: The present invention relates to a compound of formula (I), a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition and use of the compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP).



WO 2019/154886 A1

FAP Inhibitor

The present invention relates to a compound, a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition and use of the compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP).

Background of the Invention

Tumor growth and spread are not only determined by the cancer cells, but also by the non-malignant constituents of the malignant lesion, which are subsumed under the term stroma. The stroma may represent over 90% of the tumor mass in tumors with desmoplastic reaction such as breast, colon and pancreatic carcinoma. Especially a subpopulation of fibroblasts called cancer-associated fibroblasts (CAFs) is known to be involved in tumor growth, migration and progression. Therefore, these cells represent an attractive target for diagnosis and anti-tumor therapy.


A distinguishing feature of CAFs is the expression of seprase or fibroblast activation protein α (FAP- α), a type II membrane bound glycoprotein belonging to the dipeptidyl peptidase 4 (DPP4) family. FAP- α has both dipeptidyl peptidase and endopeptidase activity. The endopeptidase activity distinguishes FAP- α from the other members of the DPP4 family. Identified substrates for the endopeptidase activity so far are denatured Type I collagen, α 1-antitrypsin and several neuropeptides. FAP- α has a role in normal developmental processes during embryogenesis and in tissue modelling. It is not or only at insignificant levels expressed on adult normal tissues. However, high expression occurs in wound healing, arthritis, atherosclerotic plaques, fibrosis and in more than 90% of epithelial carcinomas.

The appearance of FAP- α in CAFs in many epithelial tumors and the fact that overexpression is associated with a worse prognosis in cancer patients led to the hypothesis that FAP- α activity is involved in cancer development as well as in cancer cell migration and spread. Therefore, the targeting of this enzyme for imaging and endoradiotherapy can be considered as a promising strategy for the detection and treatment of malignant tumors. The present inventors developed a small molecule based on a FAP- α specific inhibitor and were able to show specific uptake, rapid internalization and successful imaging of tumors in animal models as well as in tumor patients. A comparison with the commonly used radiotracer ^{18}F -fluorodeoxyglucose (^{18}F -FDG) revealed a clear superiority of the new FAP- α ligand in patients with locally advanced lung adenocarcinoma. Thus, the present invention provides inter alia: (i) detection of

smaller primary tumors and, thus the possibility of earlier diagnosis, (ii) the detection of smaller metastasis and, thus a better assessment of tumor stage, (iii) precise intra-operative guidance facilitating complete surgical removal of tumor tissue, (iv) better differentiation between inflammation and tumor tissue, (v) more precise staging of patients with tumors, (vi) better follow up of tumor lesions after antitumor therapy, (vii) the opportunity to use the molecules as theranostic agents for diagnosis and therapy. Furthermore, the molecules can be used for the diagnosis and treatment of non-malignant diseases such as chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and keloid disorders.

Summary of the Invention

In a preferred first aspect, the invention provides a compound of Formula (I)



wherein

Q, R, and U are absent;

V, W, Y, and Z are individually present or absent under the proviso that at least three of V, W, Y, and Z are present;

V, W, Y, and Z are independently selected from the group consisting of O, CH₂, NR⁴, C=O, C=S, C=NR⁴, HCR⁴ and R⁴CR⁴, with the proviso that two Os are not directly adjacent to each other;


R¹ and R² are independently selected from the group consisting of -H, halogen, OH, C₁₋₆-alkyl, -O-C₁₋₆-alkyl, and S-C₁₋₆-alkyl;

R³ is selected from the group consisting of -CN, -B(OH)₂, -H, -C(O)-alkyl, -C(O)-aryl, -C=C-C(O)-aryl, -C=C-S(O)₂-aryl, -CO₂H, -SO₃H, -SO₂NH₂, -PO₃H₂, and 5-tetrazolyl;

R⁴ is selected from the group consisting of -H, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl, and -C₁₋₆-aryl, each of said -C₁₋₆-alkyl being optionally substituted with from 1 to 3 substituents selected from -OH, oxo, halogen;

R⁵ is selected from the group consisting of -H, halogen and C₁₋₆-alkyl;

R⁶, and R⁷ are independently selected from the group consisting of -H and



, under the proviso that R^6 and R^7 are not at the same time H,


wherein D is present or absent,

wherein A, E, and B are present,

wherein when D is present: D is a linker;

A is selected from the group consisting of NR^4 , O, S, and CH_2 ;

E is selected from the group consisting of



wherein i is 1, 2, or 3;

wherein j is 1, 2, or 3;


wherein k is 1, 2, or 3;

wherein m is 1, 2, or 3;

A and E together form a group selected from: a cycloalkyl, heterocycloalkyl, aryl and heteroaryl, preferably heterocycloalkyl, wherein A and E can be mono-, bi- and multicyclic, preferably monocyclic; each A and E being optionally substituted with 1 to 4 substituents selected from -H, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl, and -C₁₋₆-aralkyl, each of said -C₁₋₆-alkyl being optionally substituted with from 1 to 3 substituents selected from -OH, oxo, halogen; and optionally

connected to A, B, D, E or ;

B is a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C₁₋₆-alkyl, aryl, and C₁₋₆-aralkyl; and; R^8 is selected from the group consisting of radioactive moiety, chelating agent, fluorescent dye, a contrast agent and combinations thereof;



is a 1-naphthyl moiety or a 5 to 10- membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, wherein there are 2 ring atoms between the N atom and X; said heterocycle optionally further comprising 1, 2 or 3 heteroatoms selected from O, N and S; and X is a C atom;

or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate, or salt thereof.

In a preferred second aspect, the invention provides a pharmaceutical composition comprising at least one compound according to the first aspect; and, a pharmaceutically acceptable carrier.

In a preferred third aspect, the invention provides the compound of the first aspect or the pharmaceutical composition of the second aspect for use in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP) in an animal or a human subject, preferably wherein the disease characterized by overexpression of fibroblast activation protein (FAP) is selected from the group consisting of cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and keloid disorder, preferably wherein the cancer is selected from the group consisting of breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharynx cancer, nasopharynx cancer, larynx cancer, myeloma cells, bladder cancer, cholangiocellular carcinoma, clear cell renal carcinoma, neuroendocrine tumor, oncogenic osteomalacia, sarcoma, CUP (carcinoma of unknown primary), thymus carcinoma, desmoid tumors, glioma, astrocytoma, cervix carcinoma and prostate cancer.

In a preferred fourth aspect, the invention provides a method for diagnosing or treating of a disease characterized by overexpression of fibroblast activation protein (FAP) in an animal or a human subject, preferably wherein the disease characterized by overexpression of fibroblast activation protein (FAP) is selected from the group consisting of cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and keloid disorder, preferably wherein the cancer is selected from the group consisting of breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharynx cancer, nasopharynx cancer, larynx cancer, myeloma cells, bladder cancer, cholangiocellular carcinoma, clear cell renal carcinoma, neuroendocrine tumor, oncogenic osteomalacia, sarcoma, CUP (carcinoma of unknown primary), thymus carcinoma, desmoid tumors, glioma, astrocytoma, cervix carcinoma and


prostate cancer, the method comprising administering the compound of the first aspect or the pharmaceutical composition of the second aspect.

In a preferred fifth aspect, there is provided use of the compound of the first aspect of the invention or the pharmaceutical composition of the second aspect of the invention for the manufacture of a medicament for diagnosing or treating of a disease characterized by overexpression of fibroblast activation protein (FAP) in an animal or a human subject,

preferably wherein the disease characterized by overexpression of fibroblast activation protein (FAP) is selected from the group consisting of cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and keloid disorder, preferably wherein the cancer is selected from the group consisting of breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharynx cancer, nasopharynx cancer, larynx cancer, myeloma cells, bladder cancer, cholangiocellular carcinoma, clear cell renal carcinoma, neuroendocrine tumor, oncogenic osteomalacia, sarcoma, CUP (carcinoma of unknown primary), thymus carcinoma, desmoid tumors, glioma, astrocytoma, cervix carcinoma and prostate cancer.

In a preferred sixth aspect, the invention provides a kit comprising or consisting of the compound of the first aspect of the invention or the pharmaceutical composition of the second aspect of the invention and instructions for the diagnosis or treatment of a disease.

In a first aspect, the present invention provides a compound of Formula (I)



wherein

Q, R, U, V, W, Y, Z are individually present or absent under the proviso that at least three of Q, R, U, V, W, Y, Z are present;

Q, R, U, V, W, Y, Z are independently selected from the group consisting of O, CH₂, NR⁴, C=O, C=S, C=NR⁴, HCR⁴ and R⁴CR⁴, with the proviso that two Os are not directly adjacent to each other;

R¹ and R² are independently selected from the group consisting of -H, -OH, halo, C₁₋₆-alkyl, -O-C₁₋₆-alkyl, S-C₁₋₆-alkyl;


R³ is selected from the group consisting of -H, -CN, -B(OH)₂, -C(O)-alkyl, -C(O)-aryl-, -C=C-C(O)-aryl-, -C=C-S(O)₂-aryl-, -CO₂H, -SO₃H, -SO₂NH₂, -PO₃H₂, and 5-tetrazolyl;

2d

R⁴ is selected from the group consisting of -H, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, aryl, and -C₁₋₆-aralkyl, each of said -C₁₋₆-alkyl being optionally substituted with from 1 to 3 substituents selected from -OH, oxo, halo and optionally connected to Q, R, U, V, W, Y or Z;

R⁵ is selected from the group consisting of -H, halo and C₁₋₆-alkyl;

R⁶, and R⁷ are independently selected from the group consisting of -H,



and $R^8-D-B-E-A$, under the proviso that R⁶ and R⁷ are not at the same time H,


wherein L is a linker,

wherein D, A, E, and B are individually present or absent, preferably wherein at least A, E, and B are present, wherein when present:

D is a linker;

5 A is selected from the group consisting of NR^4 , O, S, and CH_2 ;

E is selected from the group consisting of




wherein i is 1, 2, or 3;

10 wherein j is 1, 2, or 3;

wherein k is 1, 2, or 3;


wherein m is 1, 2, or 3;

A and E together form a group selected from a cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein A and E can be mono-, bi- and multicyclic, preferably monocyclic. Each A and E being
15 optionally substituted by 1 to 4 residues from the group consisting of -H, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl, and -C₁₋₆-aralkyl, each of said -C₁₋₆-alkyl being optionally substituted with from 1 to 3 substituents

selected from -OH, oxo, halo; and optionally connected to A, B, D, E or .

20 B is selected from the group consisting of S, NR^4 , $\text{NR}^4\text{-O}$, $\text{NR}^4\text{-C}_{1-6}\text{-alkyl}$, $\text{NR}^4\text{-C}_{1-6}\text{-alkyl-NR}^4$, and a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein $\text{NR}^4\text{-C}_{1-6}\text{-alkyl-NR}^4$ and the N-containing heterocycle is substituted with 1 to 3 substituents selected from the group consisting of C₁₋₆-alkyl, aryl, C₁₋₆-aralkyl; and;

25 R^8 is selected from the group consisting of radioactive moiety, chelating agent, fluorescent dye, a contrast agent and combinations thereof;



is a 1-naphthyl moiety or a 5 to 10- membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, wherein there are 2 ring atoms between the N atom and X; said heterocycle optionally further comprising 1, 2 or 3 heteroatoms selected from O, N and S; and X is a C atom;

5 or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate, or salt thereof.

In a second aspect, the present invention relates to a pharmaceutical composition comprising or consisting of at least one compound of the first aspect, and, optionally, a pharmaceutically acceptable carrier and/or excipient.

10 In a third aspect, the present invention relates to the compound of the first aspect or the pharmaceutical composition of the second aspect for use in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP) in an animal or a human subject.

15 In a fourth aspect, the present invention relates to a kit comprising or consisting of the compound of the first aspect or the pharmaceutical composition of the second aspect and instructions for the diagnosis or treatment of a disease.

List of Figures

In the following, the content of the figures comprised in this specification is described. In this context please also refer to the detailed description of the invention above and/or below.

20 **Figure 1: In vitro characterization of ¹²⁵I-FAPI-01 and ¹⁷⁷Lu-FAPI-02.**

A. Binding of radiolabeled FAPI-01 and FAPI-02 to different human cancer cell lines as well as cell lines transfected with human FAP- α (HT-1080-FAP), murine FAP- α (HEK-muFAP) and human CD26 (HEK-CD26) after 60 min of incubation. **B.** Internalization of radiolabeled FAPI-01 and FAPI-02 into HT-1080-FAP cells after incubation for 10 min to 24 h. The internalized proportion is shown in grey and black, respectively; the extracellularly bound fraction is indicated by the white bars. **C.** Competitive binding of radiolabeled FAPI-01 and FAPI-02 to HT-1080-FAP cells after adding increasing concentrations of unlabeled FAPI-01 and Lu-FAPI-02. **D.** Internalization of FAPI-02 into FAP- α positive and negative cell lines. Blue: DAPI; green: FAPI-02-Atto488. **E+F.** Efflux kinetics of FAPI-01 and FAPI-02 after 1 h incubation of HT-1080-FAP cells with radiolabeled compounds followed by incubation with compound-free medium for 1 to 24 h. All values are given as percentage of total applied dose normalized to 1 million cells (%ID/1 mio cells).

30

Figure 2: Binding specificity and relative internalization rates of FAPI derivatives.

A-C. Binding and internalization rates of FAPI-03 to FAPI-15 in relation to FAPI-02 (defined as 100%). Internalization rates after 1, 4 and 24 hrs of incubation are depicted in grey; the extracellular bound fraction is represented by the white bars. **D.** Binding of selected FAPI derivatives to HEK cells expressing murine FAP- α and human CD26 after 60 min of incubation. *Right side:* Ratio of muFAP to CD26 binding. **E.** Competitive binding of selected FAPI derivatives to HT-1080-FAP cells after adding increasing concentrations of unlabeled compound.

Figure 3: Imaging of FAPI-02 and -04 in mice bearing human FAP-positive (HT-1080-FAP) and negative (Capan-2, SK-LMS-1) tumor xenografts.

A+C, E+G. Small animal PET imaging was performed after intravenous administration of 4 nmol ^{68}Ga -FAPI-02 and -04 (10 MBq resp.) at indicated times. The radiotracer gets rapidly enriched within the tumor (indicated by the red arrow) while not accumulating in non-cancerous tissue. Furthermore, a rapid elimination via the kidneys and bladder is seen. **B+D, F+H.** Quantification of the PET images demonstrates a solid clearance of ^{68}Ga -FAPI-02 and -04 from the cardiovascular system and a constant uptake into the tumor.

Figure 4: Blocking experiments for analysis of binding specificity in vivo

A+D. Blocking of ^{68}Ga -FAPI-02 and -04 tumor accumulation by co-administration of 30 nmol unlabeled compound in HT-1080-FAP tumor bearing mice. **B+C, E+F.** Time-activity curves of ^{68}Ga -FAPI-02 and -04 in selected organs after intravenous administration with and without unlabeled compound as a competitor.

Figure 5: Organ distribution of ^{177}Lu -FAPI-02 and -04 in HT-1080-FAP tumor bearing nude mice

A-C. Biodistribution of ^{177}Lu -FAPI-02 and -04 was measured ex vivo at indicated times after intravenous administration of 1 MBq to mice bearing human FAP-positive HT-1080 tumor xenografts; n=3 for each time point. The values stated are expressed as percentage of injected dose per gram of tissue (% ID/g). The radiotracers are shown to accumulate within the FAP-expressing tumor, showing the highest enrichment after 1 h for FAPI-02 (4.5 %ID/g) and 2 h for FAPI-04 (5.4 %ID/g). **D-F.** Tumor-to-normal tissue ratios of ^{177}Lu -FAPI-02 and -04 1, 4 and 24 hrs after intravenous administration.

Figures 6-9: PET/CT imaging of FAPI-02 in cancer patients

6A-C. Maximum intensity projections (MIP) of PET/CT scans in a patient suffering from metastasized breast cancer. **D.** Maximum tissue uptake of ^{68}Ga -FAPI-02 10 min, 1 h and 3 h after intravenous administration to a patient with metastasized breast cancer.

7. MIP of PET/CT scans in patients with pancreatic cancer, non-small cell lung cancer (NSCLC) and esophageal and rectum carcinoma 1 h after administration of ⁶⁸Ga-FAPI-02.

8. MIP of PET/CT scans in patients with nasopharynx and larynx carcinoma 1 h after administration of ⁶⁸Ga-FAPI-02.

5 **9A+B.** Whole-body PET/CT imaging (MIP) 1 h after administration of ¹⁸F-FDG and ⁶⁸Ga-FAPI-02 to a patient with locally advanced lung adenocarcinoma. **C+D.** Transaxial view of lung adenocarcinoma patient 1 h after administration of ¹⁸F-FDG and ⁶⁸Ga-FAPI-02. FAPI-02 is selectively accumulated in FAP- α expressing tissue and shows significantly higher uptake in the malignant lesions compared to ¹⁸F-FDG.

10 **Figures 10-16: PET/CT imaging of FAPI-04 in cancer patients**

10 Maximum intensity projections (MIP) of PET/CT scans in a patient suffering from metastasized breast cancer 10 min, 1 and 3 hrs after administration of ⁶⁸Ga-FAPI-04.

11 MIP of PET/CT scans in patients with sigma carcinoma, hypopharynx carcinoma, neuroendocrine tumors, cholangio, ovarial and small intestine carcinoma 1 h after administration of ⁶⁸Ga-FAPI-04.

12 MIP of PET/CT scans in a patient with lung cancer 1 h after administration of ⁶⁸Ga-FAPI-04.

13 MIP of PET/CT scans in a patient with oncogenic rachitis 1 h after administration of ⁶⁸Ga-FAPI-04.

20 **14** Comparative imaging of one patient with metastasized prostate cancer. MIP of PET/CT scans 1 h after application of radiolabeled DOTATOC, PSMA and FAPI-04.

15 Maximum intensity projection (MIP) and time-activity curves of a dynamic ⁶⁸Ga-FAPI-04 PET/CT scan in a pancreatic cancer patient.

25 **16** Relative binding rates of Lu-177 labeled FAPI derivatives compared to FAPI-04 (set to 100%) after incubation for 1, 4 and 24 h on FAP-expressing HT-1080 cells; n=3.

Figure 17: Competitive binding of selected FAPI derivatives to HT-1080-FAP cells after adding increasing concentrations of unlabeled compound (10^{-10} to 10^{-5} M, incubation for 60 min, n=3).

30 **Figure 18:** Binding of FAPI derivatives to HEK cells expressing murine FAP and human CD26 after 60 min of incubation, n=3. Values are expressed as percentage of applied dose (%ID) per 1 mio cells.

Figure 19: Biodistribution of selected FAPI derivatives in HT-1080-FAP xenotransplants 1, 4 and 24 h after intravenous administration of the radiotracers, n=3. Values are expressed as percentage of injected dose per gram of tissue (%ID/g).

Figure 20: Tumor-to-blood ratio of selected FAPI derivatives in HT-1080-FAP xenotransplants 1, 4 and 24 h after intravenous administration of the radiotracers, n=3.

Figure 21: PET imaging of Ga-68 labeled FAPI-21 and FAPI-46 in HT-1080-FAP tumor bearing mice; n=1.

5 **Figure 22:** Maximum standardized uptake values (SUV) of selected FAPI derivatives in HT-1080-FAP tumor bearing mice; n=1.

Figure 23: Maximum (SUV max, Fig. 23 A) and mean (SUV mean, Fig. 23 B) standardized uptake values of Ga-68 labeled FAPI-02 and FAPI-04 in cancer patients; n=25.

10 **Figure 24:** Intra-individual comparison of 6 patients with 6 different tumor entities undergoing FDG-PET and FAPI-PET imaging within <9 days.

Figure 25: PET/CT imaging of Ga-68 labeled FAPI-04 in patients with peritonitis carcinomatosa (A), myocarditis (B) and hip joint arthrosis (C) 1 h p.i.

Figure 26: PET/CT imaging of Ga-68 labeled FAPI-21 in cancer patients 1 h p.i.

15 **Figure 27:** PET/CT imaging of Ga-68 labeled FAPI-46 1 h p.i. and intratherapeutical imaging of Sm-153 labeled FAPI-46 30 min p.i. in cancer patients.

Figure 28: Intratherapeutical imaging of Sm-153 labeled FAPI-46 up to 20 h p.i.

Figure 29: A. Maximum intensity projection (MIP) 1 h after intravenous administration of ⁶⁸Ga-FAPI-46 to a patient with metastasized colorectal carcinoma. B. Imaging of Bremsstrahlung 2 h after therapeutic treatment with ⁹⁰Y-FAPI-46 of the same patient.

20 **Figure 30:** PET/CT imaging of Ga-68 labeled FAPI-46 1 h p.i. in lung cancer patients with idiopathic lung fibrosis. A, B. Maximum tracer uptake into tumor tissue is significantly higher than into non-exacerbated fibrotic lesions. C. Maximum tracer uptake into tumor tissue is slightly lower than into exacerbated fibrotic tissue.

25 **Figure 31:** A. Binding of Tc-99m labeled FAPI-19 to HT-1080-FAP cells, n=3. B. Competitive binding of Tc-99m labeled FAPI-19 to HT-1080-FAP cells after adding increasing concentrations of unlabeled compound (10^{-10} to 10^{-5} M, incubation for 60 min, n=3). C. Scintigraphy of Tc-99m labeled FAPI-19 in HT-1080-FAP xenotransplants, n=1.

Figure 32: A. Binding of Tc-99m labeled FAPI-34 to HT-1080-FAP cells, n=3. B. Scintigraphy of Tc-99m labeled FAPI-34 in HT-1080-FAP xenotransplants, n=1.

30 **Figure 33:** Scintigraphy of Tc-99m labeled FAPI-34 in one patient with metastasized pancreas carcinoma.

Figure 34: A. Binding of Pb-203 labeled FAPI derivatives to HT-1080-FAP cells, n=3. B. Efflux kinetics of Pb-203 labeled FAPI derivatives after incubation of HT-1080-FAP cells with radiolabeled compound for 60 min and consequent incubation with nonradioactive

medium for 1 to 24 hours, n=3. C. Competitive binding of Pb-203 labeled FAPIs to HT-1080-FAP cells after adding increasing concentrations of unlabeled compound (10^{-10} to 10^{-5} M, incubation for 60 min, n=3).

5 **Figure 35:** Scintigraphy of Pb-203 labeled FAPI-04 and FAPI-46 in HT-1080-FAP xenotransplants, n=1.

Figure 36: Biodistribution of Pb-203 labeled FAPI-04 and FAPI-46 in HT-1080-FAP xenotransplants 1, 4, 6 and 24 h after intravenous administration of the radiotracers, n=3. Values are expressed as percentage of injected dose per gram of tissue (%ID/g).

10 **Figure 37:** A. Binding of Cu-64 labeled FAPI-42 and FAPI-52 to HT-1080-FAP cells, n=3. B. Competitive binding of Cu-64 labeled FAPI-42 and FAPI-52 to HT-1080-FAP cells after adding increasing concentrations of unlabeled compound (10^{-10} to 10^{-5} M, incubation for 60 min, n=3). C. Efflux kinetics of Cu-64 labeled FAPI-42 and FAPI-52 after incubation of HT-1080-FAP cells with radiolabeled compound for 60 min and consequent incubation with nonradioactive medium for 1 to 24 hours, n=3.

15 **Figure 38:** PET imaging of Cu-64 labeled FAPI-42 and FAPI-52 in HT-1080-FAP tumor bearing mice; n=1.

Figure 39: PET imaging of AlF-18 labeled FAPI-42 and FAPI-52 in HT-1080-FAP tumor bearing mice; n=1.

20 **Figure 40:** a. Small animal PET imaging of ^{68}Ga -labeled FAPI-02 in U87MG tumor bearing nude mice up to 140 min after intravenous administration of the radiotracer. The tumor is indicated by the red arrow. b. Biodistribution of ^{177}Lu -labeled FAPI-02 and FAPI-04 in U87MG tumor bearing nude mice 1, 4 and 24 h after intravenous administration of the radiotracers; n=3.

25 **Figure 41:** Tumor-to-organ ratios of ^{177}Lu -labeled FAPI-02 and -04 in U87MG tumor bearing mice 1, 4 and 24 h after intravenous administration.

Figure 42: Maximum intensity projection (MIP) of PET/CT scans in a glioblastoma patient 10 min, 1 and 3 h after administration of ^{68}Ga -FAPI-02.

30 **Figure 43:** Exemplary images (contrast enhanced T1 weighted MRI, FAPI-PET and fused images of both modalities) of IDH wt glioblastomas, IDH-mutant gliomas WHO grade II and IDH-mutant glioblastomas.

Figure 44: Absolute SUVmax values of all 18 gliomas.

Figure 45: Statistical Analysis of SUVmax/BG values. Boxplots of SUVmax/BG values and corresponding ROC curves in GBM versus non-GBM (a, b), IDH-mutant versus IDH wildtype gliomas (c, d) and gliomas grade II versus gliomas grade III/IV (e, f).

Figure 46: Dose-dependent inhibition of enzymatic FAP activity by FAPI-04 and Talabostat. In contrast to Talabostat, a potent DPP4 inhibitor with marginal FAP activity, FAPI-04 demonstrates robust, dose-dependent FAP inhibition.

Figure 47: Reuptake of ^{177}Lu -labeled FAPI-04 and FAPI-46 in HT-1080-FAP cells. Following incubation of the cells with the radiotracers for 60 min at 37°C , the compounds are removed and non-radioactive medium with (+ Comp.) and without unlabeled compound (- Comp.) added and incubated for 10 min to 6 h. Already within the first ten minutes of incubation, renewed uptake of the unlabeled FAPI derivatives occurs, displacing parts of the radiolabeled fraction, which results in significantly lower radioactivity values as compared to pure medium without competitor. After 6 h of incubation, almost complete displacement of the radiolabeled FAPIs has occurred. These findings indicate a continuous reuptake of intact FAP molecules back to the cell membrane upon initial internalization, allowing renewed binding and internalization of FAP ligands.

Figure 48: Organ distribution of ^{177}Lu -labeled FAPI-04 after single and multiple injection in HT-1080-FAP tumor bearing nude mice. Administration of two equal doses of ^{177}Lu -FAPI-04 at intervals of 4 h results in increased overall organ activities, including the tumor, measured 8 and 24 h after the first injection. In contrast, administration of three doses (higher initial dose, lower subsequent doses) reveals no change in the overall organ activities.

Figure 49: Binding of F-18-FAPI derivatives to HT1080 cells expressing human FAP after 10, 30, 60 and 90 min of incubation, $n=3$. Values are expressed as percentage of applied dose (%ID) per 1 mio cells.

Figure 50: PET imaging of AlF-18 labeled FAPI-74 and FAPI-52 in HT-1080-FAP tumor bearing mice; $n=1$.

Figure 51: Biodistribution of FAPI-75 in HT-1080-FAP xenotransplants 1, 4 and 24 h after intravenous administration of the radiotracer, $n=3$. Values are expressed as percentage of injected dose per gram of tissue (%ID/g).

Figure 52: PET imaging of patient with non-small cell lung cancer: Robust accumulation of F18-labeled FAPI-74 in multiple metastases

Figure 53: Time activity curves of the heart region (SUVmean) for FAPI-04 and -46 as illustration of the fast blood pool clearance.

Figure 54: FAPI-02 and FAPI-04 at the different imaging time-point (10 min, 1h and 3h p.i.) in two patients with metastasized breast cancer. Rapid tumor targeting and fast blood clearance is followed by a long plateau phase without relevant change in image contrast (top).

In comparison to FAPI-02 the ligand FAPI-04 is characterized by a prolonged tumor retention time (bottom).

Figure 55: The effective dose of FAPI-02 was 1.80E-02 mSv/MBq calculated with OLINDA (1.82E-02 with IDAC1 / ICRP60, 1.79E-02 with IDAC2 / ICRP103). The effective dose for FAPI-04 PET/CT was 1.64E-02 mSv/MBq calculated with OLINDA (1.66E-02 with IDAC1 / ICRP60, 1.35E-02 with IDAC2 / ICRP103). If the delayed scan at 3h p.i. is omitted in clinical practice, the routine activity for an FAPI-exam could be reduced to 200 MBq ⁶⁸Ga; consecutively the radiation dose of such a FAPI-PET/CT scan would be 3-4 mSv.

Figure 56: A) ⁶⁸Ga-FAPI-04 after 1h post injection in different tumor entities in PET/CT. The highest average SUVmax (>12) were found in sarcoma, esophageal, breast, cholangiocellular carcinoma and lung cancer. The lowest FAPI uptake (average SUVmax <6) was observed in renal cell, differentiated thyroid, adenoid-cystic, gastric carcinoma and pheochromocytoma. The average SUVmax of hepatocellular carcinoma, colorectal carcinoma, head-neck-cancer, ovarial carcinoma, pancreatic carcinoma was intermediate (SUV 6<x<12). Within all tumor entities a high inter-individual variation was observed. Due to low background activity (SUV 2), the tumor-to-background ratios are > 2-fold in the intermediate and > 4-fold in the high intensity uptake group. B) Primary tumour entities presented similar SUV-uptake compared tumour entities using FAPI-04

Figure 57: Exemplary PET images of different tumor entities that have been used for the quantifications shown in figure 56 A-B.

Detailed Descriptions of the Invention

Before the present invention is described in detail below, it is to be understood that this invention is not limited to the particular methodology, protocols and reagents described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

Preferably, the terms used herein are defined as described in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", Leuenberger, H.G.W, Nagel, B. and Klbl, H. eds. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland).

Throughout this specification and the claims, which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be

understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. In the following passages, different aspects of the invention are defined in more detail. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being optional, preferred or advantageous may be combined with any other feature or features indicated as being optional, preferred or advantageous.

Several documents are cited throughout the text of this specification. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions etc.), whether supra or infra, is hereby incorporated by reference in its entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention. Some of the documents cited herein are characterized as being "*incorporated by reference*". In the event of a conflict between the definitions or teachings of such incorporated references and definitions or teachings recited in the present specification, the text of the present specification takes precedence.

In the following, the elements of the present invention will be described. These elements are listed with specific embodiments; however, it should be understood that they may be combined in any manner and in any number to create additional embodiments. The variously described examples and preferred embodiments should not be construed to limit the present invention to only the explicitly described embodiments. This description should be understood to support and encompass embodiments which combine the explicitly described embodiments with any number of the disclosed and/or preferred elements. Furthermore, any permutations and combinations of all described elements in this application should be considered disclosed by the description of the present application unless the context indicates otherwise.

Definitions

In the following, some definitions of terms frequently used in this specification are provided. These terms will, in each instance of its use, in the remainder of the specification have the respectively defined meaning and preferred meanings.

As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents, unless the content clearly dictates otherwise.

In the following definitions of the terms: alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl and alkynyl are provided.

These terms will in each instance of its use in the remainder of the specification have the respectively defined meaning and preferred meanings.

The term "alkyl" refers to a saturated straight or branched carbon chain. Preferably, the chain comprises from 1 to 10 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 e.g. methyl, ethyl
5 methyl, ethyl, propyl, *iso*-propyl, butyl, *iso*-butyl, *tert*-butyl, pentyl, hexyl, pentyl, or octyl. Alkyl groups are optionally substituted.

The term "heteroalkyl" refers to a saturated straight or branched carbon chain. Preferably, the chain comprises from 1 to 9 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 e.g. methyl, ethyl, propyl, *iso*-propyl, butyl, *iso*-butyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, pentyl, octyl,
10 which is interrupted one or more times, e.g. 1, 2, 3, 4, 5, with the same or different heteroatoms. Preferably the heteroatoms are selected from O, S, and N, e.g. -O-CH₃, -S-CH₃, -CH₂-O-CH₃, -CH₂-O-C₂H₅, -CH₂-S-CH₃, -CH₂-S-C₂H₅, -C₂H₄-O-CH₃, -C₂H₄-O-C₂H₅, -C₂H₄-S-CH₃, -C₂H₄-S-C₂H₅ etc. Heteroalkyl groups are optionally substituted.

The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with
15 other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl", respectively, with preferably 3, 4, 5, 6, 7, 8, 9 or 10 atoms forming a ring, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl etc. The terms "cycloalkyl" and "heterocycloalkyl" are also meant to include bicyclic, tricyclic and polycyclic versions thereof. The term "heterocycloalkyl" preferably refers to a saturated ring having five of which at least
20 one member is a N, O or S atom and which optionally contains one additional O or one additional N; a saturated ring having six members of which at least one member is a N, O or S atom and which optionally contains one additional O or one additional N or two additional N atoms; or a saturated bicyclic ring having nine or ten members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms.
25 "Cycloalkyl" and "heterocycloalkyl" groups are optionally substituted. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, spiro[3,3]heptyl, spiro[3,4]octyl, spiro[4,3]octyl, spiro[3,5]nonyl, spiro[5,3]nonyl, spiro[3,6]decyl, spiro[6,3]decyl, spiro[4,5]decyl, spiro[5,4]decyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl,
30 adamantyl, and the like. Examples of heterocycloalkyl include 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, 1,8 diazo-spiro-[4,5] decyl, 1,7 diazo-spiro-[4,5] decyl, 1,6 diazo-spiro-[4,5] decyl, 2,8 diazo-spiro[4,5] decyl, 2,7 diazo-spiro[4,5] decyl, 2,6 diazo-spiro[4,5] decyl, 1,8 diazo-spiro-[5,4] decyl, 1,7 diazo-spiro-

[5,4] decyl, 2,8 diazo-spiro-[5,4] decyl, 2,7 diazo-spiro[5,4] decyl, 3,8 diazo-spiro[5,4] decyl, 3,7 diazo-spiro[5,4] decyl, 1-azo-7,11-dioxo-spiro[5,5] undecyl, 1,4-diazabicyclo[2.2.2]oct-2-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.

5 The term “aryl” preferably refers to an aromatic monocyclic ring containing 6 carbon atoms, an aromatic bicyclic ring system containing 10 carbon atoms or an aromatic tricyclic ring system containing 14 carbon atoms. Examples are phenyl, naphthyl or anthracenyl. The aryl group is optionally substituted.

10 The term “aralkyl” refers to an alkyl moiety, which is substituted by aryl, wherein alkyl and aryl have the meaning as outlined above. An example is the benzyl radical. Preferably, in this context the alkyl chain comprises from 1 to 8 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, or 8, e.g. methyl, ethyl methyl, ethyl, propyl, *iso*-propyl, butyl, *iso*-butyl, *sec*-butenyl, *tert*-butyl, pentyl, hexyl, pentyl, octyl. The aralkyl group is optionally substituted at the alkyl and/or aryl part of the group.

15 The term “heteroaryl” preferably refers to a five or six-membered aromatic monocyclic ring wherein at least one of the carbon atoms are replaced by 1, 2, 3, or 4 (for the five membered ring) or 1, 2, 3, 4, or 5 (for the six membered ring) of the same or different heteroatoms, preferably selected from O, N and S; an aromatic bicyclic ring system wherein 1, 2, 3, 4, 5, or 6 carbon atoms of the 8, 9, 10, 11 or 12 carbon atoms have been replaced with the same or
20 different heteroatoms, preferably selected from O, N and S; or an aromatic tricyclic ring system wherein 1, 2, 3, 4, 5, or 6 carbon atoms of the 13, 14, 15, or 16 carbon atoms have been replaced with the same or different heteroatoms, preferably selected from O, N and S. Examples are oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, 1,2,3-oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, pyridinyl,
25 pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1-benzofuranyl, 2-benzofuranyl, indoyle, isoindoyle, benzothiophenyl, 2-benzothiophenyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, 2,1-benzosoxazolyl, benzothiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, quinolinyl, 1,2,3-benzotriazinyl, or 1,2,4-benzotriazinyl.

30 The term “heteroaralkyl” refers to an alkyl moiety, which is substituted by heteroaryl, wherein alkyl and heteroaryl have the meaning as outlined above. An example is the 2-alkylpyridinyl, 3-alkylpyridinyl, or 2-methylpyridinyl. Preferably, in this context the alkyl chain comprises from 1 to 8 carbon atoms, i.e. 1, 2, 3, 4, 5, 6, 7, or 8, e.g. methyl, ethyl methyl,

ethyl, propyl, *iso*-propyl, butyl, *iso*-butyl, *sec*-butenyl, *tert*-butyl, pentyl, hexyl, pentyl, octyl. The heteroaralkyl group is optionally substituted at the alkyl and/or heteroaryl part of the group.

The terms “alkenyl” and “cycloalkenyl” refer to olefinic unsaturated carbon atoms containing chains or rings with one or more double bonds. Examples are propenyl and cyclohexenyl. Preferably, the alkenyl chain comprises from 2 to 8 carbon atoms, i.e. 2, 3, 4, 5, 6, 7, or 8, e.g. ethenyl, 1-propenyl, 2-propenyl, *iso*-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, *iso*-butenyl, *sec*-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, hexenyl, pentenyl, octenyl. Preferably the cycloalkenyl ring comprises from 3 to 8 carbon atoms, i.e. 3, 4, 5, 6, 7, or 8, e.g. 1-cyclopropenyl, 2-cyclopropenyl, 1-cyclobutenyl, 2-cyclobutenyl, 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, cyclohexenyl, cyclopentenyl, cyclooctenyl.

The term “alkynyl” refers to unsaturated carbon atoms containing chains or rings with one or more triple bonds. An example is the propargyl radical. Preferably, the alkynyl chain comprises from 2 to 8 carbon atoms, i.e. 2, 3, 4, 5, 6, 7, or 8, e.g. ethynyl, 1-propynyl, 2-propynyl, 1-butyne, 2-butyne, 3-butyne, 1-pentyne, 2-pentyne, 3-pentyne, 4-pentyne, hexynyl, pentynyl, octynyl.

In one embodiment, carbon atoms or hydrogen atoms in alkyl, heteroalkyl, cycloalkyl, aryl, aralkyl, alkenyl, cycloalkenyl, alkynyl radicals may be substituted independently from each other with one or more elements selected from the group consisting of O, S, N or with groups containing one or more elements selected from the group consisting of O, S, N.

Embodiments include alkoxy, cycloalkoxy, aryloxy, aralkoxy, alkenyloxy, cycloalkenyloxy, alkynyloxy, alkylthio, cycloalkylthio, arylthio, aralkylthio, alkenylthio, cycloalkenylthio, alkynylthio, alkylamino, cycloalkylamino, arylamino, aralkylamino, alkenylamino, cycloalkenylamino, alkynylamino radicals.

Other embodiments include hydroxyalkyl, hydroxycycloalkyl, hydroxyaryl, hydroxyaralkyl, hydroxyalkenyl, hydroxycycloalkenyl, hydroxyalanyl, mercaptoalkyl, mercaptocycloalkyl, mercaptoaryl, mercaptoaralkyl, mercaptoalkenyl, mercaptocycloalkenyl, mercaptoalkynyl, aminoalkyl, aminocycloalkyl, aminoaryl, aminoaralkyl, aminoalkenyl, aminocycloalkenyl, aminoalkynyl radicals.

In another embodiment, hydrogen atoms in alkyl, heteroalkyl, cycloalkyl, aryl, aralkyl, alkenyl, cycloalkenyl, alkynyl radicals may be substituted independently from each other with one or more halogen atoms. One radical is the trifluoromethyl radical.

If two or more radicals or two or more residues can be selected independently from each other, then the term “independently” means that the radicals or the residues may be the same or may be different.

As used herein a wording defining the limits of a range of length such as, e. g., “from 1 to 6” means any integer from 1 to 6, i. e. 1, 2, 3, 4, 5 and 6. In other words, any range defined by two integers explicitly mentioned is meant to comprise and disclose any integer defining said limits and any integer comprised in said range.

5 The term “halo” as used herein refers to a halogen residue selected from the group consisting of F, Br, I and Cl. Preferably, the halogen is F.

The term “linker” as used herein refers to any chemically suitable linker. Preferably, linker are not or only slowly cleaved under physiological conditions. Thus, it is preferred that the linker does not comprise recognition sequences for proteases or recognition structures for
10 other degrading enzymes. Since it is preferred that the compounds of the invention are administered systemically to allow broad access to all compartments of the body and subsequently enrichment of the compounds of the invention wherever in the body the tumor is located, it is preferred that the linker is chosen in such that it is not or only slowly cleaved in blood. The cleavage is considered slowly, if less than 50% of the linkers are cleaved 2 h after
15 administration of the compound to a human patient. Suitable linkers, for example, comprises or consists of optionally substituted alkyl, heteroalkyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, sulfonyl, amines, ethers, thioethers phosphines, phosphoramidates, carboxamides, esters, imidoesters, amidines, thioesters, sulfonamides, 3-thiopyrrolidine-2,5-dion, carbamates,
20 ureas, guanidines, thioureas, disulfides, oximes, hydrazines, hydrazides, hydrazones, diaza bonds, triazoles, triazolines, tetrazines, platinum complexes and amino acids, or combinations thereof. Preferably, the linker comprises or consists of 1,4-piperazine, 1,3-propane and a phenolic ether or combinations thereof.

The expression “optionally substituted” refers to a group in which one, two, three or
25 more hydrogen atoms may have been replaced independently of each other by the respective substituents.

As used herein, the term "amino acid" refers to any organic acid containing one or more amino substituents, e.g. α -, β - or γ -amino, derivatives of aliphatic carboxylic acids. In the polypeptide notation used herein, e.g. Xaa5, i.e. Xaa1Xaa2Xaa3Xaa4Xaa5, wherein Xaa1 to
30 Xaa5 are each and independently selected from amino acids as defined, the left hand direction is the amino terminal direction and the right hand direction is the carboxy terminal direction, in accordance with standard usage and convention.

The term "conventional amino acid" refers to the twenty naturally occurring amino acids, and encompasses all stereomeric isoforms, i.e. D,L-, D- and L-amino acids thereof. These

conventional amino acids can herein also be referred to by their conventional three- letter or one-letter abbreviations and their abbreviations follow conventional usage (see, for example, Immunology—A Synthesis, 2nd Edition, E. S. Golub and D. R. Gren, Eds., Sinauer Associates, Sunderland Mass. (1991)).

5 The term "non-conventional amino acid" refers to unnatural amino acids or chemical amino acid analogues, e.g. α,α -disubstituted amino acids, N-alkyl amino acids, homo-amino acids, dehydroamino acids, aromatic amino acids (other than phenylalanine, tyrosine and tryptophan), and ortho-, meta- or para-aminobenzoic acid. Non-conventional amino acids also include compounds which have an amine and carboxyl functional group separated in a 1,3 or
10 larger substitution pattern, such as β -alanine, γ -amino butyric acid, Freidinger lactam, the bicyclic dipeptide (BTD) , amino-methyl benzoic acid and others well known in the art. Statine-like isosteres, hydroxyethylene isosteres, reduced amide bond isosteres, thioamide isosteres, urea isosteres, carbamate isosteres, thioether isosteres, vinyl isosteres and other amide bond isosteres known to the art may also be used. The use of analogues or non-conventional amino
15 acids may improve the stability and biological half-life of the added peptide since they are more resistant to breakdown under physiological conditions. The person skilled in the art will be aware of similar types of substitution which may be made. A non-limiting list of non-conventional amino acids which may be used as suitable building blocks for a peptide and their standard abbreviations (in brackets) is as follows: α -aminobutyric acid (Abu), L-N-methylalanine (Nmala), α -amino- α -methylbutyrate (Mgab), L-N-methylarginine (Nmarg), aminocyclopropane (Cpro), L-N-methylasparagine (Nmasn), carboxylate L-N-methylaspartic
20 acid (Nmasp), aninoisobutyric acid (Aib), L-N-methylcysteine (Nmcs), aminonorbornyl (Norb), L-N-methylglutamine (Nmgl), carboxylate L-N-methylglutamic acid (Nmglu), cyclohexylalanine (Chexa), L-N-methylhistidine (Nmhis), cyclopentylalanine (Cpen), L-N-methylisoleucine (Nmile), L-N-methylleucine (Nmleu), L-N-methyllysine (Nmlys), L-N-methylmethionine (Nmmt), L-N-methylnorleucine (Nmnl), L-N-methylnorvaline (Nmna), L-N-methylornithine (Nmorn), L-N-methylphenylalanine (Nmphe), L-N-methylproline (Nmpro), L-N-methylserine (Nmser), L-N-methylthreonine (Nmthr), L-N-methyltryptophan (Nmtrp), D-ornithine (Dorn), L-N-methyltyrosine (Nmtyr), L-N-methylvaline (Nmval), L-N-methylethylglycine (Nmetg), L-N-methyl-t-butylglycine (Nmtbug), L-norleucine (Nle), L-norvaline (Nva), α -methyl-aminoisobutyrate (Maib), α -methyl- γ -aminobutyrate (Mgab), D- α -methylalanine (Dmala), α -methylcyclohexylalanine (Mchexa), D- α -methylarginine (Dmarg), α -methylcyclopentylalanine (Mcp), D- α -methylasparagine (Dmasn), α -methyl- α -naphthylalanine (Manap), D- α -methylaspartate (Dmasp), α -methylpenicillamine (Mpen), D- α -

methylcysteine (Dmcys), N-(4-aminobutyl)glycine (Nglu), D- α -methylglutamine (Dmgln), N-(2-aminoethyl)glycine (Naeg), D- α -methylhistidine (Dmhis), N-(3-aminopropyl)glycine (Norn), D- α -methylisoleucine (Dmile), N-amino- α -methylbutyrate (Nmaabu), D- α -methylleucine (Dmleu), α -naphthylalanine (Anap), D- α -methyllysine (Dmlys), N-benzylglycine (Nphe), D- α -methylmethionine (Dmmet), N-(2-carbamylethyl)glycine (Ngln), D- α -methylornithine (Dmorn), N-(carbamylmethyl)glycine (Nasn), D- α -methylphenylalanine (Dmphe), N-(2-carboxyethyl)glycine (Nglu), D- α -methylproline (Dmpro), N-(carboxymethyl)glycine (Nasp), D- α -methylserine (Dmser), N-cyclobutylglycine (Ncbut), D- α -methylthreonine (Dmthr), N-cycloheptyl glycerine (Nchep), D- α -methyltryptophan (Dmtrp), N-cyclohexylglycine (Nchex), D- α -methyltyrosine (Dmty), N-cyclodecylglycine (Ncdec), D- α -methylvaline (Dmval), N-cyclododecylglycine (Ncdod), D-N-methylalanine (Dnmala), N-cyclooctylglycine (Ncoct), D-N-methylarginine (Dnmarg), N-cyclopropylglycine (Ncpro), D-N-methylasparagine (Dnmasn), N-cycloundecylglycine (Ncund), D-N-methylaspartate (Dnmasp), N-(2,2-diphenylethyl)glycine (Nbhm), D-N-methylcysteine (Dnmcys), N-(3,3-diphenylpropyl)glycine (Nbhe), D-N-methylglutamine (Dnmgln), N-(3-guanidinopropyl)glycine (Narg), D-N-methylglutamate (Dnmglu), N-(1-hydroxyethyl)glycine (Ntbx), D-N-methylhistidine (Dnmhis), N-(hydroxyethyl)glycine (Nser), D-N-methylisoleucine (Dnmile), N-(imidazolylethyl)glycine (Nhis), D-N-methylleucine (Dnmleu), N-(3-indolylyethyl)glycine (Nhtrp), D-N-methyllysine (Dnnilys), N-methyl- γ -aminobutyrate (Nmgabu), N-methylcyclohexylalanine (Nmchexa), D-N-methylmethionine (Dnmmet), D-N-methylornithine (Dnmorn), N-methylcyclopentylalanine (Nmcpen), N-methylglycine (NaIa), D-N-methylphenylalanine (Dnmphe), N-methylaminoisobutyrate (Nmaib), D-N-methylproline (Dnmpro), N-(1-methylpropyl)glycine (Nile), D-N-methylserine (Dnmser), N-(2-methylpropyl)glycine (Nleu), D-N-methylthreonine (Dnmthr), D-N-methyltryptophan (Dnmtrp), N-(1-methylethyl)glycine (Nval), D-N-methyltyrosine (Dnmtyr), N-methyl- α -naphthylalanine (Nmanap), D-N-methylvaline (Dnmval), N-methylpenicillamine (Nmpen), γ -aminobutyric acid (Gabu), N-(p-hydroxyphenyl)glycine (Nhtyr), L-/butylglycine (Tbug), N-(thiomethyl)glycine (Ncys), L-ethylglycine (Etg), penicillamine (Pen), L-homophenylalanine (Hphe), L- α -methylalanine (Mala), L- α -methylarginine (Marg), L- α -methylasparagine (Masn), L- α -methylaspartate (Masp), L- α -methyl-t-butylglycine (Mtbug), L- α -methylcysteine (Mcsys), L-methylethylglycine (Metg), L- α -methylglutamine (Mgln), L- α -methylglutamate (Mglu), L- α -methylhistidine (Mhis), L- α -methylhomophenylalanine (Mhphe), L- α -methylisoleucine (Mile), N-(2-methylthioethyl)glycine (Nmet), L- α -methylleucine (Mleu), L- α -methyllysine (Mlys), L- α -

methylmethionine (Mmet), L- α -methylnorleucine (Mnle), L- α -methylnorvaline (Mnva), L- α -methylornithine (Morn), L- α -methylphenylalanine (Mphe), L- α -methylproline (Mpro), L- α -methylserine (Mser), L- α -methylthreonine (Mthr), L- α -methyltryptophan (Mtrp), L- α -methyltyrosine (Mtyr), L- α -methylvaline (Mval), L-N-methylhomophenylalanine (Nmhphe),
5 N-(N-(2,2-diphenylethyl)carbonylmethyl)glycine (Nnbhm), N-(N-(3,3-diphenylpropyl)-
carbonylmethyl)glycine (Nnbhe), 1-carboxy-1-(2,2-diphenyl-ethylamino)cyclopropane
(Nmhc), L-O-methyl serine (Omsr), L-O-methyl homoserine (Omhsr).

The term “N-containing aromatic or non-aromatic mono or bicyclic heterocycle” as
used herein refers to a cyclic saturated or unsaturated hydrocarbon compound which contains
10 at least one nitrogen atom as constituent of the cyclic chain.

The term “radioactive moiety” as used herein refers to a molecular assembly which
carries a radioactive nuclide. The nuclide is bound either by covalent or coordinate bonds which
remain stable under physiological conditions. Examples are [¹³¹I]-3-iodobenzoic acid or ⁶⁸Ga-
DOTA.

15 A “fluorescent isotope” as used herein emits electromagnetic radiation after excitation
by electromagnetic radiation of a shorter wavelength.

A “radioisotope” as used herein is a radioactive isotope of an element (included by the
term “radionuclide”) emitting α -, β -, and/or γ -radioation.

The term “radioactive drug” is used in the context of the present invention to refer to a
20 biologic active compound which is modified by a radioisotope. Especially intercalating
substances can be used to deliver the radioactivity to direct proximity of DNA (e.g. a ¹³¹I-
carrying derivative of Hoechst-33258).

The term “chelating agent” or “chelate” are used interchangeably in the context of the
present invention and refer to a molecule, often an organic one, and often a Lewis base, having
25 two or more unshared electron pairs available for donation to a metal ion. The metal ion is
usually coordinated by two or more electron pairs to the chelating agent. The terms, “bidentate
chelating agent”, “tridentate chelating agent, and “tetradentate chelating agent” refer to
chelating agents having, respectively, two, three, and four electron pairs readily available for
simultaneous donation to a metal ion coordinated by the chelating agent. Usually, the electron
30 pairs of a chelating agent forms coordinate bonds with a single metal ion; however, in certain
examples, a chelating agent may form coordinate bonds with more than one metal ion, with a
variety of binding modes being possible.

The term “fluorescent dye” is used in the context of the present invention to refer to a
compound that emits visible or infrared light after excitation by electromagnetic radiation of a

shorter and suitable wavelength. It is understood by the skilled person, that each fluorescent dye has a predetermined excitation wavelength.

The term "contrast agent" is used in the context of the present invention to refer to a compound which increases the contrast of structures or fluids in medical imaging. The enhancement is achieved by absorbing electromagnetic radiation or altering electromagnetic fields.

The term "paramagnetic" as used herein refers to paramagnetism induced by unpaired electrons in a medium. A paramagnetic substance induces a magnetic field if an external magnetic field is applied. Unlike diamagnetism the direction of the induced field is the same as the external field and unlike ferromagnetism the field is not maintained in absence of an external field.

The term "nanoparticle" as used herein refers to particles preferably of spheric shape, with diameters of sizes between 1 and 100 nanometers. Depending on the composition, nanoparticles can possess magnetical, optical or physico-chemical qualities that can be assessed. Additionally surface modification is achievable for many types of nanoparticles.

The term "pharmaceutically acceptable salt" refers to a salt of the compound of the present invention. Suitable pharmaceutically acceptable salts of the compound of the present invention include acid addition salts which may, for example, be formed by mixing a solution of choline or derivative thereof with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compound of the invention carries an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts (e.g., sodium or potassium salts); alkaline earth metal salts (e.g., calcium or magnesium salts); and salts formed with suitable organic ligands (e.g., ammonium, quaternary ammonium and amine cations formed using counteranions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl sulfonate and aryl sulfonate). Illustrative examples of pharmaceutically acceptable salts include but are not limited to: acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium edetate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, citrate, clavulanate, cyclopentanepropionate, digluconate, dihydrochloride, dodecylsulfate, edetate, edisylate, estolate, esylate, ethanesulfonate, formate, fumarate, gluceptate, glucoheptonate, gluconate, glutamate, glycerophosphate, glycolylarsanilate, hemisulfate, heptanoate, hexanoate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, hydroxynaphthoate,

iodide, isothionate, lactate, lactobionate, laurate, lauryl sulfate, malate, maleate, malonate, mandelate, mesylate, methanesulfonate, methylsulfate, mucate, 2-naphthalenesulfonate, napsylate, nicotinate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, pectinate, persulfate, 3-phenylpropionate, phosphate/diphosphate, picrate, pivalate, polygalacturonate, propionate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, undecanoate, valerate, and the like (see, for example, Berge, S. M., et al, "Pharmaceutical Salts", *Journal of Pharmaceutical Science*, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.

In addition to salt forms, the present invention provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide a compound of formula (I). A prodrug is an active or inactive compound that is modified chemically through *in vivo* physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a patient. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an *ex vivo* environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme. The suitability and techniques involved in making and using prodrugs are well known by those skilled in the art. For a general discussion of prodrugs involving esters see Svensson and Tunek *Drug Metabolism Reviews* 16.5 (1988) and Bundgaard *Design of Prodrugs*, Elsevier (1985). Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl). Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases *in vivo* releasing the free drug and formaldehyde (Bunggaard *J. Med. Chem.* 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard *Design of Prodrugs*, Elsevier (1985)).

Hydroxyl groups have been masked as esters and ethers. EP 0 039 051 (Sloan and Little, Apr. 11, 1981) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.

Compounds according to the invention can be synthesized according to one or more of the following methods. It should be noted that the general procedures are shown as it relates to preparation of compounds having unspecified stereochemistry. However, such procedures are generally applicable to those compounds of a specific stereochemistry, e.g., where the stereochemistry about a group is (S) or (R). In addition, the compounds having one stereochemistry (e.g., (R)) can often be utilized to produce those having opposite stereochemistry (i.e., (S)) using well-known methods, for example, by inversion.

Certain compounds of the present invention can exist in unsolvated forms as well as in solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.

The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (^3H), iodine-125 (^{125}I) or carbon-14 (^{14}C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

The term "pharmaceutical composition" as used in the present application refers to a substance and/or a combination of substances being used for the identification, prevention or treatment of a tissue status or disease. The pharmaceutical composition is formulated to be suitable for administration to a patient in order to prevent and/or treat disease. Further a pharmaceutical composition refers to the combination of an active agent with a carrier, inert or active, making the composition suitable for therapeutic use. Pharmaceutical compositions can be formulated for oral, parenteral, topical, inhalative, rectal, sublingual, transdermal, subcutaneous or vaginal application routes according to their chemical and physical properties. Pharmaceutical compositions comprise solid, semisolid, liquid, transdermal therapeutic systems (TTS). Solid compositions are selected from the group consisting of tablets, coated

tablets, powder, granulate, pellets, capsules, effervescent tablets or transdermal therapeutic systems. Also comprised are liquid compositions, selected from the group consisting of solutions, syrups, infusions, extracts, solutions for intravenous application, solutions for infusion or solutions of the carrier systems of the present invention. Semisolid compositions
5 that can be used in the context of the invention comprise emulsion, suspension, creams, lotions, gels, globules, buccal tablets and suppositories.

“Pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.


10 The term “carrier”, as used herein, refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic agent is administered. Such pharmaceutical carriers can be sterile liquids, such as saline solutions in water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. A saline solution is a preferred carrier when the pharmaceutical composition is
15 administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also
20 contain minor amounts of wetting or emulsifying agents, or pH buffering agents. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin.

The term “fibroblast activation protein (FAP)” as used herein is also known under the term “seprase”. Both terms can be used interchangeably herein. Fibroblast activation protein is
25 a homodimeric integral protein with dipeptidyl peptidase IV (DPPIV)-like fold, featuring an alpha/beta-hydrolase domain and an eight-bladed beta-propeller domain.

Embodiments

In the following different aspects of the invention are defined in more detail. Each aspect
30 so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.

In a first aspect, the present invention provides a compound of Formula (I)



wherein

Q, R, U, V, W, Y, Z are individually present or absent under the proviso that at least three of Q, R, U, V, W, Y, Z are present;

- 5 Q, R, U, V, W, Y, Z are independently selected from the group consisting of O, CH₂, NR⁴, C=O, C=S, C=NR⁴, HCR⁴ and R⁴CR⁴, with the proviso that two Os are not directly adjacent to each other; preferably out of the six four groups are present of which two are C=O, one is CH₂ and one is NH; more preferably four groups are present of which two are C=O, one is CH₂ and one is NH; most preferably, V, W, Y and Z are present of which V and Z are C=O and W and
- 10 Y are independently selected from CH₂ and NH;


R¹ and R² are independently selected from the group consisting of -H, -OH, halo, C₁₋₆-alkyl, -O-C₁₋₆-alkyl, S-C₁₋₆-alkyl;

R³ is selected from the group consisting of -H, -CN, -B(OH)₂, -C(O)-alkyl, -C(O)-aryl-, -C=C-C(O)-aryl, -C=C-S(O)₂-aryl, -CO₂H, -SO₃H, -SO₂NH₂, -PO₃H₂, and 5-tetrazolyl;

- 15 R⁴ is selected from the group consisting of -H, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl, and -C₁₋₆-aralkyl, each of said -C₁₋₆-alkyl being optionally substituted with from 1 to 3 substituents selected from -OH, oxo, halo and optionally connected to Q, R, U, V, W, Y or Z;

R⁵ is selected from the group consisting of -H, halo and C₁₋₆-alkyl;

- 20 R⁶, and R⁷ are independently selected from the group consisting of -H,



under the proviso that R⁶ and R⁷ are not at the same time H, preferably R⁶ is attached to the 7- or 8-quinolyl position and R⁷ is attached to the 5- or 6-quinolyl position; more preferably R⁶ is attached to the 7-quinolyl position and R⁷ is attached to the 6-quinolyl position,


- 25 wherein L is a linker,

wherein D, A, E, and B are individually present or absent, preferably wherein at least A, E, and B are present, wherein when present:

D is a linker;

A is selected from the group consisting of NR⁴, O, S, and CH₂;

- 30 E is selected from the group consisting of



wherein i is 1, 2, or 3;


wherein j is 1, 2, or 3;

5 wherein k is 1, 2, or 3;

wherein m is 1, 2, or 3;


more preferably, E is C₁₋₆-alkyl, most preferably, E is C3 or C4 alkyl;

A and E together form a group selected from: a cycloalkyl, heterocycloalkyl, aryl and heteroaryl, preferably heterocycloalkyl, wherein A and E can be mono-, bi- and multicyclic,
 10 preferably monocyclic. Each A and E being optionally substituted with 1 to 4 substituents selected from -H, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl, and -C₁₋₆-aralkyl, each of said -C₁₋₆-alkyl being optionally substituted with from 1 to 3 substituents selected from -OH, oxo, halo; and optionally connected

to A, B, D, E or  ;

15 B is selected from the group consisting of S, NR⁴, NR⁴-O, NR⁴-C₁₋₆-alkyl, NR⁴-C₁₋₆-alkyl-NR⁴, and a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein NR⁴-C₁₋₆-alkyl-NR⁴ and the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C₁₋₆-alkyl,
 20 aryl, C₁₋₆-aralkyl; and

R⁸ is selected from the group consisting of radioactive moiety, chelating agent, fluorescent dye, a contrast agent and combinations thereof;




is a 1-naphthyl moiety or a 5 to 10- membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, wherein there are 2 ring atoms between the N atom and X; said heterocycle optionally further comprising 1, 2 or 3 heteroatoms selected from O, N and S; and X is a C atom;

25

or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate, or salt thereof. Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.

In a preferred embodiment, A and E together form a group selected from the group consisting of a C₃, C₄, C₅, C₆, C₇ and C₈ monocyclic, preferably C₅ or C₆ monocyclic, or C₇, C₈, C₉, C₁₀, C₁₁ or C₁₂ bicyclic, preferably C₇, C₈, C₉ and C₁₀ bicyclic heterocycloalkyl, comprising 1, 2, 3, or 4, preferably 1 or 2 heteroatoms independently selected from the group consisting of N, O and S, preferably N and O, most preferably 1 or 2 N.

In a preferred embodiment of the first aspect of the present invention a compound of Formula (I) is provided:



wherein

Q, R, U, V, W, Y, Z are individually present or absent under the proviso that at least three of Q, R, U, V, W, Y, Z are present;

Q, R, U, V, W, Y, Z are independently selected from the group consisting of O, CH₂, NR⁴, C=O, C=S, C=NR⁴, HCR⁴ and R⁴CR⁴, with the proviso that two Os are not directly adjacent to each other; preferably out of the six four groups are present of which two are C=O, one is CH₂ and one is NH; more preferably four groups are present of which two are C=O, one is CH₂ and one is NH; most preferably, V, W, Y and Z are present of which V and Z are C=O and W and Y are independently selected from CH₂ and NH;


R¹ and R² are independently selected from the group consisting of -H, -OH, halo, C₁₋₆-alkyl, -O-C₁₋₆-alkyl, S-C₁₋₆-alkyl;

R³ is selected from the group consisting of -H, -CN, -B(OH)₂, -C(O)-alkyl, -C(O)-aryl-, -C=C-C(O)-aryl, -C=C-S(O)₂-aryl, -CO₂H, -SO₃H, -SO₂NH₂, -PO₃H₂, and 5-tetrazolyl;

R⁴ is selected from the group consisting of -H, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl, and -C₁₋₆-aralkyl, each of said -C₁₋₆-alkyl being optionally substituted with from 1 to 3 substituents selected from -OH, oxo, halo and optionally connected to Q, R, U, V, W, Y or Z;

R⁵ is selected from the group consisting of -H, halo and C₁₋₆-alkyl;

R⁶, and R⁷ are independently selected from the group consisting of -H,



, under the proviso that R^6 and R^7 are not at the same time H, preferably R^6 is attached to the 7- or 8-quinolyl position and R^7 is attached to the 5- or 6-quinolyl position; more preferably R^6 is attached to the 7-quinolyl position and R^7 is attached to the 6-quinolyl position,


5 wherein L is a linker,

wherein D, A, E, and B are individually present or absent, preferably wherein at least A, E, and B are present, wherein when present:

D is a linker;

A is selected from the group consisting of NR^4 , O, S, and CH_2 ;

10 E is selected from the group consisting of



wherein i is 1, 2, or 3;

wherein j is 1, 2, or 3;

15 wherein k is 1, 2, or 3;

wherein m is 1, 2, or 3;


more preferably, E is C_{1-6} -alkyl, most preferably, E is C3 or C4 alkyl;

B is selected from the group consisting of S, NR^4 , NR^4-O , NR^4-C_{1-6} -alkyl, NR^4-C_{1-6} -alkyl- NR^4 , and a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle,

20 preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein NR^4-C_{1-6} -alkyl- NR^4 and the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C_{1-6} -alkyl, aryl, C_{1-6} -aralkyl; and

R^8 is selected from the group consisting of radioactive moiety, chelating agent, fluorescent dye,

25 a contrast agent and combinations thereof;




is a 1-naphthyl moiety or a 5 to 10- membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, wherein there are 2 ring atoms between the N atom and X; said heterocycle optionally further comprising 1, 2 or 3 heteroatoms selected from O, N and S; and X is a C atom;

5 or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate, or salt thereof. Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.

In another preferred embodiment of the first aspect of the present invention A and E together form a group consisting of a C₃, C₄, C₅, C₆, C₇ and C₈ monocyclic, preferably C₅ or C₆ 10 monocyclic, or C₇, C₈, C₉, C₁₀, C₁₁ or C₁₂ bicyclic, preferably C₇, C₈, C₉ and C₁₀ bicyclic heterocycloalkyl, preferably comprising 1, 2, 3, or 4, more preferably 1 or 2 heteroatoms independently selected from the group consisting of N, O and S, preferably N and O, most preferably 1 or 2 N. Preferred monocyclic heterocycloalkyls are selected from the group consisting of pyrrolidinyl, piperidinyl, imidazolidinyl, 1,2-diazacyclohexanyl, 1,3- 15 diazacyclohexanyl, piperazinyl, 1-oxo-2-azacyclohexanyl, 1-oxo-3-azacyclohexanyl, or morpholinyl, preferably piperidinyl, piperazinyl, and pyrrolidinyl. Preferred bicyclic heterocycloalkyls are selected from the group consisting of bicyclo[2.2.1] 2,5-diazaheptanyl, 3,6-diazabicyclo[3.2.1]octanyl, 3,6-diazabicyclo[3.2.2]nonyl, octahydropyrrolo[2,3-b]pyrrolyl, octahydropyrrolo[3,2-b]pyrrolyl, octahydropyrrolo[3,4-b]pyrrolyl, 20 octahydropyrrolo[3,4-c]pyrrolyl, 9-methyl-3,7,9-triazabicyclo[3.3.1]nonanyl.

The bond between the heterocycle formed by A and E and B on one hand and/or R⁶ or R⁷ on the other is preferably through the heteroatom, preferably through N.

Particularly, preferred examples of the heterocycle formed by A and E are selected from the group consisting of



In a preferred embodiment of the first aspect of the present invention,

Q, R, U are CH₂ and are individually present or absent; preferably, Q and R are absent;

V is CH₂, C=O, C=S or C=NR⁴; preferably, V is C=O;

30 W is NR⁴; preferably, W is NH;

Y is HCR⁴; preferably, Y is CH₂; and
Z is C=O, C=S or C=NR⁴, preferably, Z is C=O.

In a further preferred embodiment of the first aspect of the present invention,

Q, R, U are absent;

- 5 V is CH₂;
W is NH;
Y is CH₂; and
Z is C=O.

In a further preferred embodiment of the first aspect of the present invention,

- 10 R¹ and R² are independently selected from the group consisting of -H and halo; preferably, R¹ and R² are halo; more preferably, R¹ and R² are F;
R³ is selected from the group consisting of -H, -CN, and -B(OH)₂; preferably, R³ is -CN or -B(OH)₂; more preferably, R³ is -CN;
R⁴ is selected from the group consisting of -H and -C₁₋₆-alkyl, wherein the -C₁₋₆-alkyl is
15 optionally substituted with from 1 to 3 substituents selected from -OH. Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.

In a further preferred embodiment of the first aspect of the present invention,

Q, R, U are absent;

- 20 V is CH₂;
W is NH;
Y is CH₂;
Z is C=O;
R¹ and R² are independently selected from the group consisting of -H and halo; preferably, R¹
25 and R² are halo; more preferably, R¹ and R² are F;
R³ is selected from the group consisting of -H, -CN, and -B(OH)₂; preferably, R³ is -CN or -B(OH)₂; more preferably, R³ is -CN;
R⁴ is selected from the group consisting of -H and -C₁₋₆-alkyl, wherein the -C₁₋₆-alkyl is
optionally substituted with from 1 to 3 substituents selected from -OH. Preferably, C₁₋₆-alkyl
30 is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.

In a further preferred embodiment of the first aspect of the present invention,

Q, R, U are absent;

V is CH₂;

W is CH₂;

Y is NH;


Z is C=O;

R¹ and R² are independently selected from the group consisting of -H and halo; preferably, R¹ and R² are halo; more preferably, R¹ and R² are F;

R³ is selected from the group consisting of -H, -CN, and -B(OH)₂; preferably, R³ is -CN or -B(OH)₂; more preferably, R³ is -CN;


R⁴ is selected from the group consisting of -H and -C₁₋₆-alkyl, wherein the -C₁₋₆-alkyl is optionally substituted with from 1 to 3 substituents selected from -OH. Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.

In a further preferred embodiment of the first aspect of the present invention,




optionally further comprising 1 or 2 heteroatoms selected from O, N, and S.

In a further preferred embodiment of the first aspect of the present invention,




20

In a further preferred embodiment of the first aspect of the present invention,



is selected from the group consisting of




5

R^6 , and R^7 are independently selected from the group consisting of $-H$, R^8 and L


and , under the proviso that R^6 and R^7 are not at the same time H and preferably R^6 and R^7 are attached on positions 5, 6 or 7.

10 In a preferred embodiment, is selected from the group consisting of



and

In another preferred embodiment




In a further preferred embodiment of the first aspect of the present invention, R^5 and R^6 are H;

R^7 is $R^8-D-B-E-A$, preferably R^7 is attached to the 5- or 6-quinolyl position; more preferably R^7 is attached to the 6-quinolyl position, wherein

D is absent;



A is O, S, CH_2 , NH, NCH_3 ;



E is C_{1-6} -alkyl or C_3 -alkyl, wherein m is 1, 2, or 3; Preferably, C_{1-6} -alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl; more preferably, E is C_{1-6} -alkyl, most preferably, E is C_3 or C_4 alkyl;

or

A and E together form a group selected from:




B is NR^4-C_{1-6} -alkyl or a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C_{1-6} -alkyl, aryl, C_{1-6} -aralkyl. Preferably, C_{1-6} -alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.


In a further preferred embodiment of the first aspect of the present invention, R^5 and R^6 are H;

R^7 is $R^8-D-B-E-A$, preferably R^7 is attached to the 5- or 6-quinolyl position; more preferably R^7 is attached to the 6-quinolyl position, wherein

D is absent;

A is O;




E is C₁₋₆-alkyl or , wherein m is 1, 2, or 3; Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl; more preferably, E is C₁₋₆-alkyl, most preferably, E is C₃ or C₄ alkyl;

- 5 B is NR⁴-C₁₋₆-alkyl or a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C₁₋₆-alkyl, aryl, C₁₋₆-aralkyl. Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.
- 10


In a further preferred embodiment of the first aspect of the present invention,


R⁵ and R⁶ are H;

R⁷ is , preferably R⁷ is attached to the 5- or 6-quinolyl position; more preferably R⁷ is attached to the 6-quinolyl position, wherein

- 15 D is absent;

A is S;




E is C₁₋₆-alkyl or , wherein m is 1, 2, or 3; Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl; more preferably, E is C₁₋₆-alkyl, most preferably, E is C₃ or C₄ alkyl;

- 20 B is NR⁴-C₁₋₆-alkyl or a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C₁₋₆-alkyl, aryl, C₁₋₆-aralkyl. Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.
- 25


In a further preferred embodiment of the first aspect of the present invention,


R⁵ and R⁶ are H;

R⁷ is , preferably R⁷ is attached to the 5- or 6-quinolyl position; more preferably R⁷ is attached to the 6-quinolyl position, wherein

D is absent;

A is CH₂;




E is C₁₋₆-alkyl or , wherein m is 1, 2, or 3; Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl; more preferably, E is C₁₋₆-alkyl, most preferably, E is C3 or C4 alkyl;

5 B is NR⁴-C₁₋₆-alkyl or a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C₁₋₆-alkyl, aryl, C₁₋₆-aralkyl. Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.


In a further preferred embodiment of the first aspect of the present invention,


R⁵ and R⁶ are H;

R⁷ is , preferably R⁷ is attached to the 5- or 6-quinolyl position; more preferably R⁷ is attached to the 6-quinolyl position, wherein

D is absent;

A is NH;





E is C₁₋₆-alkyl or , wherein m is 1, 2, or 3; Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl; more preferably, E is C₁₋₆-alkyl, most preferably, E is C3 or C4 alkyl;

20 B is NR⁴-C₁₋₆-alkyl or a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C₁₋₆-alkyl, aryl, C₁₋₆-aralkyl. Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.

In a further preferred embodiment of the first aspect of the present invention,

R⁵ and R⁶ are H;


R^7 is , preferably R^7 is attached to the 5- or 6-quinolyl position; more preferably R^7 is attached to the 6-quinolyl position, wherein D is an amino acid, preferably carrying a charged side chain; A is O;


5 E is C₁₋₆-alkyl or , wherein m is 1, 2, or 3; Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl; more preferably, E is C₁₋₆-alkyl, most preferably, E is C3 or C4 alkyl; B is NR⁴-C₁₋₆-alkyl or a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and

10 S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C₁₋₆-alkyl, aryl, C₁₋₆-aralkyl. Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.

In a further preferred embodiment of the first aspect of the present invention,

15 R⁵ and R⁶ are H;


R^7 is , preferably R^7 is attached to the 5- or 6-quinolyl position; more preferably R^7 is attached to the 6-quinolyl position, wherein D is an amino acid, preferably carrying a charged side chain; A is S;

20 E is C₁₋₆-alkyl or , wherein m is 1, 2, or 3; Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl; more preferably, E is C₁₋₆-alkyl, most preferably, E is C3 or C4 alkyl; B is NR⁴-C₁₋₆-alkyl or a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and

25 S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C₁₋₆-alkyl, aryl, C₁₋₆-aralkyl. Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.


In a further preferred embodiment of the first aspect of the present invention,


R⁵ and R⁶ are H;

R⁷ is , preferably R⁷ is attached to the 5- or 6-quinolyl position; more preferably R⁷ is attached to the 6-quinolyl position, wherein

D is an amino acid, preferably carrying a charged side chain;

5 A is CH₂;




E is C₁₋₆-alkyl or , wherein m is 1, 2, or 3; Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl; more preferably, E is C₁₋₆-alkyl, most preferably, E is C3 or C4 alkyl;

10 B is NR⁴-C₁₋₆-alkyl or a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C₁₋₆-alkyl, aryl, C₁₋₆-aralkyl. Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.


15 In a further preferred embodiment of the first aspect of the present invention,


R⁵ and R⁶ are H;

R⁷ is , preferably R⁷ is attached to the 5- or 6-quinolyl position; more preferably R⁷ is attached to the 6-quinolyl position, wherein

D is an amino acid, preferably carrying a charged side chain;

20 A is NH;




E is C₁₋₆-alkyl or , wherein m is 1, 2, or 3; Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl; more preferably, E is C₁₋₆-alkyl, most preferably, E is C3 or C4 alkyl;

25 B is NR⁴-C₁₋₆-alkyl or a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C₁₋₆-alkyl, aryl, C₁₋₆-aralkyl. Preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.


In a further preferred embodiment of the first aspect of the present invention,


R⁵ and R⁶ are H;

R⁷ is , preferably R⁷ is attached to the 5- or 6-quinolyl position; more preferably R⁷ is attached to the 6-quinolyl position, wherein

5 D is absent;

A is O;




E is C₁₋₆-alkyl or , wherein m is 1, 2, or 3; Preferably, E is C₁₋₆-alkyl and C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl; more preferably, E is C₁₋₆-alkyl, most preferably,

10 E is C₃ or C₄ alkyl;

B is a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 nitrogen atoms.

In a further preferred embodiment of the first aspect of the present invention,

R⁵ and R⁶ are H;

15 R⁷ is , preferably R⁷ is attached to the 5- or 6-quinolyl position; more preferably R⁷ is attached to the 6-quinolyl position, wherein

D is absent;


A is O;


E is C₃ or C₄ alkyl; more preferably, E is propyl or butyl;

20 B is a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 nitrogen atoms.

In a further preferred embodiment of the first aspect of the present invention,

the N-containing heterocycle comprised in B is an aromatic or non-aromatic monocyclic heterocycle:




25 , wherein

the heterocycle optionally further comprises 1 or 2 heteroatoms selected from O, N and S, optionally further comprises 1 nitrogen;

 is attached to position 1, 2, or 3, preferably to position 2;

l is 1 or 2.

In a further preferred embodiment of the first aspect of the present invention, the N-containing heterocycle comprised in B is an aromatic or non-aromatic monocyclic heterocycle:



, wherein


the heterocycle optionally further comprises 1 or 2 heteroatoms selected from O, N and S, optionally further comprises 1 nitrogen;

 is attached to position 1, 2, or 3, preferably to position 2;


l is 1 or 2;

wherein the N-containing heterocycle is substituted with a C₁₋₆-alkyl.

In a further preferred embodiment of the first aspect of the present invention, the N-containing heterocycle comprised in B is selected from the group consisting of:



wherein the N-containing heterocycle is substituted with a C₁₋₆-alkyl



wherein if the N-containing heterocycle comprised in B is


the heterocycle optionally further comprises 1 or 2 heteroatoms selected from O, N and S, optionally further comprises 1 nitrogen, optionally comprises one or more (e.g. amino acid derived) side chains;

20

 is attached to position 1, 2, or 3, preferably to position 2;



o is 1 or 2;

preferably, if the N-containing heterocycle comprised in B is




, the N-

containing heterocycle comprised in B is selected from the group consisting of




and



; more preferably, if the N-containing heterocycle

5 comprised in B is



, the N-containing heterocycle comprised in B is




or



In a further preferred embodiment of the first aspect of the present invention, the N-containing heterocycle comprised in B is selected from the group consisting of:

10




wherein if the N-containing heterocycle comprised in B is

the heterocycle optionally further comprises 1 or 2 heteroatoms selected from O, N and S,

15 optionally further comprises 1 nitrogen, optionally comprises one or more (e.g. amino acid derived) side chains;


 is attached to position 1, 2, or 3, preferably to position 2;
o is 1 or 2;



preferably, if the N-containing heterocycle comprised in B is




, the N-

containing heterocycle comprised in B is selected from the group consisting of




5  and  ; more preferably, if the N-containing heterocycle

comprised in B is




, the N-containing heterocycle comprised in B is




In a further preferred embodiment of the first aspect of the present invention, the N-containing heterocycle comprised in B is selected from the group consisting of:

10




In a further preferred embodiment of the first aspect of the present invention, the N-containing heterocycle comprised in B is selected from the group consisting of:



15 In a further preferred embodiment of the first aspect of the present invention,


R⁵ and R⁶ are H;

R⁷ is  , preferably R⁷ is attached to the 6-quinolyl position, wherein

D is absent;

A is O;

20 E is propyl or butyl;



In a further preferred embodiment of the first aspect of the present invention,

Q, R, U are absent;

V is C=O;

5 W is NH;

Y is CH₂;

Z is C=O;


R¹ and R² are independently selected from the group consisting of -H and halo; preferably, R¹

and R² are independently selected from the group consisting of -H and F; more preferably, R¹


10 and R² are the same and are selected from the group consisting of -H and F;


R³ is -CN;





R⁵ and R⁶ are H;


R⁷ is , preferably R⁷ is attached to the 6-quinolyl position, wherein D is absent;


15 A is O;



E is C₁₋₆-alkyl or , wherein m is 1, 2, or 3; preferably, E is C₁₋₆-alkyl; preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl; more preferably, E is C₁₋₆-alkyl, most preferably, E is C₃ or C₄ alkyl;

20 B is NH-C₁₋₆-alkyl, , ,  or ; preferably, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl,

butyl, sec-butyl, tert-butyl, pentyl and hexyl; preferably, B is ; and



In a further preferred embodiment of the first aspect of the present invention,

Q, R, U are absent;

V is C=O;

W is NH;


Y is CH₂;

5 Z is C=O;

R¹ and R² are the same and are selected from the group consisting of -H and F;

R³ is -CN;

R⁵ and R⁶ are H;



R⁷ is , preferably R⁷ is attached to the 6-quinolyl position, wherein


10 D is absent;


A is O, S, CH₂, NH, NCH₃;


E is methyl, ethyl, propyl or butyl;

A and E together form a group selected from:



15 B is , optionally B is

substituted with a C₁₋₃ alkyl; preferably, B is ; and



In a further preferred embodiment of the first aspect of the present invention,

20 Q, R, U are absent;

V is C=O;

W is NH;


Y is CH₂;

Z is C=O;

R¹ and R² are the same and are selected from the group consisting of -H and F;

R³ is -CN;


R⁵ and R⁶ are H;


5 R⁷ is , preferably R⁷ is attached to the 6-quinolyl position, wherein


D is absent;

A is O;

E is methyl, ethyl, propyl or butyl;

B is ; preferably, B is

10 ; and



In a further preferred embodiment of the first aspect of the present invention,

Q, R, U are absent;

V is C=O;

15 W is NH;


Y is CH₂;

Z is C=O;

R¹ and R² are the same and are selected from the group consisting of -H and F;

R³ is -CN;


20 R⁵ and R⁶ are H;

R⁷ is , R⁷ is attached to the 6-quinolyl position, wherein

D is absent;

A is O;

E is methyl, ethyl, propyl or butyl;



5 In a further preferred embodiment of the first aspect of the present invention, C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl.

In a further preferred embodiment of the first aspect of the present invention, C₁₋₃-alkyl is selected from the group consisting of methyl, ethyl, propyl and i-propyl.


10 In a further preferred embodiment of the first aspect of the present invention, C₁₋₆-aralkyl is selected from the group consisting of benzyl, phenyl-ethyl, phenyl-propyl, and phenyl-butyl.


In a preferred embodiment of the first aspect of the present invention, the compound of the first aspect of the invention is selected from the compounds of table 1. More preferably, the compound of the first aspect of the invention is selected from the compounds of table 2. More preferably, the compound of the first aspect of the invention is selected from the group consisting of FAPI-02 and FAPI-04.







20 In a preferred embodiment of the first aspect of the present invention, the compound of the first aspect of the invention is selected from the compounds of table 1 and/or table 3. More preferably, the compound of the first aspect of the invention is selected from the compounds of table 2 and/or table 4. More preferably, the compound of the first aspect of the invention is selected from the group consisting of FAPI-02, FAPI-04, FAPI-46, FAPI-34, FAPI-42, FAPI-52, FAPI-69, FAPI-70, FAPI-71, FAPI-72 and FAPI-73.














Table 1: Preferred compounds of the first aspect of the invention.

§ fluorescent compounds; § ^{99m}Tc-chelators; * Pb-chelators; R¹ and R² are located at the 4-















pyrrolidine position; Q, R, U are absent;  is , R⁵ is H; R⁶ is attached to the 7-quinolyl position; R⁷ is attached to the 6-quinolyl position; ‘-’ indicates that

5 R⁶ or R⁷ being H; ‘+’ indicates R⁶ or R⁷ being ; V is C=O; W is NH; Y is CH₂; Z is C=O; R³ is -CN; A is O (except FAPI-01: A is absent, R⁷ is attached to the 5-quinolyl position).

| name | R ¹ /R ² | R ⁶ | R ⁷ | R ⁸ | D | B | E |
|-------------------------------------|--------------------------------|----------------|----------------|---|---|---|---|
| FAPI-01 | H/H | - | + | I | - | - | - |
| FAPI-02 | H/H | - | + |  | - |  | <i>n</i> -C ₃ H ₆ |
| FAPI-02 atto 488[§] | H/H | - | + |  | - |  | <i>n</i> -C ₃ H ₆ |
| FAPI-02 dy800 CW[§] | H/H | - | + |  | - |  | <i>n</i> -C ₃ H ₆ |
| FAPI-03 | H/H | - | + |  | - |  | <i>n</i> -C ₄ H ₈ |
| FAPI-04 | F/F | - | + |  | - |  | <i>n</i> -C ₃ H ₆ |



| name | R ¹ /R ² | R ⁶ | R ⁷ | R ⁸ | D | B | E |
|--|--------------------------------|----------------|----------------|---|--|---|---|
| FAP-04 atto 488^s | F/F | - | + |  | - |  | <i>n</i> -C ₃ H ₆ |
| FAP-05 | F/F | - | + |  | - |  | <i>n</i> -C ₄ H ₈ |
| FAP-06 | H/H | - | + |  | - | NH | <i>n</i> -C ₃ H ₆ |
| FAP-07 | F/F | - | + |  | - | NH | <i>n</i> -C ₃ H ₆ |
| FAP-08 | H/H | + | - |  | - |  | <i>n</i> -C ₃ H ₆ |
| FAP-09 | F/F | + | - |  | - |  | <i>n</i> -C ₃ H ₆ |
| FAP-10 | F/F | - | + |  |  |  | <i>n</i> -C ₃ H ₆ |
| FAP-11 | F/F | - | + |  | - |  | CH ₂ |
| FAP-12 | F/F | - | + |  | - |  | <i>n</i> -C ₂ H ₄ |
| FAP-13 | F/F | - | + |  | - |  | <i>n</i> -C ₃ H ₆ |

| name | R ¹ /R ² | R ⁶ | R ⁷ | R ⁸ | D | B | E |
|----------------------------|--------------------------------|----------------|----------------|----------------|---|---|---|
| FAP1-14 | F/F | - | + | | - | | <i>n</i> -C ₄ H ₈ |
| FAP1-15 | F/F | - | + | | - | | (C ₂ H ₄ O) 2C ₂ H ₄ |
| FAP1-16 | F/F | - | + | | - | | <i>n</i> -C ₃ H ₆ |
| FAP1-17 | F/F | - | + | | | | <i>n</i> -C ₃ H ₆ |
| FAP1-18 | F/F | - | + | | | | <i>n</i> -C ₃ H ₆ |
| FAP1-19^S | F/F | - | + | | - | | <i>n</i> -C ₃ H ₆ |
| FAP1-20 | F/F | - | + | | - | | <i>n</i> -C ₃ H ₆ |
| FAP1-21 | F/F | - | + | | - | | <i>n</i> -C ₃ H ₆ |
| FAP1-22 | F/F | - | + | | - | | <i>n</i> -C ₃ H ₆ |
| FAP1-23 | F/F | - | + | | - | | <i>n</i> -C ₃ H ₆ |

| name | R ¹ /R ² | R ⁶ | R ⁷ | R ⁸ | D | B | E |
|----------------------------|--------------------------------|----------------|----------------|---|--|---|---|
| FAPI-24 | F/F | - | + |  | - |  | (C ₂ H ₄ O) 3C ₂ H ₄ |
| FAPI-25 | F/F | - | + |  |  |  | <i>n</i> -C ₃ H ₆ |
| FAPI-26 | F/F | - | + |  | - |  | (C ₂ H ₄ O) 2C ₂ H ₄ |
| FAPI-27^s | F/F | - | + |  | - |  | <i>n</i> -C ₃ H ₆ |
| FAPI-28^s | F/F | - | + |  | - |  | <i>n</i> -C ₃ H ₆ |
| FAPI-29^s | F/F | - | + |  | - |  | <i>n</i> -C ₃ H ₆ |
| FAPI-30 | F/F | - | + |  | - |  | <i>n</i> -C ₃ H ₆ |
| FAPI-31 | F/F | - | + |  | - |  | <i>n</i> -C ₃ H ₆ |
| FAPI-32* | F/F | - | + |  | - |  | <i>n</i> -C ₃ H ₆ |
| FAPI-33^s | F/F | - | + |  | - |  | (C ₂ H ₄ O) 2C ₂ H ₄ |

| name | R ¹ /R ² | R ⁶ | R ⁷ | R ⁸ | D | B | E |
|----------------------|--------------------------------|----------------|----------------|----------------|-------|---|---|
| FAPI-34 ^S | F/F | - | + | | - | | <i>n</i> -C ₃ H ₆ |
| FAPI-35 | F/F | - | + | | - | | <i>n</i> -C ₃ H ₆ |
| FAPI-36 | F/F | - | + | | - | | <i>n</i> -C ₃ H ₆ |
| FAPI-37 | F/F | - | + | | | | <i>n</i> -C ₃ H ₆ |
| FAPI-38 | F/F | - | + | | D-Arg | | <i>n</i> -C ₃ H ₆ |

Table 2: Compounds of special interest. Q, R, U, D are absent; R¹ and R² are located at the 4-

pyrrolidine position;  is , R⁵, R⁶ are H; R⁷ is attached to the 6-quinolyl position; V is C=O; W is NH; Y is CH₂; Z is C=O; R³ is -CN; B is 1,4-piperazine; E is 1,3-propane; A is O.

| name | Purpose | R ¹ /R ² | R ⁸ |
|--------------------------|---------|--------------------------------|----------------|
| ⁶⁸ Ga-FAPI-02 | PET | H/H | |
| ⁶⁸ Ga-FAPI-04 | PET | F/F | |










| | | | |
|----------------------------|--------------------------------|-----|--|
| Gd-FAPI-04 | MRI (contrast agent) | F/F |  |
| ⁹⁰ Y-FAPI-04 | radiotherapy (β ⁻) | F/F |  |
| ^{99m} Tc-FAPI-29 | SPECT | F/F |  |
| ²⁰³ Pb-FAPI-32 | SPECT | F/F |  |
| ¹⁸ F-FAPI-n.a. | PET | F/F |  |
| ¹⁸⁸ Re-FAPI-60 | radiotherapy (β ⁻) | F/F |  |
| Al ¹⁸ F-FAPI-42 | PET | F/F |  |
| ¹⁸ F-FAPI-72 | PET | F/F |  |

Table 3: Further preferred compounds of the first aspect of the invention.














§ fluorescent compounds; § ^{99m}Tc-chelators; * precursors for ¹⁸F-labeling; Q, R, U are absent; R¹ and R² are located at the 4-pyrrolidine position;



| name | R ¹ /R ² | R ⁸ | D | B | E | A |
|----------------------------|--------------------------------|----------------|---|---|---|-----------------|
| FAPI-39 | F/F | | - | | <i>n</i> -C ₃ H ₆ | CH ₂ |
| FAPI-40 | F/F | | - | | <i>n</i> -C ₃ H ₆ | S |
| FAPI-41 | F/F | | - | | <i>n</i> -C ₃ H ₆ | NH |
| FAPI-42 | F/F | | - | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-43^S | F/F | | - | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-44^S | F/F | | - | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-45^S | F/F | | - | | <i>n</i> -C ₃ H ₆ | O |



| name | R ¹ /R ² | R ⁸ | D | B | E | A |
|----------------|--------------------------------|----------------|---|---|---|-----|
| FAPI-46 | F/F | | - | | <i>n</i> -C ₃ H ₆ | NMe |
| FAPI-47 | F/F | | - | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-48 | F/F | | - | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-49 | F/F | | - | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-50 | F/F | | - | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-51 | F/F | | - | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-52 | F/F | | - | | <i>n</i> -C ₃ H ₆ | NMe |
| FAPI-53 | F/F | | - | | <i>n</i> -C ₃ H ₆ | NMe |
| FAPI-54 | F/F | | - | | | |
| FAPI-55 | F/F | | - | | <i>n</i> -C ₃ H ₆ | NMe |

| name | R ¹ /R ² | R ⁸ | D | B | E | A |
|----------------------------|--------------------------------|----------------|---|---|---|-----|
| FAPI-56 | F/F | | - | | | |
| FAPI-57 | F/F | | - | | | |
| FAPI-58 | F/F | | - | | <i>n</i> -C ₃ H ₆ | NMe |
| FAPI-59 | F/F | | - | | <i>n</i> -C ₃ H ₆ | NMe |
| FAPI-60^S | F/F | | - | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-61^S | F/F | | - | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-62^S | F/F | | - | | <i>n</i> -C ₃ H ₆ | NMe |
| FAPI-63 | F/F | | - | | | |
| FAPI-64 | F/F | | - | | | |
| FAPI-65 | F/F | | - | | | |
| FAPI-66 | F/F | | - | | | |

| name | R ¹ /R ² | R ⁸ | D | B | E | A |
|----------------------------|--------------------------------|---|--|---|---|-----|
| FAPI-67 | F/F |  | - |  |  | |
| FAPI-68 | F/F |  | - |  |  | |
| FAPI-69^S | F/F |  | - |  | <i>n</i> -C ₃ H ₆ | NMe |
| FAPI-70^S | F/F |  | - |  | <i>n</i> -C ₃ H ₆ | NMe |
| FAPI-71^S | F/F |  | - |  | <i>n</i> -C ₃ H ₆ | NMe |
| FAPI-72⁺ | F/F |  | - |  | <i>n</i> -C ₃ H ₆ | NMe |
| FAPI-73⁺ | F/F |  | - |  | <i>n</i> -C ₃ H ₆ | O |
| FAPI-74 | H/H |  | - |  | <i>n</i> -C ₃ H ₆ | O |
| FAPI-75 | F/F |  |  |  | <i>n</i> -C ₃ H ₆ | O |
| FAPI-76 | F/F |  | - |  | <i>n</i> -C ₃ H ₆ | O |

| name | R ¹ /R ² | R ⁸ | D | B | E | A |
|------------------------------|--------------------------------|----------------|---|---|---|-----|
| FAPI-77 | F/F | | | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-77 protected | F/F | | | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-78 | F/F | | | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-78 protected | F/F | | | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-79 | F/F | | | | <i>n</i> -C ₃ H ₆ | O |
| FAPI-80 | F/F | | | | <i>n</i> -C ₃ H ₆ | NMe |

Table 4: Compounds of special interest. Q, R, U, D are absent; R¹ and R² are fluorine atoms

located at the 4-pyrrolidine position;  is , R⁵, R⁶ are H; R⁷ is attached to the 6-quinolyl position; V is C=O; W is NH; Y is CH₂; Z is C=O; R³ is -CN; B is 1,4-piperazine; E is 1,3-propane; A is O.

5






| name | Purpose | R ⁸ |
|----------------------------|--------------------------------|---|
| ¹⁸⁸ Re-FAPI-60 | radiotherapy (β ⁻) |  |
| Al ¹⁸ F-FAPI-42 | PET |  |
| ¹⁸ F-FAPI-73 | PET |  |

Table 5: Preferred precursors for radiolabelling with ¹⁸F-18; ⁶⁴Cu-64; ⁶⁸Ga-68; ^{99m}Tc-99m, Re-188; * Y-90, Sm-153, Lu-177.

| | |
|------------------------|--|
| FAPI-02 ^{ε,*} |  |
| FAPI-04 ^{ε,*} |  |

| | |
|-------------------------------------|--|
| <p>FAPI- 34^ε</p> | |
| <p>FAPI- 42^{§,§,ε}</p> | |
| <p>FAPI- 46^{ε,*}</p> | |
| <p>FAPI- 52^{§,§,ε}</p> | |
| <p>FAPI- 69^ε</p> | |
| <p>FAPI- 70^ε</p> | |
| <p>FAPI- 71^ε</p> | |

triazacyclononane-1,4,7-triacetic acid (NOTA), triethylenetetramine (TETA), iminodiacetic acid, diethylenetriamine-N,N,N',N',N''-pentaacetic acid (DTPA), bis-(carboxymethylimidazole)glycine and 6-Hydrazinopyridine-3-carboxylic acid (HYNIC).

In a further preferred embodiment of the first aspect of the present invention, R⁸ is a contrast agent which comprises or consists of a paramagnetic agent, preferably, wherein the paramagnetic agent comprises or consists of paramagnetic nanoparticles.

In a further preferred embodiment of the first aspect of the invention, R⁸ is selected from any R⁸ of tables 1 to 5.

In a second aspect, the present invention relates to a pharmaceutical composition comprising or consisting of at least one compound of the first aspect, and, optionally, a pharmaceutically acceptable carrier and/or excipient.

In a third aspect, the present invention relates to the compound of the first aspect or the pharmaceutical composition of the second aspect for use in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP) in an animal or a human subject. Preferably, the disease characterized by overexpression of fibroblast activation protein (FAP) is selected from the group consisting of cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and keloid disorder.

Preferably, if the disease characterized by overexpression of fibroblast activation protein (FAP) is cancer, the cancer is selected from the group consisting of breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharynx cancer, nasopharynx cancer, larynx cancer, myeloma cells, bladder cancer, cholangiocellular carcinoma, clear cell renal carcinoma, neuroendocrine tumor, oncogenic osteomalacia, sarcoma, CUP (carcinoma of unknown primary), thymus carcinoma, desmoid tumors, glioma, astrocytoma, cervix carcinoma and prostate cancer. Preferably, the cancer is glioma, breast cancer, colon cancer, lung cancer, head and neck cancer, liver cancer or pancreatic cancer. More preferably, the cancer is glioma.

Preferably, if the disease characterized by overexpression of fibroblast activation protein (FAP) is chronic inflammation, the chronic inflammation is selected from the group consisting of rheumatoid arthritis, osteoarthritis and Crohn's disease. Preferably, the chronic inflammation is rheumatoid arthritis.

Preferably, if the disease characterized by overexpression of fibroblast activation protein (FAP) is fibrosis, the fibrosis is selected from the group consisting of pulmonary fibrosis, such as idiopathic pulmonary fibrosis and liver cirrhosis.

Preferably, if the disease characterized by overexpression of fibroblast activation protein (FAP) is tissue remodeling, the tissue remodeling occurs after myocardial infarction.

Preferably, if the disease characterized by overexpression of fibroblast activation protein (FAP) is a keloid disorder, the keloid disorder is selected from the group consisting of scar formation, keloid tumors and keloid scar.

In a fourth aspect, the present invention relates to a kit comprising or consisting of the compound of the first aspect or the pharmaceutical composition of the second aspect and instructions for the diagnosis or treatment of a disease. Preferably, the disease is a disease as specified above.

10

Examples

Example 1: Compound synthesis and radiochemistry

Based on a FAP- α specific inhibitor (Jansen et al., *ACS Med Chem Lett*, 2013) two radiotracers were synthesized. Radioiodine labeled FAPI-01 was obtained via an organotin stannylated precursor, which was prepared through palladium catalyzed bromine/tin exchange. FAPI-02 is a precursor for the chelation of radio metals which was synthesized in five steps. By application of the same or slightly modified procedures additional compounds were prepared. The structures of these compounds are listed in table 1 and 2. Radioiodinations of the stannylated precursor were performed with peracetic acid. For chelation with Lu-177 and Ga-68 the pH of the reaction mixture was adjusted with sodium acetate and heated to 95 °C for 10 min. Stability in human serum was analyzed by precipitation and radio-HPLC analysis of the supernatant.

15

20

Reagents

All solvents and non-radioactive reagents were obtained in reagent grade from ABCR (Karlsruhe, Germany), Sigma-Aldrich (München, Germany), Acros Organics (Geel, Belgium) or VWR (Bruchsal, Germany) and were used without further purification. Atto 488 NHS-ester was obtained from AttoTec (Siegen, Germany). 2,2',2''-(10-(2-(4-nitrophenyl)oxy)-2-oxoethyl)-1,4,7,10-tetraazacyclo-dodecane-1,4,7-triyl)triacetic acid (DOTA-PNP) was synthesized following the protocol of Mier et al. (Mier et al., *Bioconjug Chem*, 2005). The intermediates 6-methoxyquinoline-4-carboxylic acid (**7**), 5-bromoquinoline-4-carboxylic acid (**3**) and (*S*)-1-(2-aminoacetyl)pyrrolidine-2-carbonitrile 4-methylbenzenesulfonate were synthesized following the protocols of Jansen et al. (Jansen et al., *ACS Med Chem Lett*, 2013).


25

30

The substance (*S*)-*N*-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-5-bromoquinoline carboxamide was synthesized by a modified HBTU amidation protocol.


Compound synthesis

- 5 Scheme 1 depicts the initial synthesis of FAPI-01 which was achieved by performing a Br/Li-exchange with *n*-butyllithium at 5-bromoquinoline-4-carboxylic acid (**3**) and quenching with elemental iodine to obtain iodoquinoline **4**. This compound was coupled to the Gly-Pro-CN fragment by HBTU/HOBt-activation to provide non-radioactive reference material of FAPI-01 (**1**).



10

Scheme 1. Synthesis of non-radioactive FAPI-01. i) *n*BuLi, then I₂, THF; ii) HBTU/HOBt, DIPEA, H-Gly-Pro-CN, DMF. For the synthesis of radioactive FAPI-01 (**1***), the stannylated precursor **6** was obtained by palladium-catalyzed stannylation of inhibitor **5** in dioxane at 80°C (Scheme 2).




- 15 **Scheme 2.** Synthesis of radioactive FAPI-1 via the stannylated precursor **4**. i) (Me₃Sn)₂; (PPh₃)₂PdCl₂; dioxane 80 °C; ii) I-125 or I-131; AcOOH; 1 M HCl; MeOH.

To enable radiolabeling by incorporation of radiometals, the chelator DOTA was chemically linked to the basic scaffold of the FAP-inhibitor. As shown by Jansen et al. (Jansen et al., *ACS Med Chem Lett*, 2013), modifications at the 6-position of the quinoline-4-carboxylic acid are well tolerated without impairing target affinity and specificity. Therefore, a bifunctional linker was attached to the hydroxyl group of **8** via an ether linkage, leading way to the synthesis shown in Scheme 3. Ready available 1-bromo-3-chloropropane was chosen to create a spacer, which is unharmed during the saponification of the simultaneously formed ester bond at the end of the one-pot-process. Compound **9** was converted to the *N*-Boc protected quinolinecarboxylic acid **10** which was further coupled to H-Gly-Pro-CN by HBTU. Due to the high hygroscopicity of the free amine, compound **11** was directly converted to FAPI-02 (**2**) after the Boc-removal, solvent exchange and neutralization of excess *p*-toluenesulfonic acid.


20

25




Scheme 3. Chemical synthesis of FAPI-02. i) aq. HBr 48%, 130 °C; ii) 1-bromo-3-chloropropane, Cs_2CO_3 , DMF then 6 M NaOH; iii) 1-Boc-piperazine, KI, DMF; iv) HBTU/HOBt, DIPEA, H-Gly-Pro-CN, DMF; v) TosOH, MeCN, then DOTA-PNP, DIPEA, DMF.

- 5 In case of compounds incorporating group A \neq O, the quinoline-4-carboxylic acid intermediates were synthesized by a different reaction scheme. The key step of this approach is a palladium catalyzed coupling reaction (e.g. Buchwald-Hartwig cross-coupling), which requires additional protection before and deprotection of the carboxylic acid function after the cross-coupling reaction (scheme 4).



10

Scheme 4. Synthesis of the building block 6-(3-(4-Boc-piperazin-1-yl)propyl)-1-(methylamino)quinoline-4-carboxylic acid for the synthesis of FAPI-46. i) DCC, tBuOH, CuCl; ii) 3-methylamino-1-propanol, Cs_2CO_3 , $\text{Pd}_2(\text{dba})_3$, BINAP; iii) MsCl, NEt_3 , DCM then 1-Boc-piperazine, KI, DMF; iv) TFA then Boc_2O , NEt_3 , DMF.




(*S*)-*N*-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-5-(trimethylstannyl)quinoline caboxamide (**6**)

3.88 mg (10.0 μmol) (*S*)-*N*-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-5-bromoquinoline caboxamide, 20 μL (32 mg; 96 μmol) hexamethylditin and 0.75 mg (1.07 μmol)

5 bis(triphenylphosphine)palladium(II) dichloride in 1 mL dry dioxane are stirred at 80 °C over night under an inert atmosphere. Volatiles are removed and the residue is taken up in 2 mL 50% acetonitrile/water and filtered through a C18-light cartridge before HPLC-purification. 2.78 mg (5.90 μmol; 59%) of the product are obtained after freeze drying.

LC-MS R_t 14.77 min, m/z 473.0786 [$M(^{120}\text{Sn})+H$]⁺

10




5-iodoquinoline-4-carboxylic acid (**4**)

5.42 mg (136 μmol) of sodium hydride suspension (60% in mineral oil) are added to an solution of 30.27 mg (120 μmol) 5-bromoquinoline-4-carboxylic acid (**3**) in 3 mL dry THF under Ar at

15 0°C. The ice bath is removed and the reaction mixture is cooled to -78 °C before 100 μL (160 μmol) *n*BuLi (1.6 M in hexanes) are added dropwise. After 15 min 64.71 mg (254 μmol) iodine in 2 mL THF are added dropwise and the reaction is stirred for 30 min at -78 °C before allowed

20 to reach room temperature. After 1 h the reaction is quenched by addition of 1 mL 0.5 M NaHCO₃ and ca. 30 mg (170 μmol) sodium dithionite to remove excessive iodine. After the removal of THF under reduced pressure the mixture is acidified to pH 2 and extracted three times with ethyl acetate (25 mL). The combined organic phases are evaporated to dryness and purified by HPLC. 18.14 mg (60.7 μmol; 45%) of the title compound are obtained after freeze drying.


25 ¹H NMR (500 MHz, DMSO-*d*₆) 13.95 (br, 0.3H), 8.93 (s, 1H), 8.34 (d, *J* = 7.2 Hz, 1H), 8.12 (d, *J* = 8.4 Hz, 1H), 7.60 (s, 1H), 7.52 (t, *J* = 7.9 Hz, 1H); ¹³C NMR (125 MHz, DMSO-*d*₆) 168.8, 150.3, 148.8, 141.3, 130.6, 121.0, 109.5; **LC-MS** R_t 8.65 min, m/z 299.9383 [$M+H$]⁺



(*S*)-*N*-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-5-trimethylstannylquinoline-4-carboxamide (**1**; FAPI-01)

9.07 mg (23.9 μmol) HBTU in 50 μL DMF are added to a solution of 6.21 mg (20.8 μmol) 5-iodoquinoline-4-carboxylic acid, 7.45 mg (55.2 μmol) HOBt and 10 μL DIPEA in 50 μL DMF. After 15 min (29.9 μmol) (*S*)-1-(2-aminoacetyl)pyrrolidine-2-carbonitrile 4-methylbenzenesulfonate in 50 μL DMF are added. The reaction is quenched with 850 μL water and purified by HPLC. Freeze drying provides 6.86 mg (15.8 μmol ; 76%) of the product.


$^1\text{H NMR}$ (600 MHz, DMSO- d_6) 9.06, 8.97, 8.33, 8.13, 7.56, 7.51, 4.81, 4.34, 4.06, 3.74, 3.56, 2.21, 2.17, 2.09, 2.05; $^{13}\text{C NMR}$ (150 MHz, DMSO- d_6) 167.1, 150.2, 148.8, 145.3, 141.5, 130.7, 125.3, 121.9, 119.3, 92.0, 46.3, 45.4, 42.1, 29.5, 24.9; **LC-MS** R_t 11.95 min, m/z 435.0102 $[\text{M}+\text{H}]^+$



15 6-Hydroxyquinoline-4-carboxylic acid (**8**)

105 mg (477 μmol) of raw 6-methoxyquinoline-4-carboxylic acid (**7**) are dissolved in 3 mL of 48% hydrobromic acid in water. The solution is heated to 130 $^\circ\text{C}$ for 4 h. The solution is brought to a slightly basic pH with 6 M NaOH after reaching room temperature. 79.2 mg (419 μmol ; 88%) of the product are obtained after by HPLC-purification and lyophilization.

20 $^1\text{H NMR}$ (500 MHz, DMSO- d_6) 13.65 (br, 0.6H) 10.24 (s, 1H), 8.78 (d, $J = 4.4$ Hz, 1H), 8.06 (d, $J = 2.6$ Hz, 1H), 7.95 (d, $J = 9.1$ Hz, 1H), 7.84 (d, $J = 4.4$ Hz, 1H), 7.37 (dd, $J = 9.1, 2.6$ Hz, 1H), $^{13}\text{C NMR}$ (125 MHz, DMSO- d_6) 167.7, 156.9, 146.5, 144.1, 133.4, 131.2, 126.2, 122.3, 122.6, 106.5; **LC-MS** R_t 6.66 min, m/z 190.0415 $[\text{M}+\text{H}]^+$




25

tert-butyl 6-bromoquinoline-4-carboxylate

98.3 mg (390 μmol) 6-bromoquinoline-4-carboxylic acid (raw) were suspended in 5 mL tetrahydrofuran and 25.0 μL (18.3 mg; 181 μmol) triethylamine and added to *O*-*tert*-butyl-*N,N'*-dicyclohexylisourea (prepared the day before from neat 426 mg (2.07 mmol) dicyclohexylcarbodiimide, 173 mg (2.33 mmol) *tert*-butanol and 10.2 mg (103 μmol) copper(I)chloride). The mixture was heated to 50 $^{\circ}\text{C}$ over night. The mixture was filtered, solvents evaporated and the product isolated by HPLC. 49.7 mg (161 μmol ; 41%) of the title compound were obtained after freeze drying.


LC-MS R_t 20.40 min, m/z 251.9642 $[\text{M}-t\text{Bu}]^+$



10 6-(3-chloro-1-propoxy)quinoline-4-carboxylic acid (**9**)

42.4 μL (67.4 mg; 430 μmol) 1-bromo-1-chloropropane are added to a suspension of 23.2 mg (123 μmol) 6-hydroxyquinoline-4-carboxylic acid (**8**) and 190 mg (1.38 μmol) potassium carbonate in 250 μL DMF and heated to 60 $^{\circ}\text{C}$ over night. The reaction mixture is cooled to room temperature, diluted with 500 μL water and 500 μL acetonitrile before 100 μL 6 M NaOH are added. The reaction mixture is directly purified via HPLC (5-40%) after the complete ester hydrolysis is accomplished. 26.45 mg (99.4 μmol ; 81%) of the product are obtained after lyophilization.

$^1\text{H NMR}$ (500 MHz, DMSO- d_6) 13.75 (br, 0.4H), 8.88 (d, $J = 4.4$ Hz, 1H), 8.19 (d, $J = 2.0$ Hz, 1H), 8.04 (d, $J = 9.2$ Hz, 1H), 7.94 (d, $J = 4.4$ Hz, 1H), 7.52 (dd, $J = 9.2, 2.0$ Hz, 1H), 4.24 (t, $J = 5.95$ Hz, 2H), 3.85 (t, $J = 6.5$ Hz, 2H), 2.27 (m, 2H); $^{13}\text{C NMR}$ (125 MHz, DMSO- d_6) 167.6, 157.5, 147.6, 144.8, 134.0, 131.2, 125.9, 122.7, 122.2, 104.5, 64.7, 41.9, 31.6; LC-MS R_t 11.46 min, m/z 266.0461 $[\text{M}+\text{H}]^+$




25 *tert*-butyl 6-(3-hydroxypropylmethylamino)quinoline-4-carboxylate

204.6 mg (664 μmol) *tert*-butyl 6-bromoquinoline-4-carboxylate, 34.10 mg (54.7 μmol) BINAP, 21.51 mg (23.5 μmol) $\text{Pd}_2(\text{dba})_3$ and 480.3 mg (1.47 mmol) cesium carbonate were dissolved in 6 mL toluene and 128.0 μL (118 mg; 1.32 mmol) *N*-methyl-1,3-propanolamine were added. The mixture was stirred at 90 $^{\circ}\text{C}$ over night before solvents were removed, the

residue suspended in water/acetonitrile 1:1 and filtered before HPLC-purification. 172.7 mg (547 μmol ; 82%) of the title compound were obtained after freeze drying.

LC-MS R_t 13.41 min, m/z 261.1213 $[\text{M}-t\text{Bu}+\text{H}]^+$




5

tert-butyl 6-(3-(4-Boc-piperazin-1-yl)propyl)-1-(methylamino)quinoline-4-carboxylate
62.8 mg (199 μmol) *tert*-butyl 6-(3-hydroxypropylmethylamino)quinoline-4-carboxylate were dissolved in 5 mL dichloromethane and 90.0 μL (66.6 mg; 659 μmol) triethylamine. 20.0 μL (29.6 mg; 258 μmol) methanesulfonyl chloride were added at 0 $^\circ\text{C}$ and the mixture reacted for 60 min. 194.6 mg (1.05 mmol) 1-Boc-piperazine were added before volatiles were removed. 500 μL dimethylformamide and 47.4 mg (286 μmol) potassium iodide were added to the residue. The mixture was shaken at 60 $^\circ\text{C}$ for 120 minutes before the product was isolated by HPLC. 81.05 mg (167 μmol ; 84%) of the title compound were obtained after freeze drying.

10

LC-MS R_t 13.99 min, m/z 485.3086 $[\text{M}+\text{H}]^+$

15




6-(3-(4-*tert*-butoxycarbonylpiperazin-1-yl)-1-propoxy)quinoline-4-carboxylic acid (**10**)

15.13 mg (56.9 μmol) of 6-(3-chloro-1-propoxy)quinoline-4-carboxylic acid (**9**), 55.43 mg (298 μmol) *N*-*tert*-butoxycarbonylpiperazine and 51.05 mg (30.8 μmol) potassium iodide are dissolved in 250 μL DMF. The reaction is shaken at 60 $^\circ\text{C}$ over night. The resulting suspension is diluted with 750 μL water before the product is purified by HPLC. After freeze drying 28.73 mg (54.3 μmol ; 95%) of the product are obtained as the corresponding TFA-salt.

20

^1H NMR (500 MHz, D_2O) 8.93 (d, J = 5.5 Hz, 1H), 8.17 (d, J = 9.3 Hz, 1H), 7.94 (d, J = 5.5 Hz, 1H), 7.79 (dd, J = 9.3, 2.5 Hz, 1H), 7.65 (d, J = 2.5 Hz, 1H), 4.36 (t, J = 5.6 Hz, 2H), 4.27 (d, J = 13.55 Hz, 2H), 3.67 (d, J = 11.95 Hz), 3.47 (t, J = 15.5 Hz, 2 H), 3.27 (t, J = 12.7 Hz), 3.12 (td, J = 12.2, 2.65 Hz), 2.37 (m2 H), 1.47 (s, 9H); **^{13}C NMR** (125 MHz, D_2O) 155.5, 153.5, 149.0, 141.4, 134.4, 127.9, 126.6, 122.3, 118.4, 110.0, 105.1, 82.8, 65.5, 54.3, 51.5, 48.6, 40.7, 29.6, 27.4; **LC-MS** R_t 10.62 min, m/z 416.1997 $[\text{M}+\text{H}]^+$


25



6-(3-(4-Boc-piperazin-1-yl)propyl-1-(methyl)amino)quinoline-4-carboxylic acid

100.12 mg (206 μmol) *tert*-butyl 6-(3-(4-Boc-piperazin-1-yl)propyl-1-(methyl)amino)quinoline-4-carboxylate were treated with 900 μL trifluoroacetic acid, 25 μL triisopropylsilane, 25 μL water and 50 μL trifluoromethanesulfonic acid for 60 min. The deprotected compound was precipitated with diethyl ether, dried and reacted with 60.83 mg (279 μmol) di-*tert*-butyldicarbonate and 50.0 μL (36.5 mg; 361 μmol) triethylamine in 1 mL dimethylformamide for another 60 min. 55.42 mg (129 μmol ; 65% over 2 steps) were obtained after HPLC-purification and freeze-drying.

10 **LC-MS** R_t 10.52 min, m/z 429.2463 $[\text{M}+\text{H}]^+$




(*S*)-*N*-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-6-(3-(4-*tert*-butoxycarbonylpiperazin-1-yl)-1-propoxy)quinoline-4-carboxamide (**11**)

15 9.43 mg (24.9 μmol) HBTU in 50 μL DMF are added to a solution of 10.56 mg (19.9 μmol) 6-(3-(4-*tert*-butoxycarbonylpiperazin-1-yl)-1-propoxy)quinoline-4-carboxylic acid (**10**), 5.38 mg (39.8 μmol) HOBT and 10 μL DIPEA in 50 μL DMF. After 15 min (29.9 μmol) (*S*)-1-(2-aminoacetyl)pyrrolidine-2-carbonitrile 4-methylbenzenesulfonate in 50 μL DMF are added. The reaction is quenched with 850 μL water and purified by HPLC. Freeze drying provides

20 12.88 mg (19.4 μmol ; 97%) of the title compound.

^1H NMR (500 MHz, DMSO- d_6) 9.04 (d, J = 5.5 Hz, 1H), 8.24 (d, J = 9.6 Hz, 1H), 8.10 (d, J = 5.5 Hz, 1H), 7.89 (d, J = 2.3 Hz, 1H), 7.85 (dd, J = 9.6, 2.3 Hz, 1H), 4.84 (t, J = 6 Hz, 1H), 4.46–4.36 (m, 4H), 4.26 (d, J = 12.0 Hz, 2H), 3.83 (m, 1H), 3.67 (m, 3H), 3.47 (t, J = 7.7 Hz, 2H), 3.27 (br, 2H), 3.11 (t, J = 11.5 Hz), 2.37 (m, 4H), 2.22 (m, 2H), 1.46 (s, 9H); **^{13}C NMR** (125 MHz, DMSO- d_6) 168.6, 168.0, 159.4, 155.5, 147.7, 141.8, 135.1, 128.2, 127.5, 123.1, 120.0, 119.1, 104.7, 82.9, 66.0, 54.3, 51.5, 47.0, 46.3, 42.3, 29.4, 27.4, 24.7, 23.1; **LC-MS** R_t 11.81 min, m/z 551.2736 $[\text{M}+\text{H}]^+$


25



(*S*)-*N*-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(3-(4-*tert*-butoxycarbonyl-piperazin-1-yl)-1-propoxy)quinoline-4-carboxamide

13.2 mg (22.4 μmol ; 75%) were obtained following the previous protocol.


5 LC-MS R_t 11.84 min, m/z 605.2610 $[\text{M}+\text{H}]^+$



N-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(3-(4-Boc-piperazin-1-yl)propyl-1-(methyl)amino)quinoline-4-carboxamide

10 1.17 mg (1.95 μmol ; 92%) were obtained following the previous protocol.

LC-MS R_t 12.66 min, m/z 600.3057 $[\text{M}+\text{H}]^+$




FAPI-02 (2)

15 4.85 mg (8.80 mmol) (*S*)-*N*-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-6-(3-(4-*tert*-butoxycarbonyl-piperazin-1-yl)-1-propoxy)quinoline-4-carboxamide (**11**) are dissolved in 1 mL acetonitrile and 4.2 mg (22.0 μmol) 4-methylbenzenesulfonic acid monohydrate are added. The reaction is shaken at 45 °C over night, before volatiles are removed under reduced pressure. The residue is taken up in 190 μL dimethylformamide and 10 μL (7.3 mg; 72 μmol) triethylamine before 6.77 mg (12.9 mmol) of DOTA-*p*-nitrophenol ester are added. The reaction mixture is diluted with 1 mL water and purified by HPLC after shaking for two hours. 5.04 mg (6.02 μmol ; 68%) are obtained after freeze drying.

^1H NMR (600 MHz, D_2O) 9.02, 8.23, 8.07, 7.87, 7.83, 4.85, 4.45, 4.41, 4.40, 4.39, 3.83, 3.67, 3.50, 3.49, 2.40, 2.38, 2.36, 2.26, 2.22, 2.16; ^{13}C NMR (150 MHz, D_2O) 167.9, 159.1, 147.2,


141.8, 135.4, 127.9, 127.2, 119.8, 119.0, 104.5, 65.8, 54.1, 46.8, 46.1, 42.1, 29.2, 24.5, 23.0:
LC-MS R_t 8.37 min, m/z 837.3872 $[M+H]^+$



5 FAPI-04

3.97 mg (4.55 μ mol; 57%) were obtained following the previous protocol.


LC-MS R_t 8.80 min, m/z 873.3664 $[M+H]^+$



10 FAPI-42

1.91 mg (2.47 μ mol; 88%) were obtained following the previous protocol.


LC-MS R_t 9.37 min, m/z 386.6807 $[M+2H]^{2+}$



15 FAPI-46

39.21 mg (44.3 μ mol; 85%) were obtained following the previous protocol.


LC-MS R_t 9.03 min, m/z 443.7196 $[M+2H]^{2+}$



FAPI-19

1.09 mg (1.86 μmol) of (*S*)-*N*-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(3-(4-*tert*-butoxycarbonylpiperazin-1-yl)-1-propoxy)quinoline-4-carboxamide were Boc-deprotected by the method applied for FAPI-02 and reacted with 2.74 mg (5.91 μmol) bis((1-(2-(*tert*-butoxy)-2-oxoethyl)-1H-imidazol-2-yl)methyl)glycine, which were preactivated with 2.13 mg (5.62 μmol) HBTU and 2.50 μL (1.85 mg; 14.3 μmol) DIPEA. After HPLC purification and solvent removal the residue was treated with 200 μL of 2.5% trifluoromethanesulfonic acid in acetonitrile/trifluoroacetic acid 1:1. After precipitation with diethyl ether and HPLC purification 1.06 mg (1.29 μmol ; 70%) of the title compound were obtained.


LC-MS R_t 8.91 min, m/z 820.2933 $[\text{M}+\text{H}]^+$



FAPI-28

1.00 μL (0.74 mg; 5.73 μmol) DIPEA was added to a solution of 0.95 mg (1.16 μmol) FAPI-19, 0.42 mg (3.14 μmol) HOBT and 1.10 mg (2.89 μmol) HBTU in 50 μL DMF. After 10 min 2.30 mg (5.34 μmol) H-Asn(Trt)-OtBu were added and reacted for 120 min. The *tert*-butyl protecting groups were removed by 2.5% TFOH in TFA/acetonitrile 8:2. After HPLC-purification and freeze-drying. 0.79 mg (0.75 μmol ; 65%) of the title compound were obtained.

LC-MS R_t 9.23 min, m/z 524.7100 $[\text{M}+2\text{H}]^{2+}$




FAPI-34

1.01 mg (0.87 μmol ; 52%) were obtained following the previous protocol.

LC-MS R_t 8.87 min, m/z 583.6988 $[\text{M}+2\text{H}]^{2+}$

5




FAPI-60

3.91 mg (6.66 μmol) of (*S*)-*N*-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(3-(4-*tert*-butoxycarbonylpiperazin-1-yl)-1-propoxy)quinoline-4-carboxamide were deprotected for
 10 30 min by 50 μL acetonitrile and 100 μL trifluoroacetic acid. After evaporation of the solvents and washing with diethyl ether a 10 min preincubated mixture of 8.02 mg (9.27 μmol) acetyl-
 Cys(Trt)-Gly-Cys(Trt)-Gly-OH, 4.31 mg (31.9 μmol) HOBt and 4.47 mg (11.8 μmol) HBTU
 in 150 μL dimethylformamide and 2.50 μL (1.85 mg; 14.3 μmol) DIPEA was added to the
 residue and reacted for 120 min. 4.66 mg (3.49 μmol ; 52%) of the *S*-trityl protected title
 15 compound were obtained after HPLC-purification and freeze-drying.

3.36 mg (2.52 μmol) of the trityl protected compound were dissolved in 50 μL acetonitrile. 3
 μL Triethylsilane were and 100 μL trifluoroacetic acid were added and reacted for 30 min. 2.01
 mg (2.36 μmol ; 94%; 49% over two steps) of the title compound were obtained after HPLC
 purification and freeze-drying.

20 **LC-MS** R_t 10.26 min, m/z 871.2703 $[\text{M}+\text{Na}]^+$




FAPI-69

0.59 mg (0.60 μmol ; 39%) were obtained following the previous protocol.

LC-MS R_t 10.25 min, m/z 991.3490 $[\text{M}+\text{H}]^+$


5



FAPI-70

0.61 mg (0.54 μmol ; 33%) were obtained following the previous protocol.


10 LC-MS R_t 10.14 min, m/z 1120.3884 $[\text{M}+\text{H}]^+$



FAPI-71

0.79 mg (0.66 μmol ; 34%) were obtained following the previous protocol.


15 LC-MS R_t 10.17 min, m/z 596.7075 $[\text{M}+2\text{H}]^{2+}$



Atto488-FAPI-02 (14)

0.66 mg (1.20 μmol) of **11** are treated with 1.33 mg (6.96 μmol) 4-methylbenzenesulfonic acid monohydrate in 250 μL acetonitrile at 45 °C for 4 hours. After removal of the solvent the residue is dissolved in 95 μL dimethylformamide and 5 μL (3.65 mg; 36.1 μmol) triethylamine. 0.54 mg (0.55 μmol) Atto 488 NHS-ester in 25 μL DMSO were added. After 60 minutes 0.49 mg (0.43 μmol ; 78%) of the title compound were isolated by HPLC and freeze drying.


LC-MS R_t 10.19 min, m/z 1022.2706 $[\text{M}]^+$



FAP1-73

10.95 mg (18.7 μmol) of (*S*)-*N*-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(3-(4-*tert*-butoxycarbonylpiperazin-1-yl)-1-propoxy)quinoline-4-carboxamide were deprotected for 30 min by 100 μL acetonitrile and 200 μL trifluoroacetic acid. After evaporation of the solvents and washing with diethyl ether 15.02 mg (9.27 μmol) *N,N,N*-trimethyl-5-((2,3,5,6-tetrafluorophenoxy)-carbonyl)pyridine-2-aminium chloride was added and the mixture dissolved in 200 μL dimethylformamide and 10.0 μL (7.30 mg; 72.3 μmol) triethylamine. After 120 min the mixture was purified by HPLC and 11.24 mg (14.7 μmol ; 79%) of the title compound were obtained freeze-drying.

LC-MS R_t 9.37 min, m/z 649.2892 $[\text{M}-\text{CF}_3\text{CO}_2]^+$




20

FAP1-72

9.80 mg (12.6 μmol ; 70%) were obtained following the previous protocol.


LC-MS R_t 9.28 min, m/z 662.3237 $[\text{M}-\text{CF}_3\text{CO}_2]^+$

25 **General Attachment of side chain protected Fmoc-amino acids**




(*S*)-*N*-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(3-(4-(γ,γ -di-*tert*-butyl)-*L*-carboxy-glutamylpiperazin-1-yl)-1-propoxy)quinoline-4-carboxamide

14.04 mg (23.9 μ mol) of (*S*)-*N*-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(3-(1-*tert*-butoxycarbonyl-piperidin-4-yl)-1-propoxy)quinoline-4-carboxamide were dissolved in 50 μ L acetonitrile and 100 μ L trifluoroacetic acid. After 10 min the volatiles were removed; the residue was washed with diethyl ether. A solution of 14.95 mg (28.4 μ mol) Fmoc-*L*-Gla(*t*Bu)₂-OH, 7.74 mg (57.4 μ mol) HOBt, 13.46 mg (35.5 μ mol) HBTU and 20.0 μ L (14.8 mg; 115 μ mol) DIPEA in 200 μ L dimethylformamide was added to the dried residue. After 60 min 50.0 μ L (50.4 mg; 578 μ mol) morpholine were added and the product was isolated by HPLC after 30 min. 15.95 mg (20.7 μ mol; 86%) of the title compound were obtained after freeze drying.
LC-MS R_t 12.85 min, m/z 772.3643 [M+H]⁺



FAPI-75


3.37 mg (4.37 μ mol) of (*S*)-*N*-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(3-(4-(γ,γ -di-*tert*-butyl)-*L*-carboxyglutamylpiperazin-1-yl)-1-propoxy)quinoline-4-carboxamide were and 4.52 mg (10.7 μ mol) NOTA-*p*-nitrophenol were dissolved in 100 μ L dimethylformamide and 10.0 μ L (7.30 mg; 72.3 μ mol) triethylamine. After HPLC-purification and freeze-drying the intermediate compound was deprotected by a 60 min incubation in a solution of 50 μ L acetonitrile, 100 μ L trifluoroacetic acid, 2.5 μ L triisopropylsilane and 2.5 μ L water. 2.62 mg (2.77 μ mol; 63%) were obtained after HPLC-purification and freeze-drying.
LC-MS R_t 9.38 min, m/z 945.3668 [M+H]⁺



FAPI-77-precursor

3.23 mg (3.06 μ mol; 73%) were obtained following the general active ester modification protocol. Note: The *tert*-butyl protecting groups were removed after radiofluorination, HPLC-purification and evaporation of solvents by treatment with neat TFA at 95 °C for 3 min followed by SPE work up.


LC-MS R_t 16.02 min, m/z 1219.5858 [M+H]⁺



2-(2-(4,7,10-tris(2-(*tert*-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetoxyl)acetic acid

- 5 28.99 mg (50.6 μmol) tris-*t*Bu-DOTA, 90.65 (278 μmol) cesium carbonate and 10.28 μL (15.0 mg; 65.5 μmol) benzyl 2-bromoacetate were suspended in 300 μL dimethylformamide and shaken for 2 h. The product was isolated by HPLC, freeze dried and dissolved in 25 ml 10% acetic acid in methanol. 50 mg 10% Pd/C and hydrogen (ambient pressure) were added. After 2 hours. Solvents were removed and the title compound isolated by HPLC. After freeze drying
- 10 25.19 mg (39.9 μmol ; 79%) of the title compound were obtained.


LC-MS R_t 14.14 min, m/z 631.4784 $[\text{M}+\text{H}]^+$



tBu-FAPI-79

- 15 2.00 mg (3.41 μmol) (*S*)-*N*-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-6-(3-(1-*tert*-butoxycarbonyl-piperidin-4-yl)-1-propoxy)quinoline-4-carboxamide were dissolved in 50 μL acetonitrile and 100 μL trifluoroacetic acid. After 10 min the volatiles were removed; the residue was washed with diethyl ether. 4.20 mg (6.60 μmol) 2-(2-(4,7,10-tris(2-(*tert*-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetoxyl)acetic acid and 3.35 mg (8.84 μmol)
- 20 HBTU dissolved in 100 μL dimethylformamide and 10.0 μL (7.40 mg; 57.4 μmol) DIPEA were added to the dried residue and reacted for 60 min. 2.26 mg (2.06 μmol ; 60%) of the title compound were obtained after HPLC purification and freeze drying.

LC-MS R_t 12.98 min, m/z 1099.7481 $[\text{M}+\text{H}]^+$



FAPI-79

2.26 mg (2.06 μmol) tBu-FAPI-79 were dissolved in 25 μL acetonitrile and 100 μL trifluoroacetic acid and shaken at 35 $^{\circ}\text{C}$ for 30 min. After evaporation of the solvents the product was isolated by HPLC. 1.58 mg (1.70 μmol ; 82%) of the title compound were obtained after freeze drying.

LC-MS R_t 8.84 min, m/z 466.2737 $[\text{M}+2\text{H}]^{2+}$

Compound analysis

Reverse-phase high-performance liquid chromatography (RP-HPLC) was conducted using linear gradients of acetonitrile in water (0-100% acetonitrile in 5 min; 0.1% TFA; flowrate 2 mL/min) on a Chromolith Performance RP-18e column (100 \times 3 mm; Merck KGaA Darmstadt, Germany). UV-absorbance was detected at 214 nm. An additional γ -detector was used for the HPLC-analysis of radioactive compounds. HPLC-MS characterization was performed on an ESI mass spectrometer (Exactive, Thermo Fisher Scientific, Waltham, MA, USA) connected to an Agilent 1200 HPLC system with a Hypersil Gold C18 1.9 μm column (200 \times 2.1 mm; 0-100% acetonitrile in 20 min; flowrate 200 $\mu\text{L}/\text{min}$). Analytical Radio-HPLC was performed using a Chromolith Performance RP-18e column (100 \times 3mm; Merck; 0-30% acetonitrile in 10 min; flowrate 2 mL/min). HPLC-purifications were performed on a LaPrep P110-System (Knauer, Berlin, Germany) and a Reprosil Pur 120 column (C18-aq 5 μm 250 \times 25mm; Dr. Maisch, Ammerbuch-Entringen, Germany). The water/acetonitrile-gradient (15 or 25 min; 0.1% TFA; flowrate 20 mL/min) was modified for the individual products.

Radiochemistry

Radioiodine (I-125) was purchased from Hartmann Analytik (Göttingen, Germany); radioactive lutetium (Lu-177) was obtained from ITG (München, Germany); radioactive gallium (Ga-68) was eluted from a Ge-68/Ga-68 generator purchased from Themba Labs (Somerset West, South Africa). Tc-99m was eluted from a Mo-99/Tc-99m generator (Curium Pharma, Berlin, Germany). Cu-64 was provided by UKT Tübingen (Tübingen, Germany). Sm-153 was provided by DSD Pharma (Purkersdorf, Austria). Pb-203 was provided by Lantheus (N. Billerica MA, USA). F-18-FDG and F-18-flouride were provided by the ZAG Zyklotron AG (Eggenstein, Germany). CRS Kit for tricarbonyl was obtained from Paul Scherrer Institut (Villingen-PSI, Switzerland).

For iodinations 10 μL of the organotin precursor of FAPI-01 (1 $\mu\text{mol}/\text{mL}$ in ethanol) were diluted with 10 μL of 1 M HCl and 10 μL water before 1-20 MBq iodine-125 in 0.05 M NaOH

were added. The reaction was started by addition of 5 μL of a fresh 1.9% solution of peracetic acid in glacial acetic acid. After 60 s 15 μL of 1 M NaOH were added and the reaction was quenched by addition of 5 μL of 5% ascorbic acid in water before HPLC purification. The obtained solution was directly used for *in vitro* experiments or evaporated to dryness under reduced pressure and taken up in 0.9% NaCl (Braun, Melsungen, Germany) in case of animal studies.

Cu-64, Lu-177 and Pb-203 labeling of DOTA-compounds was performed by addition of 5 MBq of the radionuclide to 100 μL of a 10 μM solution of the individual precursor in 0.1 M NaOAc (pH 5) and incubation at 95 °C for 10 min. The solution is directly used for *in vitro* experiments or diluted with 0.9% NaCl (Braun, Melsungen, Germany) in case of biodistribution studies. For imaging studies in mice (scintigraphy, PET) the radiotracer was worked up by solid phase extraction (sep-pak light C18, Waters).

Tc(I) labeling was preceded by addition of 1 mL of the Tc-99m-pertechnetate in 0.9% saline to a CRS Kit and incubation for 20 min. After cooling to room temperature a mixture of 25.0 μL of the precursor (1 mM in water), 150 μL phosphate buffer (0.4 M, pH 7.4) and 240 μL hydrochloric acid (1.0 M) was added and the final mixture adjusted to pH 5 if necessary. The reaction was performed at 95 °C for 20 minutes and worked up by solid phase extraction (sep-pak light C18, Waters). For *in vivo* experiments and animal studies the labeling was performed with one fifth of the reagents and 200 μL of the CRS Kit solution after Tc(VII) reduction.

Tc(V) labeling was preceded by incubation of 30 μL SnCl₂-solution containing 200 mM glucoheptonate with 200 μL Tc-99m-pertechnetate in 0.9% saline for 10 min at room temperature. 5.00 μL of the precursor (1 mM in water) and 3.75 μL sodium hydroxide solution (0.1 M in water) were added and the final mixture was reacted at 95 °C for 20 min. For imaging studies in mice (scintigraphy) the radiotracer was worked up by solid phase extraction (sep-pak light C18, Waters).

Labeling with Ga-68 for animal studies was performed by incubating 255 μL generator eluate (0.6 M HCl; approx. 230 MBq) with a mixture of 1 nmol DOTA-precursor, 1 μL of 20% ascorbic acid in water and 72 μL NaOAc (2.5 M) at 95 °C for 10 min. Remaining free radioactivity was removed by dilution with 2 mL water, solid phase extraction (sep-pak light C18, Waters), washing with 2 mL water and elution of the product with 1 mL water/ethanol 1:1. The obtained solution was evaporated to dryness under reduced pressure and the residue taken up in 0.9% NaCl (Braun).

For the formation of AlF-NOTA complexes F-18 fluoride was trapped on a waters Sep-Pak QMA plus light cartridge (46 mg sorbent; preconditioned with 0.5 M NaOAc, pH 3.9), washed

with water and eluted with 500 μL 0.1 M NaOAc (pH 3.9). For animal studies 150 μL of the eluate were preincubated with 2 μL of an AlCl_3 solution (10 mM in water) and 50 μL DMSO. After 5 min the mixture was added to 40 nmol NOTA-precursor (10 μL of a 4 mM solution in water) and 1 μL of 20% ascorbic acid in water. The solution was reacted at 95 $^\circ\text{C}$ for 15 min.

5 The product was isolated by HPLC (0-20% acetonitrile in 10 min), freed from solvents and taken up in 0.9% saline before injection.

For the formation of 6-fluoronicotinamides F-18 fluoride was trapped on a waters Sep-Pak QMA plus light cartridge (46 mg sorbent; preconditioned with 0.5 M KHCO_3), washed with water, dried and eluted with a mixture of 7.50 mg (19.9 μmol) cryptofix 222, 1.99 mg (1.99 μmol) KHCO_3 in 450 μL acetonitrile and 50 μL water. After removal of the solvent the residue was dried by azeotropic distillation with 3 \times 1 mL acetonitrile. The residue was taken up in 100 μL *tert*-butanol/acetonitril 1:1 and added to 1 mg (ca. 1.3 μmol) of a trimethylpyridin-2-aminium precursor. The solution was reacted at 75 $^\circ\text{C}$ for 10 min. The product was isolated by HPLC (0-30% acetonitrile in 10 min), freed from solvents and taken up in 0.9% saline before
15 injection.

Alternatively 6-fluoronicotinamides were synthesized by trapping F-18 fluoride on a waters Sep-Pak QMA plus light cartridge (46 mg sorbent; preconditioned with 0.5 M KHCO_3), washed with acetonitrile, dried and eluted with 0.5 mg (ca. 0.4 – 0.6 μmol) of the (protected) FAPI-precursor in 0.5 mL methanol. The solvent was removed *in vacuo* and the residue taken up in
20 100 μL acetonitrile/*tert*-butanol 1:4. After 20 min at 70 $^\circ\text{C}$ the reaction mixture was diluted with water and the protected intermediates worked up by solid phase extraction (sep-pak light C18, Waters). The solvents were removed and 200 μL of trifluoroacetic acid were added to the residue. The mixture was heated to 95 for 3 min, dried *in vacuo* and diluted with water before the product was isolated by HPLC, which was directly performed with the diluted reaction
25 mixture in case of compounds lacking protecting groups. The products were freed from solvents and taken up in 0.9% saline before injection in case of animal studies. (Uncorrected radiochemical yield approx. 25%)

For determination of the stability in human serum the radiolabeled compounds (approx. 2.5 MBq for I-125 or 15 MBq for Lu-177) were purified (HPLC or solid phase extraction) and
30 freed from solvent. The residues were taken up in 250 μL human serum (Sigma-Aldrich) and incubated at 37 $^\circ\text{C}$. Samples were precipitated with 30 μL acetonitrile and analyzed by HPLC (0-30% acetonitrile in 10 min).

Example 2: In vitro characterization of FAPI derivatives

In vitro binding studies were performed using the human tumor cell lines BxPC3, Capan-2, MCF-7 (purchased from Sigma Aldrich Chemie GmbH) and SK-LMS-1 (purchased from ATCC) as well as stably transfected FAP-cell lines HT-1080-FAP, HEK-muFAP and the CD26
5 expressing cell line HEK-CD26 (obtained from Stefan Bauer, NCT Heidelberg). All cells were cultivated in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum at 37°C/5% carbon dioxide. For fluorescence internalization experiments, cells were seeded on coverslips and stained with FAPI-02-Atto488 and DAPI for cell nucleus staining. Images were acquired on a laser scanning confocal microscope using a 63x oil immersion objective.
10 Radioligand binding studies were performed using HT-1080-FAP cells. The radiolabeled compound was added to the cell culture and incubated for different time intervals ranging from 10 min to 24 h. Competition experiments were performed by simultaneous exposure to unlabeled (10^{-5} M to 10^{-9} M) and radiolabeled compound for 60 min. For efflux experiments, radioactive medium was removed after incubation for 60 min and replaced by non-radioactive
15 medium for time intervals ranging from 1 to 24 h. For internalization experiments, surface bound activity was removed by incubating the cells with 1 M glycine-HCl buffer for 10 min. The radioactivity was measured using a γ -counter, normalized to 1 mio cells and calculated as percentage of applied dose (%ID).

20 Cell staining and microscopy

For internalization experiments HT-1080-FAP and HEK muFAP cells were seeded on uncoated coverslips in a 24-well plate and cultivated in culture medium containing 10% fetal calf serum to a final confluence of approx. 80-90%. The medium was removed and cells were washed with 0.5 mL PBS pH 7.4 for 2 times. FAPI-02-Atto488 (20 μ M in DMEM) was added to the cells
25 and incubated for 2 hrs at 37°C. Cells were washed with 0.5 mL PBS pH 7.4 for 3 times and fixed with paraformaldehyde (2% in PBS) for 15 min. The overgrown coverslips were placed on microscope slides using mounting medium containing DAPI for cell nucleus staining (Fluoroshield, Sigma-Aldrich). Images were acquired on a laser scanning confocal microscope (Zeiss LSM 700; Zeiss, Oberkochen, Germany) using the Zeiss Plan-Apochromat 63x/1.4 Oil
30 DIC III immersion objective at xy pixel settings of 0.099 x 0.099 μ m and 1 Airy unit pinhole size for each fluorophore used (488 nm for FAPI-02-Atto488, 405 nm for DAPI). The pictures were processed consistently using the ZEN 2008 software and ImageJ.

Radioligand binding studies

For radioligand binding studies, cells were seeded in 6-well plates and cultivated for 48 h to a final confluence of approx. 80-90% (1.2 - 2 mio cells/well). The medium was replaced by 1 mL fresh medium without fetal calf serum. The radiolabeled compound was added to the cell culture and incubated for different time intervals ranging from 10 min to 24 h. Competition experiments were performed by simultaneous exposure to unlabeled (10^{-5} M to 10^{-9} M) and radiolabeled compound for 60 min. For efflux experiments, radioactive medium was removed after incubation for 60 min and replaced by non-radioactive medium for time intervals ranging from 1 to 24 h. In all experiments, the cells were washed with 1 mL phosphate-buffered saline pH 7.4 for 2 times and subsequently lysed with 1.4 ml lysis buffer (0.3 M NaOH, 0.2% SDS). Radioactivity was determined in a γ -counter (Cobra II, Packard), normalized to 1 mio cells and calculated as percentage of the applied dose (%ID). Each experiment was performed 3 times, and 3 repetitions per independent experiment were acquired.

For internalization experiments the cells were incubated with the radiolabeled compound for 60 min at 37 °C and 4 °C. Cellular uptake was terminated by removing medium from the cells and washing 2 times with 1 mL PBS. Subsequently, cells were incubated with 1 mL of glycine-HCl (1 M in PBS, pH 2.2) for 10 min at room temperature to remove the surface bound activity. The cells were washed with 2 mL of ice-cold PBS and lysed with 1.4 mL of lysis buffer to determine the internalized fraction. For the cells incubated at 4 °C, all washing and elution steps were carried out using ice-cold buffers. The radioactivity was measured using a γ -counter, normalized to 1 mio cells and calculated as percentage of applied dose (%ID).

FAPI-01 selectively targets human and murine FAP- α .

In order to analyze the binding properties of FAPI-01 to its target protein, radioligand binding assays were performed using different cancer cell lines and cell lines transfected with human and murine FAP as well as the closely related membrane protein CD26, also known as DPPiV. Both murine FAP and CD26 show a high homology to human FAP- α (muFAP: 90 % identity and 94 % similarity on amino acid level; CD26: 52 % identity and 71 % similarity with high structural resemblance) (Kelly T., *Drug Resist Updat*, 2005).

As shown in Figure 1A, FAPI-01 shows no significant binding to FAP-negative cancer cell lines while targeting human and murine FAP- α expressing cells with high affinity (IC_{50} human FAP- α = 39.4 nM). Additionally, no substantial binding to CD26 expressing cells was observed (0.05 ± 0.01 %), proving that FAPI-01 is selectively targeting FAP- α . This is of particular importance as CD26 is highly expressed in a variety of normal tissues including the kidneys, the liver and the small intestine. To avoid a high background signal due to unspecific CD26-

binding, high selectivity of the ligand to FAP- α is of great advantage, resulting in optimal image quality.

FAPI-01 rapidly internalizes in FAP-positive cells but shows time-dependent efflux and robust deiodination.

Cell-based internalization assays demonstrate a rapid uptake of FAPI-01 into the cells (Figure 1B). After 10 min of incubation, 95 % of the total bound fraction is located intracellularly (total 19.70 ± 0.28 %). In the course of 4 h, only a marginal decrease in activity is observed (total 17.00 ± 0.40 %, of which internalized 94 %).

Iodine-labeled compounds often show a time-dependent enzymatic deiodination. This was also observed for FAPI-01 resulting in low intracellular radioactivity of this compound after longer incubation times (3.25 ± 0.29 % after 24 h). Deiodination can be minimized by reduction of deiodinase activity after lowering the temperature to 4°C, resulting in an increased radioactivity of 26.66 ± 1.59 % after 24 h.

FAPI-02 shows enhanced binding and uptake to human FAP- α as compared to FAPI-01.

To avoid rapid loss of activity of FAPI-01 due to enzymatic deiodination, the non-halogen derivative FAPI-02 was designed in which the FAP-binding moiety is chemically linked to the chelator DOTA. In addition to the resulting enhanced stability, this modification offers the possibility to easily incorporate either diagnostic or therapeutic radionuclides, allowing FAPI-02 to be used as a theranostic compound. Similar to its iodized analogue, FAPI-02 specifically binds to human and murine FAP- α (IC_{50} human FAP- α = 21 nM) expressing cells without addressing CD26 (%ID = 0.13 ± 0.01 %; Figure 1A). FAPI-02 internalizes rapidly into FAP- α expressing cells (20.15 ± 1.74 %ID after 60 min, of which 96 % internalized; Figure 1B), showing more stable and higher uptake rates in the course of time. Compared to the binding of FAPI-01 after 10 min of incubation, only 5 % of the activity remains after 24 h. In contrast, 34 % of the initial radioactivity of FAPI-02 is detected after 24 h of incubation. Efflux experiments demonstrate that FAPI-02 gets eliminated significantly slower than FAPI-01, showing retention of 12 % of the originally accumulated radioactivity after 24 h (FAPI-01 1.1 % ID after 24 h; Figure 1E).

Robust internalization of FAPI-02 into human and murine FAP- α expressing cells was confirmed by fluorescence laser scanning microscopy. To this end, HT-1080-FAP and HEK-muFAP cells were stained with a fluorescently labeled FAPI-02 derivative (FAPI-02-Atto488) for 1 to 2 hrs. As shown in Figure 1D, the compound gets completely internalized and

accumulates in the inner of FAP- α expressing cells whereas no uptake is detectable in FAP- α negative HEK-CD26 cells.

Design of FAPI derivatives with enhanced binding properties and pharmacokinetics

5 Further variants of FAPI-02 were designed to increase tumor retention time, aiming for the development of a theranostic FAP-targeting agent. The variants FAPI-03 to FAPI-15 have been characterized with respect to target binding, internalization rate and target specificity. The results are shown in Figure 2.

10 Example 3: PET imaging and biodistribution analysis in mice

All experiments were performed in accordance with the German animal protection laws and complied with European Commission regulations for the care and use of laboratory animals. The mice were anaesthetized using isoflurane inhalation.

For *in vivo* experiments, 8 week old BALB/c *nu/nu* mice (Charles River) were subcutaneously
15 inoculated into the right trunk with 5×10^6 with HT-1080-FAP, Capan-2 or SK-LMS-1 cells, respectively. When the size of the tumor reached approximately 1 cm^3 , the radiolabeled compound was injected via the tail vein ($\sim 10 \text{ MBq}$ for small-animal PET imaging; $\sim 1 \text{ MBq}$ for organ distribution). PET imaging was performed up to 140 min after intravenous injection of 1 MBq of Ga-68 labeled compound per mouse using the Inveon PET small-animal PET
20 scanner (Siemens). Images were reconstructed iteratively using the 3D-OSEM+MAP method and were converted to standardized uptake value (SUV) images. Quantification was done using a ROI technique and expressed as SUV mean. For organ distribution of Lu-177 labeled compound (approx. 10 MBq per mouse), the animals ($n = 3$ for each time point) were sacrificed after indicated time points (from 30 min to 24 h). The distributed radioactivity was measured
25 in all dissected organs and in blood using a γ -counter (Cobra Autogamma, Packard). The values are expressed as percentage of injected dose per gram of tissue (%ID/g).

For pharmacokinetic modeling the transport constant K_1 and the rate constants k_2 – k_4 were calculated using a two-tissue compartment model implemented in the PMOD software [4], taking into account the vascular fraction (v_B), which is associated with the volume of blood
30 exchanging with tissue in a VOI. The rate constants that describe the compartmental fluxes include k_1 (binding to the receptor), k_2 (detachment) as well as k_3 (internalization) and k_4 (efflux) in the tumor tissue. In this model the fractional volume of distribution ($DV = K_1/k_2$) is the proportion of the region of interest in which ^{15}O -labelled water is distributed.

FAPI variants accumulate in human FAP-expressing xenografts as well as in xenografts without FAP expression by recruitment and activation of mouse fibroblasts.

Tumor accumulation of FAPI-02 and -04 was assessed by small-animal PET imaging of mice bearing xenografts from both human FAP-positive and negative tumor cells. In both cases the radiotracer gets rapidly enriched within the tumor and is maintained for at least 140 min (Figure 3A, C, E, G). At the same time, FAPI-02 and -04 show negligibly low unspecific binding and get quickly eliminated from the blood predominantly via the kidneys and bladder resulting in a low background and beneficial tumor-to-organ ratios. Simultaneous administration of unlabeled compound as competitor resulted in a complete absence of radioactivity in the tumor, demonstrating the specificity of the radiotracer to its target protein (Figure 4). Interestingly, a high tumor uptake of FAPI-02 was observed in mice bearing FAP- α positive (HT-1080-FAP) as well as FAP- α negative (Capan-2) tumor cell lines due to recruitment and activation of activated mouse fibroblasts. Pharmacokinetic characteristics of the radiotracer, calculated from PET data using a two-tissue compartment model according to Burger et al., *Nucl Med*, 1997, are given in Table 6.

Pharmacokinetic analysis of FAPI-02

| | Unit | Capan-2 - comp. | HT-1080-FAP - comp. | HT-1080-FAP + comp. |
|------------------------|------------|--------------------|------------------------|------------------------|
| vB | l/l | 0.08 | 0.04 | 0.04 |
| k1 | ml/ccm/min | 0.08 | 0.07 | 0.10 |
| k2 | l/min | 0.16 | 0.13 | 0.32 |
| k3 | l/min | 0.08 | 0.10 | 0.04 |
| k4 | l/min | 0.05 | 0.02 | 0.07 |
| Vs | ml/ccm | 0.93 | 2.31 | 0.18 |
| Vt | ml/ccm | 1.44 | 0.87 | 0.48 |
| Flux | ml/ccm/min | 0.03 | 0.03 | 0.01 |
| Chi² | ---- | 0.10 | 0.11 | 0.26 |

Table 6. Pharmacokinetic characteristics of ⁶⁸Ga-FAPI-02, calculated from dynamic PET data using a two-tissue compartment model according to Burger et al., *Nucl Med*, 1997. vB: vascular fraction, associated with the volume of blood exchanging with tissue in a VOI (volume of interest); k1-k4: calculated rate constants; Vs: ratio of specific binding concentration to total parent at equilibrium; Vt: total distribution volume.

These observations were confirmed using ¹⁷⁷Lu-FAPI-02 and -04 in a biodistribution study, proving rapid tumor accumulation in both human FAP- α positive and negative tumors with very low activity in all the other organs (quantified uptake values see Table 7), resulting in

beneficial tumor-to-organ ratios (Figure 5D-F). Similar results were obtained for ^{177}Lu -FAPI-04 in HT-1080-FAP tumor bearing mice. Compared to FAPI-02, FAPI-04 shows a higher tumor uptake especially after 24 h (Figure 5C). A calculation of the area under curve (AUC) is shown in Table 8.

5

| | FAPI-02 (Capan-2) | FAPI-02 (HT-1080-FAP) | FAPI-04 (HT-1080-FAP) |
|-------------------|------------------------------|----------------------------------|----------------------------------|
| Blood | 0.83 ± 0.127 | 1.20 ± 0.178 | 1.70 ± 0.206 |
| Brain | 0.05 ± 0.010 | 0.06 ± 0.006 | 0.08 ± 0.010 |
| Heart | 0.37 ± 0.031 | 0.56 ± 0.085 | 0.80 ± 0.089 |
| Intestines | 0.30 ± 0.064 | 0.37 ± 0.046 | 0.66 ± 0.196 |
| Kidneys | 1.45 ± 0.106 | 1.60 ± 0.075 | 2.28 ± 0.477 |
| Liver | 0.36 ± 0.015 | 0.45 ± 0.074 | 0.73 ± 0.118 |
| Lungs | 0.72 ± 0.021 | 1.02 ± 0.152 | 1.50 ± 0.151 |
| Muscle | 0.94 ± 0.168 | 1.17 ± 0.332 | 0.92 ± 0.020 |
| Spleen | 0.25 ± 0.015 | 0.38 ± 0.051 | 0.48 ± 0.072 |
| Tumor | 3.82 ± 0.390 | 4.51 ± 0.816 | 4.89 ± 0.817 |

Table 7. Quantification of biodistribution data 1 h after intravenous administration of Lu-177 labeled FAPI-02 and -04 to tumor bearing Balb/c nude mice; $n=3$; values reported as mean %ID/g ± SD.

| %ID/g | 1 h | 4 h | 24 h | AUC |
|----------------|------------|------------|-------------|------------|
| FAPI-02 | 4.5 ± 0.82 | 4.0 ± 0.56 | 1.12 ± 0.13 | 64.0 |
| FAPI-04 | 4.9 ± 0.82 | 5.4 ± 1.51 | 3.0 ± 0.23 | 99.4 |
| FAPI-05 | 6.0 ± 0.90 | 5.8 ± 0.60 | 2.8 ± 0.40 | 103.3 |
| FAPI-10 | 3.2 ± 0.72 | 2.9 ± 0.12 | 1.1 ± 0.04 | 49.3 |
| FAPI-13 | 6.3 ± 0.57 | 8.7 ± 0.77 | 4.8 ± 1.71 | 157.5 |
| FAPI-15 | 3.4 ± 1.13 | 4.6 ± 0.32 | 1.1 ± 0.25 | 68.0 |

10

Table 8. Tumor uptake of selected FAPI derivatives in HT-1080-FAP tumor bearing nude mice, $n=3$. Values are reported as mean ID/g ± SD).

Example 4: Clinical PET/CT studies.

15 Diagnostic imaging of more than 100 patients was performed under the conditions of the updated declaration of Helsinki, § 37 (Unproven interventions in clinical practice) and in accordance to the German Pharmaceuticals Law §13 (2b) for medical reasons using either ^{68}Ga -

FAP1-02 or -04, which was applied intravenously (20 nmol, 122-336 MBq), 10 min, 1 and 3 hours post tracer administration. Variation of injected radiotracer activity is due to the short half-life of ^{68}Ga and the variable elution efficiencies obtained during the lifetime of the $^{68}\text{Ge}/^{68}\text{Ga}$ generator. FDG imaging of one patient was conducted 1 h after intravenous injection of 358 MBq ^{18}F -FDG. The PET/CT scans were performed with a Biograph mCT FlowTM PET/CT-Scanner (Siemens Medical Solution) using the following parameters: slice thickness of 5 mm, increment of 3-4 mm, soft-tissue reconstruction kernel, care dose. Immediately after CT scanning, a whole-body PET was acquired in 3D (matrix 200x200) in FlowMotionTM with 0.7 cm/min. The emission data were corrected for random, scatter and decay. Reconstruction was conducted with an ordered subset expectation maximisation (OSEM) algorithm with 2 iterations/21 subsets and Gauss-filtered to a transaxial resolution of 5 mm at full-width half-maximum (FWHM). Attenuation correction was performed using the low-dose non-enhanced CT data. The quantitative assessment of standardized uptake values (SUV) was done using a region of interest technique.

15

FAP1-02 and -04 rapidly accumulate in breast, pancreatic, lung, HNO, small intestine and ovarian cancer metastases in humans.

Diagnostic PET/CT scans were performed 1 h after intravenous administration of ^{68}Ga -FAP1-02 and -04 in patients with metastasized breast, lung, pancreatic, HNO, small intestine and ovarian cancer. In all patients a robust accumulation of the tracer was observed in the primary tumor as well as in lymph node and bone metastases with maximum SUV values of 48.0. In contrast, tracer uptake into normal tissue was very low (Figures 6-14). The radioactivity was cleared rapidly from the blood stream and excreted predominantly via the kidneys, resulting in high contrast images. Comparative imaging in one patient with locally advanced lung adenocarcinoma revealed an obvious advantage of FAP1-02 compared to the commonly used PET tracer ^{18}F -FDG. As shown in Figure 9, FAP1-02 shows a higher uptake with lower background activity leading to a higher contrast with better visibility of metastatic lesions. In contrast to FDG, which is highly accumulating in cells with high glucose consumption e.g. the brain, FAP1-02 selectively targets tissues where FAP- α is expressed. Comparative imaging in one patient with prostate cancer revealed an obvious advantage of FAP1-04 compared to the commonly used PET tracers ^{68}Ga -DOTATOC and ^{68}Ga -PSMA, allowing the detection of smaller tumor lesions with reduced tracer accumulation in the kidneys (Figure 14).

Discussion

The reliable diagnosis of primary tumors, metastatic lesions and affected lymph nodes is of utmost importance to allow for effective and adequate therapy planning including tumor staging and choice of treatment. For this purpose, imaging techniques represent indispensable tools for the assessment of many cancer types. Due to its high diagnostic accuracy and the possibility to evaluate both anatomic and physiologic details, combined PET/CT is the method of choice for modern tumor diagnostics. In contrast to non-invasive imaging techniques such as MRT or CT alone, combined PET/CT, however, requires the use of radiotracers with a high affinity to target structures with enhanced expression in tumors as compared to normal tissues. An ideal tracer should specifically bind to its target protein to ensure reliable differentiation of cancerous and healthy tissue as well as low background signals resulting in high-contrast images. Affinity and specificity become even more important if the radiotracer represents a theranostic compound, i.e. offers the possibility to be loaded with either diagnostic or therapeutic nuclides, which facilitates and improves targeted and personalized treatment. Regarding a potential application of the tracer for therapeutical purposes, high target specificity assures reduced side-effects, which is especially important for the protection of radiation sensitive tissue such as bone marrow, reproductive and digestive organs.

With that in mind, the inventors developed a theranostic tracer targeting cancer-associated fibroblasts which form a major component of the tumor stroma. They are known to play a critical role in tumor growth, migration and progression and are genetically more stable than cancer cells, therefore, being less susceptible to the development of therapy resistance. In contrast to normal fibroblasts, CAFs express particular proteins which can be used as tumor-specific markers. Among these is the membrane protein FAP- α which is broadly expressed in the microenvironment of a variety of tumors and thus enables targeting of different tumor entities including pancreas, breast and lung cancer, which account for a large part of the entirety of solid tumors.

Based on a small molecule enzyme inhibitor with high affinity to its target protein, we developed the radiotracers FAPI-01 to FAPI-73 by focused chemical modification. All compounds show specific binding to human and murine FAP- α with a rapid and almost complete internalization without addressing the closely related protein CD26/DPP4. Since iodinated molecules undergo an enzymatic deiodination with efflux of free iodine, longer incubation times result in a low intracellular radioactivity. On this account, FAPI-02 and subsequent compounds were designed with the FAP-binding moiety being chemically linked to the chelator DOTA. This results in a set of theranostic compounds with favorable

pharmacokinetic and biochemical properties, of which FAPI-02, FAPI-04, FAPI-46, FAPI-34, FAPI-42, FAPI-52, FAPI-69, FAPI-70, FAPI-71, FAPI-72 and FAPI-73 represent the most favored ligands. FAPI-02 and FAPI-04 both get eliminated significantly slower than FAPI-01, with retention of 12 % (FAPI-02) and 49 % (FAPI-04) of the originally accumulated radioactivity after 24 h (FAPI-01 1.1 %) with the other favored compounds having an even stronger binding (figure 16). They rapidly internalize into FAP- α expressing cells and show high tumor uptake rates in both tumor bearing mice and patients with metastasized epithelial carcinomas. In contrast, there is no accumulation in normal tissue and rapid clearance from the blood system, resulting in high-contrast images. The robust internalization into both human and murine FAP- α expressing cells was confirmed by confocal microscopy using fluorescence-labeled FAPI-02. In contrast to the first generation FAP-antibody F19, which has high affinity to its target protein without being internalized, FAPI-02 shows complete intracellular uptake after 1 h of incubation. The mechanism of internalization after FAP binding has been studied by Fischer et al. using FAP antibody fragments (Fabs) and a DyLight 549 anti-mouse antibody in SK-Mel-187 cells. Incubation at 37 °C led to internalization of the FAP-antibody complexes. As with our small molecule, the internalization process occurred rapidly with an almost complete internalization. Colocalization of the Fabs with a marker for early endosomes was observed after 20 minutes and with a marker for late endosomes and lysosomes after 40 minutes. Fab-mediated FAP- α internalization was suppressed by an inhibitor for dynamin dependent endocytosis, indicating that endocytosis occurs by a dynamin-dependent mechanism.

FAPI-02 and -04 get quickly eliminated from the organism by renal clearance without being retained in the renal parenchyma. In contrast to ^{18}F -FDG, which is highly accumulating in cells with high glucose consumption including inflammatory tissue or the brain, FAPI-02 gets selectively enriched in tissues where its target protein is expressed. This opens new perspectives for the detection of malign lesions in these regions. Additionally, FAP- α was also shown to be expressed by rheumatoid myofibroblast-like synoviocytes in patients with rheumatoid arthritis and osteoarthritis, atherosclerosis, fibrosis as well as in ischemic heart tissue after myocardial infarction. These observations suggest the application of FAPI-02 and -04 as imaging tracers for further indications.

The limiting factor for the detection of tumor lesions is the degree of FAP- α expression within the tumor. This largely depends on the number of activated fibroblasts, i.e. the percentage of stromal content, and/or the number of FAP- α molecules per fibroblast which may be determined by the microenvironment. Since tumor growth exceeding a size of 1 to 2 mm essentially

requires the formation of a supporting stroma, visualization of small lesions in the range of 3-5 mm should be possible using FAPI-PET/CT.

As with any other targeted approach, the FAPI derivatives only achieve optimal results in tissues with sufficiently high FAP- α expression which is known to be rather heterogeneous in different cancer types and patients. Besides breast, colon and pancreatic cancer, which are excellent candidates for FAPI imaging, further analyses have to explore whether other tumor entities such as lung cancer, head and neck cancer, ovarian cancer or hepatomas represent favorable targets.

Also, FAP- α expression was demonstrated in wound healing and fibrotic tissue, which should be kept in mind when interpreting radiological findings. These facts emphasize the necessity to properly evaluate which patients are likely to benefit from a potential FAPI therapy. Given the ability to use either diagnostic or therapeutic nuclides, FAPI-02 and -04 allow simple stratification of the appropriate patient cohort. Either way, it is already clear that both FAPI tracers represent ideal candidates for the development of a targeted radiopharmaceutical. Due to their high target affinity, rapid tumor internalization and fast body clearance, they are already ideally suitable for tumor imaging.

Example 5: FAPI characterization *in vitro* and *in vivo*

Experimental procedures and clinical evaluation

All *in vitro* and *in vivo* experiments as well as the clinical evaluation of the FAPI derivatives have been performed as described above and according to Loktev *et al.*¹ and Lindner *et al.*² A preliminary dosimetry estimate for FAPI-02 and FAPI-04 was based on two patients examined at 0.2 h, 1 h and 3 h post tracer injection using the QDOSE dosimetry software suit. Further PET/CT scans of tumor patients were acquired 1 h after injection of either FAPI-02 (n=25) or FAPI-04 (n=25); for 6 patients an intra-individual related FDG-scan (also acquired 1 h p.i.) was available. For the normal tissue of 16 organs, a 2 cm Spheric-VOI was placed in the parenchyma, for tumor lesions a threshold segmented VOI was used to quantify SUV_{mean}/max³.

In vitro characterization of DOTA-FAPI derivatives

To assess target binding and internalization rate of the DOTA-FAPI derivatives as compared to FAPI-04, Lu-177-labeled compounds were incubated with FAP-expressing HT-1080 cells for 1, 4 and 24 h, respectively (figure 16). The membrane-bound fraction was removed by acidic

elution using glycine-HCl pH 2.2 followed by alkaline cell lysis to determine the internalized fraction. As shown in Figure 16, all derivatives demonstrate higher cell binding as compared to FAPI-04 with binding values up to 500 % of the lead compound after 1 h of incubation (up to 750 % after 4 h).

- 5 To evaluate target affinity and specificity, competitive binding assays were performed using increasing concentrations of unlabeled compound as competitor of Lu-177-labeled compound (Figure 17; respective IC₅₀ values listed in Table 9). Specificity of binding was also confirmed in a radioligand binding assay using murine FAP- and CD26-expressing HEK cells (Figure 18).

| Compound | IC ₅₀ (nM) | Compound | IC ₅₀ (nM) |
|----------|-----------------------|----------|-----------------------|
| FAPI-04 | 6.5 | FAPI-39 | 11.3 |
| FAPI-05 | 17.2 | FAPI-40 | 12.7 |
| FAPI-10 | 19.9 | FAPI-41 | 8.3 |
| FAPI-13 | 4.5 | FAPI-46 | 13.5 |
| FAPI-15 | 9.1 | FAPI-47 | 42.0 |
| FAPI-20 | 7.2 | FAPI-48 | 26.3 |

Table 9. IC₅₀ values of selected FAPI derivatives as determined by competitive binding assays

10 Organ distribution of DOTA-FAPI derivatives in tumor-bearing mice

For analysis of pharmacokinetic profile as well as tumor uptake *in vivo*, Lu-labeled DOTA-FAPI derivatives were administered i.v. to HT-1080-FAP tumor-bearing mice. Organ distribution of the radiolabeled compounds was determined *ex vivo* in the blood, healthy tissues and the tumor. As shown in Figure 19, most of the compounds demonstrate higher tumor uptake rates as compared to FAPI-02 and FAPI-04, notably 24 h after administration. Due to increased lipophilicity, some of the radiotracers show higher blood activities as well as an increased retention in the kidneys. Determination of tumor-blood-ratios yet reveals a clear advantage of the compounds FAPI-21 and FAPI-46 which demonstrate significantly higher ratios than FAPI-04 at all times examined (Figure 20).

20

Small-animal imaging of DOTA-FAPI derivatives in tumor-bearing mice

Based on these findings, small animal PET-imaging was performed using Ga-68-labeled DOTA-FAPI derivatives up to 140 min after i.v. administration of the radiotracers in HT-1080-FAP tumor-bearing mice. The beneficial tumor-blood ratios of FAPI-21 and FAPI-46 result in high contrast images, enabling excellent visualization of the FAP-positive tumors (Figure 21).

25

A quantitative analysis of the tracer accumulation in the tumor, the kidneys, the liver and muscle tissue (given as SUV max values) reveals slightly lower muscular, renal and hepatic activities of FAPI-46 as compared to FAPI-21 (Figure 22).

5 Biodistribution and dosimetry estimate of FAPI-02 and FAPI-04 compared to FDG in cancer patients

Very similar to literature values for F-18-FDG, Ga-68-DOTATATE or Ga-68-PSMA-11, an exam with 200 MBq Ga-68-FAPI-02 and -04 corresponds to an equivalent dose of approx. 3-4 mSv. After a fast clearance via the kidneys, the normal organs show a low tracer uptake with only minimal changes between 10 min and 3 h p.i. In FAPI-02, the tumor uptake from 1 h to 3 h p.i. decreases by 75 %, whereas the tumor retention is slightly prolonged with FAPI-04 (50 % washout). At 1 h p.i. both FAPI-tracers perform equally (Figure 23). In comparison to FDG, tumor uptake is almost equal (average SUV max FDG 7.41; SUV max FAPI-02 7.37; n.s.); the background uptake in brain (11.01 vs 0.32), liver (2.77 vs 1.69) and oral/pharyngeal mucosa (4.88 vs 2.57) is significantly lower with FAPI-02; other organs were not relevantly different between FDG and FAPI-02 (Figure 24). For detailed information and results see Giesel *et al.*³ which is incorporated by reference herewith.

20 PET imaging of FAPI-04 in patients with various cancers as well as non-cancerous malignancies

In addition to a rapid uptake of Ga-68-labeled FAPI-04 in different cancers including breast, pancreas, ovarian and HNO tumors, tracer accumulation was also demonstrated in peritonitis carcinomatosa (Figure 25A) as well as several inflammatory malignancies such as myocarditis (Figure 25B) and arthrosis (Figure 25C). These results indicate a potential application of Ga-68-labeled FAPIs for the detection of non-cancerous malignancies which are characterized by a chronic inflammation process involving recruitment of activated fibroblasts.

PET imaging of FAPI-21 and FAPI-46 in patients with various cancers

As shown in Figure 26, robust accumulation of Ga-68-labeled FAPI-21 was observed in different cancers including ovarian, rectal and mucoepidermoid carcinoma. Similar tumor uptake was shown for Ga-68-labeled FAPI-46 which rapidly accumulated in cholangiocellular and colorectal carcinoma, lung cancer as well as solitary fibrous sarcoma (Figure 27). Following PET/CT examination using Ga-68 labeled FAPI-46, a first therapeutical approach

using the Sm-153 labeled radiotracer was taken in two cancer patients. As shown in Figure 28, robust tumor accumulation of the tracer is detectable up to 20 h after administration.

FAPI-46-PET/CT imaging of three lung cancer patients with idiopathic pulmonary fibrosis revealed a clear difference of tracer accumulation in the cancerous vs. fibrotic lesions. As shown in Figure 30, tumor uptake of Ga-68 labeled FAPI-46 was significantly higher in two patients (A, B) but slightly lower in one patient (C), as compared to the activity measured in the fibrotic tissue. The patient shown in Figure C suffered from an exacerbated lung fibrosis as compared to the two non-exacerbated cases. Therefore, the tracer is possibly useful for the differentiation of fibrosis patients with bad prognosis from patients with a good prognosis.

10

FAPI derivatives for radiolabeling with alternative radionuclides, e.g. Tc-99m, Pb-203, Cu-64 and F18

To enable the use of alternative radionuclides, a series of FAPI derivatives have been designed and characterized with respect to target affinity, specificity and pharmacokinetics. In some of these compounds, the original chelator DOTA has been replaced by different chelating moieties, which are ideally suitable for the incorporation of Tc-99m (FAPI-19, -27, -28, -29, -33, -34, -43, -44, -45, -60, -61, -62). FAP affinity *in vitro* and biodistribution in HT-1080-FAP xenografted mice are shown exemplarily for FAPI-19 and FAPI-34. Both compounds demonstrate a robust binding to human FAP *in vitro* (IC₅₀ FAPI-19: 6.4 nM). In contrast to FAPI-19, which shows insufficient tumor uptake *in vivo* as well as a rapid accumulation in the liver due to a shift of renal towards hepatic elimination, FAPI-34 is continuously enriched within the tumor and demonstrates significantly less hepatic uptake (Figures 31, 32). A first diagnostic application of Tc-99m labeled FAPI-34 in a pancreas cancer patient with liver metastases shows a stable tumor accumulation of the tracer up to 4 h after administration. In addition, the overall background activity is comparably low, resulting in high-contrast images (Figure 33). This offers a widespread application for diagnosis by scintigraphy and therapy after labeling with Re-188.

Pb-203 radiolabeled FAPI derivatives (FAPI-04, -32, -46 and FAPI-04tcmc) show comparable cell binding to HT-1080-FAP cells with FAPI-32 and FAPI-04tcmc reaching the highest binding values after 60 min of incubation (26.93 ± 0.846 and 21.62 ± 0.61 %ID/1 mio cells, Figure 34A). While FAPI-32 is rapidly eliminated from the tumor cells upon initial binding ($t_{1/2} = 2$ h), FAPI-04tcmc demonstrates considerably slower cell efflux ($t_{1/2} = 7$ h) but also the lowest FAP affinity as shown by the competition assay (IC₅₀ = 5.7 μM, Figure 34C). On this account, FAPI-04 and FAPI-46, characterized by optimal half-lives and IC₅₀-values, were selected for

30

further analysis *in vivo*. As shown in Figure 35, both compounds get continuously enriched within the tumor while showing only negligibly low binding to healthy tissue. The scintigraphic findings are confirmed in a biodistribution study, where both radiotracers demonstrate a robust tumor uptake, overall low organ activities as well as rapid renal excretion (Figure 36).

- 5 To enable radioactive labeling using Cu-64, the NOTA-derivatives FAPI-42 and FAPI-52 have been developed and characterized with respect to target affinity, specificity and pharmacokinetics. As shown in Figure 37, both tracers show a robust binding to HT-1080-FAP cells up to 24 h of incubation with similar IC₅₀-values in the lower nanomolar range (Figure 37A, B). Yet, FAPI-42 gets eliminated significantly slower than FAPI-52, resulting in a
- 10 calculated *in vitro*-half-life of 12 h (Figure 37C). These results are confirmed by small animal imaging of HT-1080-FAP xenografted mice. As shown in Figure 38, both compounds demonstrate a robust tumor uptake as well as a rapid clearance from the blood stream *in vivo*. Notably, renal excretion of FAPI-42 occurs significantly faster as compared to FAPI-52, while its tumor activity remains slightly higher in the course of 2 to 24 h after administration.
- 15 The NOTA-derivatives FAPI-42 and FAPI-52 have been deployed for the formation of aluminum fluoride complexes to allow imaging with F-18. As shown in Figure 39, both compounds demonstrate a rapid tumor uptake in small animal imaging of HT-1080-FAP xenografted mice. Although both compounds are mainly excreted by the renal pathway, a biliary elimination is also observed. While the renal excretion is faster for FAPI-52 the higher
- 20 tumor accumulation, longer tumor retention and the lower proportion of the biliary pathway are in favor of FAPI-42.

References

- 1 Loktev, A. *et al.* A new method for tumor imaging by targeting cancer associated
25 fibroblasts. *Journal of nuclear medicine : official publication, Society of Nuclear
Medicine*, doi:10.2967/jnumed.118.210435 (2018).
- 2 Lindner, T. *et al.* Development of quinoline based theranostic ligands for the targeting
of fibroblast activation protein. *Journal of nuclear medicine : official publication,
Society of Nuclear Medicine*, doi:10.2967/jnumed.118.210443 (2018).
- 3 Giesel, F. *et al.* FAPI-PET/CT: biodistribution and preliminary dosimetry estimate of
30 two DOTA-containing FAP-targeting agents in patients with various cancers. *Journal
of nuclear medicine : official publication, Society of Nuclear Medicine*,
doi:10.2967/jnumed.118.215913 (2018).

Example 6: FAPI characterization *in vitro* and *in vivo*Preclinical data

With the objective of selectively targeting FAP-positive brain tumors, initial experiments were performed in tumor bearing mice using the human glioblastoma xenograft model U87MG.

- 5 Tumor accumulation and organ distribution of radiolabeled FAPI-02 and -04 were analyzed by small animal PET imaging as well as in a biodistribution study. As shown in Fig. 40 and 41, both FAPI-02 and -04 demonstrate rapid tumor uptake and negligibly low activities in healthy organs and the blood.

10 Clinical data

According to the WHO classification of 2016, gliomas are subdivided in IDH-wildtype gliomas WHO grade I-IV and IDH-mutant gliomas WHO grade II-IV. The most frequent WHO grade IV gliomas are glioblastomas.

- 15 Clinical PET-imaging was performed in 18 glioma patients (5 IDH mutant gliomas, 13 IDH-wildtype glioblastomas; see Table 10). As shown in Fig. 42-44, IDH-wildtype glioblastomas and grade III/IV, but not grade II IDH-mutant gliomas showed elevated tracer uptake. In glioblastomas, spots with increased uptake in projection on contrast enhancing areas were observed.

20 Conclusion

Increased tracer uptake in IDH-wildtype glioblastomas and high-grade IDH-mutant astrocytomas, but not in diffuse astrocytomas may allow non-invasive distinction between low-grade IDH-mutant and high-grade gliomas and be useful for follow-up studies. The heterogeneous tracer uptake in glioblastomas may be helpful for biopsy planning.

Table 10: Patient characteristics

| Patient Number | Age (years) | IDH status | Diagnosis | WHO Grade | Localization | Biopsy Surgery | Pretreatment |
|----------------|-------------|---------------------|------------------------|-----------|------------------------------|-------------------|--------------------|
| 1 | 57 | wildtype | Glioblastoma | IV | parietal right | Biopsy | Radio-chemotherapy |
| 2 | 65 | wildtype | Glioblastoma | IV | bifrontal | Biopsy | none |
| 3 | 66 | wildtype | Glioblastoma | IV | parieto-temporal left | Biopsy | none |
| 4 | 64 | wildtype | Glioblastoma | IV | temporal right | Resection | Radio-chemotherapy |
| 5 | 58 | wildtype | Glioblastoma | IV | Splenium | Biopsy | none |
| 6 | 48 | wildtype | Glioblastoma | IV | fronto-temporo-parietal left | Resection | Radio-chemotherapy |
| 7 | 20 | wildtype | Glioblastoma | IV | Thalamus / temporal right | Biopsy | none |
| 8 | 54 | wildtype | Glioblastoma | IV | temporal left | Resection | none |
| 9 | 56 | wildtype | Glioblastoma | IV | basal ganglia | Partial Resection | none |
| 10 | 61 | wildtype | Glioblastoma | IV | temporal right | Resection | none |
| 11 | 86 | wildtype | Glioblastoma | IV | Corona radiata left | Biopsy | Chemotherapy |
| 12 | 68 | wildtype | Glioblastoma | IV | Corpus callosum | Biopsy | none |
| 13 | 71 | wildtype | Glioblastoma | IV | temporal left | Biopsy | none |
| 14 | 29 | IDH1 R132H Mutation | Glioblastoma | IV | temporo-parietal right | Resection | none |
| 15 | 47 | IDH1 R132H Mutation | Anaplastic astrocytoma | III | frontal right | Resection | none |
| 16 | 47 | IDH1 R132H Mutation | Diffuse astrocytoma | II | parietal left | Biopsy | none |
| 17 | 47 | IDH1 R132C Mutation | Diffuse astrocytoma | II | frontal right | Resection | none |
| 18 | 43 | IDH1 R132H Mutation | Diffuse astrocytoma | II | fronto-temporal left | Biopsy | Chemotherapy |

Example 7: FAPI characterization *in vitro* and *in vivo*Reuptake experiments

For reuptake experiments, ¹⁷⁷Lu-labeled FAPI-04 and -46 (5 MBq/nmol in DMEM) were added to HT-1080-FAP cells and incubated for 60 min at 4 and 37°C, respectively. Radioactive medium was removed and cells were washed twice with phosphate-buffered saline (PBS) pH 7.4. Subsequently, non-radioactive medium with and without unlabeled FAPI (1 μM) was added for time intervals ranging from 10 min to 6 h. The cells were washed twice with PBS pH 7.4. To remove the surface bound activity, the cells were incubated with glycine-HCl (1 M in PBS, pH 2.2) for 10 min at room temperature. After washing twice with ice-cold PBS, the cells were lysed with 1.4 mL of lysis buffer (0.3 M NaOH, 0.2% SDS) to determine the internalized fraction. For the cells incubated at 4 °C, all washing and elution steps were carried out using ice-cold buffers. The radioactivity was measured using a γ-counter (Packard Cobra II), normalized to 1 mio cells and calculated as percentage of applied dose (%AD; see Fig. 47).

15 Enzyme inhibition assay

To determine potential inhibitory effects of FAPI-04 on the enzymatic FAP activity, enzyme inhibition assays were performed using recombinant human FAP protein (1 pmol/well) in a 48-well plate. After incubation of FAPI-04 or Talabostat (0 – 1000 nM/well) with human FAP for 30 min at 37 °C, the fluorogenic FAP substrate Z-GP-AMC was added to a final concentration of 0 – 200 μM/well and incubated for 60 min at 37°C. The enzymatic activity of FAP was determined by measuring the fluorescence intensity of the reaction product AMC at 360/460 nm using the SpectraMax M2 Plate Reader (Molecular Devices, San José, USA) (see Fig. 46).

Multiple administration of FAPI-04 to HT-1080-FAP tumor bearing mice

25 For biodistribution experiments, 8 week old BALB/c *nu/nu* mice (Charles River) were subcutaneously inoculated into the right trunk with 5 mio HT-1080-FAP cells, respectively. When the size of the tumor reached approximately 1 cm³, the radiolabeled compound was injected via the tail vein. The first group of animals was administered a single dose of ¹⁷⁷Lu-FAPI-04 (2 MBq per animal), whereas the second group received two doses of 1 MBq each, with the second dose given 4 h after the first injection. The third group was administered three doses in total, with an initial dose of 1 MBq per mouse, followed by 0.5 MBq 2 h and additional 0.5 MBq 4 h after the first injection. The animals (*n* = 3 for each time point) were sacrificed 8 and 24 h after the first injection. The distributed radioactivity was measured in all dissected

organs and in blood using a γ -counter (Cobra Autogamma, Packard). The values are expressed as percentage of injected dose per gram of tissue (%ID/g) (see Fig. 48).

Example 8: FAPI characterization *in vitro* and *in vivo*

5 Experimental Procedures and Clinical Evaluation

All *in vitro* and *in vivo* experiments as well as the clinical evaluation of the FAPI derivatives have been performed as described in the initial document and according to Loktev *et al.*¹ and Lindner *et al.*²

10 Results

In vitro Characterization of F-18-FAPI Derivatives

All experiments were carried out analogous to FAPI-42 (AIF-18 labeling) or FAPI-72 (F-18 nicotinamide labeling).

| Compound | IC ₅₀ (nM) | Compound | IC ₅₀ (nM) |
|----------|--------------------------|----------|--------------------------|
| FAPI-72 | 2.4 | FAPI-74 | 9.2 |
| FAPI-73 | 5.4 | FAPI-75 | 2.9 |

15 **Table 11.** EC₅₀ values of selected FAPI derivatives as determined by competitive binding assays

Determination of blood pool clearance

To estimate the rate of clearance of the compound, half-life times were calculated by a presumed two phase exponential decay from the SUVmean values (0.375-60 min) of the heart as representation of the blood pool. All selected compounds were cleared very fast with half-life times below 10 min. The calculated plateau values, which were higher for Ga-68 labeled FAPI-13, -21, -36 and AIF-18 labeled FAPI-74 theoretically correspond to a higher fraction of compound which is not cleared due to unspecific binding or by remaining in circulating (Table 12). As an example for the fast clearance the time activity curves for FAPI-04 and -46 between 25 0 and 15 min are shown in Figure 53.

| Compound | Blood pool-clearance ($T_{1/2}$ [min]) | Plateau value (SUVmean) |
|----------|---|-------------------------|
| FAPI-04 | 7.1 | 0.21 |
| FAPI-13 | 5.5 | 0.27 |
| FAPI-21 | 5.1 | 0.31 |
| FAPI-36 | 5.0 | 0.58 |
| FAPI-46 | 5.3 | 0.19 |
| FAPI-74 | 2.4 | 0.32 |

Table 12. Blood pool half lifes and the hypothetical plateau value of selected FAPI-derivatives calculated from SUVmean-values by a presumed two phase exponential decay. For clarity only the rate determining half-life values are listed.

5 *Small-Animal Imaging of F-18-FAPI Derivatives in Tumor-Bearing Mice*

Based on these findings, small animal PET-imaging was performed using F-18-labeled NOTA- and F-18-nicotinamide-labeled FAPI derivatives up to 140 min after i.v. administration of the radiotracers in HT-1080-FAP tumor-bearing mice. The F-18-nicotinamide derivatives FAPI-72, -73 and -77 showed an unfavorable accumulation in the liver as well as a biliary excretion, while FAPI-78 was renally excreted but showed no tumor uptake. In case of the AlF-18 labeled
 10 NOTA derivatives FAPI-74 and -75 a high target specificity and fast clearance was observed, resulting in high contrast images, which enable excellent visualization of the FAP-positive tumors (Figure 50).


15 *Organ Distribution of F-18-FAPI Derivatives in Tumor-Bearing Mice*

For analysis of pharmacokinetic profile as well as tumor uptake *in vivo*, AlF-18-labeled FAPI-75 was administered i.v. to HT-1080-FAP tumor-bearing mice. Organ distribution of the radiolabeled compound was determined *ex vivo* in the blood, healthy tissues and the tumor. As shown in Figure 51, the compounds demonstrates high tumor uptake, although in comparison
 20 to Ga-68 labeled DOTA derivatives a higher accumulation in healthy tissue is observed, while performance in PET imaging was equal.

Items

The following items represent preferred embodiments of the present invention.

1. A compound of Formula (I)



wherein

Q, R, U, V, W, Y, Z are individually present or absent under the proviso that at least three of Q, R, U, V, W, Y, Z are present;

10 Q, R, U, V, W, Y, Z are independently selected from the group consisting of O, CH₂, NR⁴, C=O, C=S, C=NR⁴, HCR⁴ and R⁴CR⁴, with the proviso that two Os are not directly adjacent to each other;


R¹ and R² are independently selected from the group consisting of -H, -OH, halo, C₁₋₆-alkyl, -O-C₁₋₆-alkyl, S-C₁₋₆-alkyl;

15 R³ is selected from the group consisting of -H, -CN, -B(OH)₂, -C(O)-alkyl, -C(O)-aryl-, -C=C-C(O)-aryl, -C=C-S(O)₂-aryl, -CO₂H, -SO₃H, -SO₂NH₂, -PO₃H₂, and 5-tetrazolyl;

R⁴ is selected from the group consisting of -H, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl, and -C₁₋₆-aryl, each of said -C₁₋₆-alkyl being optionally substituted with from 1 to 3 substituents selected from -OH, oxo, halo and optionally connected to Q, R, U, V, W, Y or Z;

20 R⁵ is selected from the group consisting of -H, halo and C₁₋₆-alkyl;

R⁶, and R⁷ are independently selected from the group consisting of -H,



same time H,


wherein L is a linker,

25 wherein D, A, E, and B are individually present or absent, preferably wherein at least A, E, and B are present, wherein when present:

D is a linker;

A is selected from the group consisting of NR⁴, O, S, and CH₂;

E is selected from the group consisting of



wherein i is 1, 2, or 3;

wherein j is 1, 2, or 3;

5 wherein k is 1, 2, or 3;


wherein m is 1, 2, or 3;

A and E together form a group selected from: a cycloalkyl, heterocycloalkyl, aryl and heteroaryl, preferably heterocycloalkyl, wherein A and E can be mono-, bi- and multicyclic, preferably monocyclic; each A and E being optionally substituted with 1 to 4 substituents selected from -H, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl, and -C₁₋₆-aralkyl, each of said -C₁₋₆-alkyl being optionally substituted with from 1 to 3 substituents selected

10 from -OH, oxo, halo; and optionally connected to A, B, D, E or ;

B is selected from the group consisting of S, NR⁴, NR⁴-O, NR⁴-C₁₋₆-alkyl, NR⁴-C₁₋₆-alkyl-NR⁴, and a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein NR⁴-C₁₋₆-alkyl-NR⁴ and the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C₁₋₆-alkyl, aryl, C₁₋₆-aralkyl; and;

20 R⁸ is selected from the group consisting of radioactive moiety, chelating agent, fluorescent dye, a contrast agent and combinations thereof;



25 is a 1-naphtyl moiety or a 5 to 10- membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, wherein there are 2 ring atoms between the N atom and X; said heterocycle optionally further comprising 1, 2 or 3 heteroatoms selected from O, N and S; and X is a C atom;

or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate, or salt thereof.

2. The compound of item 1, wherein

(i) Q, R, U are CH₂ and are individually present or absent;

V is CH₂, C=O, C=S or C=NR⁴;

5 W is NR⁴;

Y is HCR⁴; and

Z is C=O, C=S or C=NR⁴; and/or

(ii) Q and R are absent;


U is CH₂ and is present or absent;

10 R¹ and R² are independently selected from the group consisting of -H and halo;

R³ is selected from the group consisting of -H, -CN, and -B(OH)₂;

R⁴ is selected from the group consisting of -H and -C₁₋₆-alkyl, wherein the -C₁₋₆-alkyl is optionally substituted with from 1 to 3 substituents selected from -OH.

15 3. The compound of item 1 or 2, wherein




20

4. The compound of any of the preceding items, wherein




is selected from the group consisting of



5


5. The compound of any of the preceding items, wherein R^5 and R^6 are H;



10


D is absent;

A is O, S, CH_2 , NH, NCH_3 ;



E is C_{1-6} -alkyl or , wherein m is 1, 2, or 3;


A and E together form a group selected from:



B is $\text{NR}^4\text{-C}_{1-6}\text{-alkyl}$ or a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of $\text{C}_{1-6}\text{-alkyl}$, aryl, $\text{C}_{1-6}\text{-aralkyl}$.

6. The compound of any of the preceding items, wherein

(i) the N-containing heterocycle comprised in B is an aromatic or non-aromatic monocyclic heterocycle:



10 , wherein


the heterocycle optionally further comprises 1 or 2 heteroatoms selected from O, N and S, optionally further comprises 1 nitrogen;

 is attached to position 1, 2, or 3, preferably to position 2;

l is 1 or 2;


15 optionally wherein the N-containing heterocycle is substituted with a $\text{C}_{1-6}\text{-alkyl}$; and/or


(ii) the N-containing heterocycle comprised in B is selected from the group consisting of:



20


optionally wherein the N-containing heterocycle is substituted with a $\text{C}_{1-6}\text{-alkyl}$;






wherein if the N-containing heterocycle comprised in B is , the heterocycle optionally further comprises 1 or 2 heteroatoms selected from O, N and S, optionally further comprises 1 nitrogen, optionally comprises one or more (e.g. amino acid derived) side chains;

5

 is attached to position 1, 2, or 3, preferably to position 2;
o is 1 or 2,


preferably, if the N-containing heterocycle comprised in B is , the


N-containing heterocycle comprised in B is ,  or



; more preferably, if the N-containing heterocycle comprised in

10

B is , the N-containing heterocycle comprised in B is



or .

7. The compound of any of the preceding items, wherein

Q, R, U are absent;

15

V is C=O;

W is NH;

Y is CH₂;


Z is C=O;

R¹ and R² are independently selected from the group consisting of -H and halo;

20


R³ is -CN;

R⁵ and R⁶ are H;







D is absent;

A is O, S, CH₂, NH, NCH₃;




5

A and E together form a group selected from:



10



8. The compound of any of the preceding items, wherein C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl, and/or

15 wherein C₁₋₆-aralkyl is selected from the group consisting of benzyl, phenyl-ethyl, phenyl-propyl, and phenyl-butyl.

9. The compound of any of the preceding items, wherein R⁸ is a radioactive moiety, wherein the radioactive moiety is a fluorescent isotope, a radioisotope, a radioactive drug or combinations thereof, preferably wherein the radioactive moiety is selected from the group consisting of alpha radiation emitting isotopes, beta radiation emitting isotopes, gamma radiation emitting isotopes, Auger electron emitting isotopes, X-ray emitting

20

- isotopes, fluorescence emitting isotopes, such as ^{11}C , ^{18}F , ^{51}Cr , ^{67}Ga , ^{68}Ga , ^{111}In , $^{99\text{m}}\text{Tc}$, ^{186}Re , ^{188}Re , ^{139}La , ^{140}La , ^{175}Yb , ^{153}Sm , ^{166}Ho , ^{88}Y , ^{90}Y , ^{149}Pm , ^{165}Dy , ^{169}Er , ^{177}Lu , ^{47}Sc , ^{142}Pr , ^{159}Gd , ^{212}Bi , ^{213}Bi , ^{72}As , ^{72}Se , ^{97}Ru , ^{109}Pd , ^{105}Rh , $^{101\text{m}}\text{Rh}$, ^{119}Sb , ^{128}Ba , ^{123}I , ^{124}I , ^{131}I , ^{197}Hg , ^{211}At , ^{151}Eu , ^{153}Eu , ^{169}Eu , ^{201}Tl , ^{203}Pb , ^{212}Pb , ^{64}Cu , ^{67}Cu , ^{188}Re , ^{186}Re , ^{198}Au , ^{225}Ac , ^{227}Th and ^{199}Ag , preferably ^{18}F , ^{64}Cu , ^{68}Ga , ^{90}Y , $^{99\text{m}}\text{Tc}$, ^{153}Sm , ^{177}Lu , ^{188}Re .
- 5
10. The compound of any of items 1 to 8, wherein R^8 is a fluorescent dye select from the group consisting of the following classes of fluorescent dyes: Xanthenes, Acridines, Oxazines, Cynines, Styryl dyes, Coumarines, Porphines, Metal-Ligand-Complexes, Fluorescent proteins, Nanocrystals, Perylenes, Boron-dipyrrromethenes and Phtalocyanines as well as conjugates and combinations of these classes of dyes.
10
 11. The compound of any of items 1 to 8, wherein R^8 is a chelating agent which forms a complex with divalent or trivalent metal cations, preferably wherein the chelating agent is selected from the group consisting of 1,4,7,10-tetraazacyclododecane- N,N',N,N' -tetraacetic acid (DOTA), ethylenediaminetetraacetic acid (EDTA), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), triethylenetetramine (TETA), iminodiacetic acid, diethylenetriamine- N,N,N',N',N'' -pentaacetic acid (DTPA), bis-(carboxymethylimidazole)glycine and 6-Hydrazinopyridine-3-carboxylic acid (HYNIC).
15
 12. The compound of any of items 1 to 8, wherein R^8 is a contrast agent which comprises or consists of a paramagnetic agent, preferably, wherein the paramagnetic agent comprises or consists of paramagnetic nanoparticles.
20
 13. Pharmaceutical composition comprising or consisting of at least one compound according to any of items 1 to 12; and, optionally, a pharmaceutically acceptable carrier and/or excipient.
25
 14. The compound of any of items 1 to 12 or the pharmaceutical composition of claim 13 for use in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP) in an animal or a human subject, preferably wherein the disease characterized by overexpression of fibroblast activation protein (FAP) is selected from the group consisting of cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and keloid disorder, preferably wherein the cancer is selected from the group consisting of breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma,
30
35

esophageal cancer, hypopharynx cancer, nasopharynx cancer, larynx cancer, myeloma cells, bladder cancer, cholangiocellular carcinoma, clear cell renal carcinoma, neuroendocrine tumor, oncogenic osteomalacia, sarcoma, CUP (carcinoma of unknown primary), thymus carcinoma, desmoid tumors, glioma, astrocytoma, cervix carcinoma and prostate cancer.


5

15. A kit comprising or consisting of the compound of any of items 1 to 12 or the pharmaceutical composition of claim 13 and instructions for the diagnosis or treatment of a disease.

10

CLAIMS

1. A compound of Formula (I)



wherein

Q, R, and U are absent;

V, W, Y, and Z are individually present or absent under the proviso that at least three of V, W, Y, and Z are present;

V, W, Y, and Z are independently selected from the group consisting of O, CH₂, NR⁴, C=O, C=S, C=NR⁴, HCR⁴ and R⁴CR⁴, with the proviso that two Os are not directly adjacent to each other;


R¹ and R² are independently selected from the group consisting of -H, halogen, OH, C₁₋₆-alkyl, -O-C₁₋₆-alkyl, and S-C₁₋₆-alkyl;

R³ is selected from the group consisting of -CN, -B(OH)₂, -H, -C(O)-alkyl, -C(O)-aryl-, -C=C-C(O)-aryl, -C=C-S(O)₂-aryl, -CO₂H, -SO₃H, -SO₂NH₂, -PO₃H₂, and 5-tetrazolyl;

R⁴ is selected from the group consisting of -H, -C₁₋₆-alkyl, -O-C₁₋₆-alkyl, -S-C₁₋₆-alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl, and -C₁₋₆-aralkyl, each of said -C₁₋₆-alkyl being optionally substituted with from 1 to 3 substituents selected from -OH, oxo, halogen ;

R⁵ is selected from the group consisting of -H, halogen and C₁₋₆-alkyl;

R⁶, and R⁷ are independently selected from the group consisting of -H and



, under the proviso that R⁶ and R⁷ are not at the same time H,


wherein D is present or absent,

wherein A, E, and B are present,

wherein when D is present: D is a linker;

A is selected from the group consisting of NR⁴, O, S, and CH₂;

E is selected from the group consisting of



wherein i is 1, 2, or 3;

wherein j is 1, 2, or 3;

wherein k is 1, 2, or 3;


wherein m is 1, 2, or 3;

A and E together form a group selected from: a cycloalkyl, heterocycloalkyl, aryl and heteroaryl, preferably heterocycloalkyl, wherein A and E can be mono-, bi- and multicyclic, preferably monocyclic; each A and E being optionally substituted with 1 to 4 substituents selected from -H, - C_{1-6} -alkyl, -O- C_{1-6} -alkyl, -S- C_{1-6} -alkyl, alkenyl, heteroalkenyl, cycloalkenyl, cycloheteroalkenyl, alkynyl, aryl, and - C_{1-6} -aralkyl, each of said - C_{1-6} -alkyl being optionally substituted with from 1 to 3 substituents selected from

-OH, oxo, halogen; and optionally connected to A, B, D, E or ;

B is a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C_{1-6} -alkyl, aryl, and C_{1-6} -aralkyl; and;

R^8 is selected from the group consisting of radioactive moiety, chelating agent, fluorescent dye, a contrast agent and combinations thereof;




is a 1-naphthyl moiety or a 5 to 10- membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, wherein there are 2 ring atoms between the N atom and X; said heterocycle optionally further comprising 1, 2 or 3 heteroatoms selected from O, N and S; and X is a C atom;


or a pharmaceutically acceptable tautomer, racemate, hydrate, solvate, or salt thereof.


2. The compound of claim 1, wherein
- (i) V is CH₂, C=O, C=S or C=NR⁴;
 W is NR⁴;
 Y is HCR⁴; and
 Z is C=O, C=S or C=NR⁴; and/or
- (ii) R¹ and R² are independently selected from the group consisting of -H and halogen;
 R³ is selected from the group consisting of -H, -CN, and -B(OH)₂;
 R⁴ is selected from the group consisting of -H and -C₁₋₆-alkyl, wherein the -C₁₋₆-alkyl is optionally substituted with from 1 to 3 substituents selected from -OH.

3. The compound of any one of the preceding claims, wherein




4. The compound of any one of the preceding claims, wherein








5. The compound of any one of the preceding claims 1, wherein R^5 and R^6 are H;



D is absent;


A is O, S, CH_2 , NH, NCH_3 ;



B is a 5- to 10-membered N-containing aromatic or non-aromatic mono- or bicyclic heterocycle, preferably further comprising 1 or 2 heteroatoms selected from O, N, and S, preferably further comprising 1 or 2 nitrogen atoms, preferably wherein the N-containing heterocycle is substituted with 1 to 3 substituents selected the group consisting of C_{1-6} -alkyl, aryl, and C_{1-6} -aralkyl.

6. The compound of any one of the preceding claims, wherein

- (i) the N-containing heterocycle comprised in B is an aromatic or non-aromatic monocyclic heterocycle:



, wherein


the heterocycle optionally further comprises 1 or 2 heteroatoms selected from O, N and S, and optionally further comprises 1 nitrogen;

 is attached to position 1, 2, or 3, preferably to position 2;


l is 1 or 2;

optionally wherein the N-containing heterocycle is substituted with a C₁₋₆-alkyl; and/or

- (ii) the N-containing heterocycle comprised in B is selected from the group consisting of:



optionally wherein the N-containing heterocycle is substituted with a C₁₋₆-alkyl;









wherein if the N-containing heterocycle comprised in B is

the heterocycle optionally further comprises 1 or 2 heteroatoms selected from O, N and S, optionally further comprises 1 nitrogen;

 is attached to position 1, 2, or 3, preferably to position 2;

o is 1 or 2,

preferably, if the N-containing heterocycle comprised in B is , the N-containing heterocycle comprised in B is  or ; more preferably, if the N-containing heterocycle comprised in B is , the N-containing heterocycle comprised in B is  or .

7. The compound of any one of the preceding claims, wherein

V is C=O;

W is NH;


Y is CH₂;

Z is C=O;

R¹ and R² are independently selected from the group consisting of -H and halogen;


R³ is -CN;

R⁵ and R⁶ are H;




R⁷ is , wherein



D is absent;

A is O, S, CH₂, NH, NCH₃;

E is C₁₋₆-alkyl or , wherein m is 1, 2, or 3; or

A and E together form a group selected from: , ,

, , ;



8. The compound of any one of the preceding claims, wherein C₁₋₆-alkyl is selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, tert-butyl, pentyl and hexyl, and/or wherein C₁₋₆-aralkyl is selected from the group consisting of benzyl, phenyl-ethyl, phenyl-propyl, and phenyl-butyl.
9. The compound of any one of the preceding claims, wherein R⁸ is a radioactive moiety, wherein the radioactive moiety is a fluorescent isotope, a radioisotope, a radioactive drug or combinations thereof, preferably wherein the radioactive moiety is selected from the group consisting of alpha radiation emitting isotopes, beta radiation emitting isotopes, gamma radiation emitting isotopes, Auger electron emitting isotopes, X-ray emitting isotopes, fluorescence emitting isotopes, such as ¹⁸F, ⁵¹Cr, ⁶⁷Ga, ⁶⁸Ga, ¹¹¹In, ^{99m}Tc, ¹⁸⁶Re, ¹⁸⁸Re, ¹³⁹La, ¹⁴⁰La, ¹⁷⁵Yb, ¹⁵³Sm, ¹⁶⁶Ho, ⁸⁸Y, ⁹⁰Y, ¹⁴⁹Pm, ¹⁶⁵Dy, ¹⁶⁹Er, ¹⁷⁷Lu, ⁴⁷Sc, ¹⁴²Pr, ¹⁵⁹Gd, ²¹²Bi, ²¹³Bi, ⁷²As, ⁷²Se, ⁹⁷Ru, ¹⁰⁹Pd, ¹⁰⁵Rh, ^{101m}Rh, ¹¹⁹Sb, ¹²⁸Ba, ¹²³I, ¹²⁴I, ¹³¹I, ¹⁹⁷Hg, ²¹¹At, ¹⁵¹Eu, ¹⁵³Eu, ¹⁶⁹Eu, ²⁰¹Tl, ²⁰³Pb, ²¹²Pb, ⁶⁴Cu, ⁶⁷Cu, ¹⁸⁸Re, ¹⁸⁶Re, ¹⁹⁸Au, ²²⁵Ac, ²²⁷Th and ¹⁹⁹Ag.
10. The compound of any one of claims 1 to 8, wherein R⁸ is a fluorescent dye selected from the group consisting of the following classes of fluorescent dyes: Xanthenes, Acridines, Oxazines, Cynines, Styryl dyes, Coumarines, Porphines, Metal-Ligand-Complexes, Fluorescent proteins, Nanocrystals, Perylenes, Boron-dipyrrromethenes and Phthalocyanines as well as conjugates and combinations of these classes of dyes.
11. The compound of any one of claims 1 to 8, wherein R⁸ is a chelating agent selected from the group consisting of 1,4,7,10-tetraazacyclododecane-N,N',N,N'-tetraacetic acid (DOTA), ethylenediaminetetraacetic acid (EDTA), 1,4,7-triazacyclononane-1,4,7-

triacetic acid (NOTA), triethylenetetramine (TETA), iminodiacetic acid, diethylenetriamine-N,N,N',N',N''-pentaacetic acid (DTPA), bis-(carboxymethylimidazole)glycine and 6-Hydrazinopyridine-3-carboxylic acid (HYNIC).

12. The compound of any one of claims 1 to 8, wherein R⁸ is a contrast agent which comprises a paramagnetic agent, preferably, wherein the paramagnetic agent comprises paramagnetic nanoparticles.
13. Pharmaceutical composition comprising at least one compound according to any one of claims 1 to 12; and a pharmaceutically acceptable carrier.
14. The compound of any of claims 1 to 12 or the pharmaceutical composition of claim 12 for use in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP) in an animal or a human subject, preferably wherein the disease characterized by overexpression of fibroblast activation protein (FAP) is selected from the group consisting of cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and keloid disorder, preferably wherein the cancer is selected from the group consisting of breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharynx cancer, nasopharynx cancer, larynx cancer, myeloma cells, bladder cancer, cholangiocellular carcinoma, clear cell renal carcinoma, neuroendocrine tumor, oncogenic osteomalacia, sarcoma, CUP (carcinoma of unknown primary), thymus carcinoma, desmoid tumors, glioma, astrocytoma, cervix carcinoma and prostate cancer.
15. A method for diagnosing or treating of a disease characterized by overexpression of fibroblast activation protein (FAP) in an animal or a human subject, preferably wherein the disease characterized by overexpression of fibroblast activation protein (FAP) is selected from the group consisting of cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and keloid disorder, preferably wherein the cancer is selected from the group consisting of breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharynx cancer, nasopharynx cancer, larynx cancer, myeloma cells, bladder cancer, cholangiocellular carcinoma, clear cell

renal carcinoma, neuroendocrine tumor, oncogenic osteomalacia, sarcoma, CUP (carcinoma of unknown primary), thymus carcinoma, desmoid tumors, glioma, astrocytoma, cervix carcinoma and prostate cancer, the method comprising administering the compound of any of claims 1 to 12 or the pharmaceutical composition of claim 13.

16. Use of the compound of any of claims 1 to 12 or the pharmaceutical composition of claim 13 for the manufacture of a medicament for diagnosing or treating of a disease characterized by overexpression of fibroblast activation protein (FAP) in an animal or a human subject, preferably wherein the disease characterized by overexpression of fibroblast activation protein (FAP) is selected from the group consisting of cancer, chronic inflammation, atherosclerosis, fibrosis, tissue remodeling and keloid disorder, preferably wherein the cancer is selected from the group consisting of breast cancer, pancreatic cancer, small intestine cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, ovarian cancer, hepatocellular carcinoma, esophageal cancer, hypopharynx cancer, nasopharynx cancer, larynx cancer, myeloma cells, bladder cancer, cholangiocellular carcinoma, clear cell renal carcinoma, neuroendocrine tumor, oncogenic osteomalacia, sarcoma, CUP (carcinoma of unknown primary), thymus carcinoma, desmoid tumors, glioma, astrocytoma, cervix carcinoma and prostate cancer.
17. A kit comprising or consisting of the compound of any of claims 1 to 12 or the pharmaceutical composition of claim 13 and instructions for the diagnosis or treatment of a disease.

Figure 1




Figure 1 continued




Figure 1 continued




Figure 1 continued




Figure 2




Figure 2 continued




Figure 2 continued




Figure 3




Figure 3 continued




Figure 3 continued




Figure 3 continued





Figure 4




Figure 4 continued





Figure 4 continued




Figure 4 continued




Figure 5




Figure 5 continued




Figure 5 continued




Figure 6
Breast cancer




Figure 6 continued




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12

Lung cancer




Figure 13

Oncogenic Rachitis




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18






Figure 19

Tumor



Blood



Kidneys





Figure 20



5

Figure 21




Figure 22





Figure 22 continued





Figure 23




Figure 23 continued




Figure 24




Figure 24 continued





Figure 25






Figure 26



Rectal ca.



Mucoepidermoid ca.



Ovarial ca.




Figure 27




Figure 28




Figure 29






Figure 30



A.

Figure 30 continued








Figure 30 continued



C.

Figure 31






Figure 32




Figure 33




Figure 34




Figure 35




Figure 36




Figure 37




Figure 38




Figure 39




Figure 40




Figure 41




Figure 42




Figure 43




Figure 44




Figure 45




Figure 46






Figure 47

FAP1-04



FAP1-46




Figure 48




Figure 49




Figure 50






Figure 51

AIF-FAPI-75





Figure 52



1 h p.i.

3 h p.i.

Figure 53

blood pool clearance




Figure 54

⁶⁸Ga-FAPI-02






Figure 54 continued


⁶⁸Ga-FAPI-04



10 min

1 h

3 h



10 min

1 h

3 h

Figure 55

| | FAPI-2 | FAPI-4 |
|-------------------------------------|---------------|---------------|
| Adrenals | 1.23E-02 | 1.12E-02 |
| Brain | 9.54E-03 | 9.11E-03 |
| Breasts | 9.58E-03 | 8.88E-03 |
| Gallbladder Wall | 1.19E-02 | 1.13E-02 |
| LLI Wall | 1.23E-02 | 1.17E-02 |
| Small Intestine | 1.19E-02 | 1.13E-02 |
| Stomach Wall | 1.13E-02 | 1.06E-02 |
| ULI Wall | 1.17E-02 | 1.11E-02 |
| Heart Wall | 4.73E-02 | 2.02E-02 |
| Kidneys | 4.45E-02 | 4.43E-02 |
| Liver | 1.51E-02 | 1.46E-02 |
| Lungs | 1.09E-02 | 9.89E-03 |
| Muscle | 1.04E-02 | 9.91E-03 |
| Ovaries | 1.24E-02 | 1.19E-02 |
| Pancreas | 1.23E-02 | 1.13E-02 |
| Red Marrow | 3.28E-02 | 2.08E-02 |
| Osteogenic Cells | 2.94E-02 | 2.16E-02 |
| Skin | 9.01E-03 | 8.63E-03 |
| Spleen | 2.62E-02 | 1.05E-02 |
| Testes | 1.04E-02 | 1.01E-02 |
| Thymus | 1.15E-02 | 1.01E-02 |
| Thyroid | 1.03E-02 | 9.82E-03 |
| Urinary Bladder Wall | 8.89E-02 | 9.91E-02 |
| Uterus | 1.33E-02 | 1.30E-02 |
| Total Body | 1.19E-02 | 1.09E-02 |
| Effective Dose (mSv/MBq) | 1.80E-02 | 1.64E-02 |

Figure 56

A)

Tumour entity (primary + metastases)




Figure 56 continued

B)




Figure 57

